Genes encoding an insect calcium channel

ABSTRACT

The present invention provides for the isolation and characterization of an invertebrate calcium channel subunit gene.

This application is a continuation, of application Ser. No. 08/374,888, filed Jan. 19, 1995, now abandoned.

FIELD OF THE INVENTION

The present invention relates generally to the voltage-dependent calcium channel multigene family. More particularly, the present invention relates to the characterization and isolation of an insect calcium channel α₁ and β subunits particularly from Drosophila melanogaster.

BACKGROUND OF THE INVENTION

Early electrophysiological studies on invertebrate preparations revealed the presence of calcium currents and suggested the presence of multiple types of voltage-dependent calcium channels (reviewed by Hille, B., (1992), In: Ion Channels of Excitable Membranes, 2nd Ed., Sinauer, Sunderland, Mass.). Continuing studies of calcium channels have shown that they are ubiquitous since they are found in excitable cells in species ranging from Paramecium to humans. Calcium channels are involved in many cell functions including: membrane excitability, synaptic transmission, and differentiation (Tsien et al., (1988), Trends Neurosci., vol. 11, pp. 431-438). Voltage-dependent calcium channels have been studied extensively in vertebrate neuronal tissue using electrophysiological and pharmacological approaches and as a result have been divided into four classes designated L, N, T, and P (Bean, B. P., (1989), Annu. Rev., Physiol., vol. 51, pp. 367-384; Hess, P., (1990), Annu. Rev. Neurosci., vol. 13, pp. 1337-1356).

Gene cloning studies, which up to this point have focused exclusively on vertebrate species, have helped to elucidate the molecular nature of calcium channel structure and have suggested a remarkable degree of channel heterogeneity beyond that predicted from physiological and pharmacological approaches. This molecular diversity of calcium channels arises from several mechanisms. Calcium channels are comprised of multiple subunits designated α₁, α₂, β, γ, and δ (Catterall, W. A., (1991a), Cell, vol. 64, pp. 871-874; Catterall, W. A., (1991b), Science, vol. 253, pp. 1499-1500). The α₂ and δ subunits are encoded by the same gene and are cleaved during posttranslational processing whereas each of the other subunits arise from different genes. One way that calcium channel diversity arises is through the presence of a family of genes each encoding genetic variants of a given subunit. For example, in rat brain the α₁ subunit appears to be encoded by a family of at least five different genes (Snutch et al., (1990), Proc. Natl. Acad. Sci. USA, vol. 87, pp. 3391-3395; Snutch et al., (1991), Neuron, vol. 7, pp. 45-57; Hui et al., (1991), Neuron, vol. 7, pp. 35-44; Starr et al., (1991), Proc. Natl. Acad. Sci. USA, vol. 88, pp. 5621-5625; Dubel et al., (1992), Proc. Natl. Acad. Sci. USA, vol. 89, pp. 5058-5062; Soong et al., (1993), Science, vol. 260, pp. 1133-1136). For each member of the gene family further diversity is introduced by alternative splicing (Biel et al., (1990), FEBS Lett., vol. 269, pp. 409-412; Koch et al., (1990), J. Biol. Chem., 265, pp. 17786-17791; Perez-Reyes et al., (1990), J. Biol. Chem., 265, pp. 20430-20436; Snutch et al., (1991), Neuron, vol. 7, pp. 45-57). Recent studies point to the existence of similar molecular diversity for the other subunits as well (Williams et al., (1992a), Science, vol. 257, pp. 389-395; Williams et al., (1992b), Neuron, vol. 8, pp. 71-84). The α₁ subunit is the essential portion of the calcium channel as it is involved in forming the pore in a membrane. The β subunit is of special interest since its coexpression with α₁ in an artificial expression system often significantly increases the channel current and the drug binding ability and brings channel kinetics closer to the physiological norm [Lacerda et al. (1991), Nature, Vol. 352, pp. 527-530; Varadi et al. (1991), Nature, vol 352, pp. 159-162; Neely et al. (1993), Science, vol 262, pp. 575-578]. In some cases, no functional expression is detected without coexpression of the β subunit. β subunits have also been implicated in the regulation of calcium channels by protein phosphorylation [Singer et al. (1992), FEBS Lett., vol 306, pp. 113-118].

Generally the cloned vertebrate calcium channel β subunits are highly conserved, but there are three nonconserved regions within the molecule. We report here a PCR strategy that showed that invertebrate calcium channels also contain a β subunit. We report here the deduced amino acid structure, expression pattern, and chromosome mapping of a β subunit from the fruitfly Drosophila melanogaster. We also show that alternative splicing occurs in at least three regions to generate multiple isoforms. These studies set the stage for genetic analysis of β subunit function in the intact organism.

If each subunit variant can interact with more than one form of each of the other subunits to form functional channels, then there is a potential for even further molecular diversity.

Although studies of the molecular diversity of calcium channels in Drosophila are just beginning, there is evidence for structural and functional heterogeneity in this system. Binding of phenylalkylamines (calcium channel blocking agents) to Drosophila head extracts showed curvilinear Scatchard plots indicative of multiple classes differing in ligand affinity (Greenberg et al., (1989), Insect Biochem., vol. 19, 309-322). Pelzer et al., (1989), EMBO J., vol. 8, pp. 2365-2371, reported at least 8 distinct voltage-sensitive calcium channels in Drosophila head membranes following reconstitution into phospholipid bilayers. Patch clamp studies on cultured embryonic Drosophila myocytes and neurons also showed variability of channel properties, suggesting at least two types of calcium channels in Drosophila (Leung and Byerly, 1991). Further evidence for channel heterogeneity comes from differential sensitivity of Drosophila calcium channels to a purified toxin from the spider Hololena curta (Leung, H. T. and Byerly, L., (1991), J. Neurosci., vol. 11, pp. 3047-3059). This heterogeneity is further supported in another insect (Periplaneta americana) where radiotracer flux studies have demonstrated the presence of dihydropyridine-insensitive and -sensitive components of phenylalkylamine-sensitive calcium uptake in nervous system and skeletal muscle membranes, respectively (Skeer et al., (1992), Insect Biochem. Molec. Biol., vol. 22, pp. 539-545).

Given the heterogeneity of calcium channels in insects, Drosophila provides an ideal system for a molecular genetic approach to define the significance of channel diversity by mutating individual subunit genes and determining the physiological and behavioral consequences.

Other ion channels have also been reported to date. For example, electrophysiological studies of ligand-gated ion currents in insect nerve and muscle cells provide evidence for the existence of chloride channels gated by glutamate, histamine, and taurine, as well as those gated by α-Aminobutyric acid (“GABA”) (Sattelle, D. B., (1990), Adv. Insect Physiol., vol. 22, pp. 41-56 and Lummis et al., (1990), Annu. Rev. Entomol., vol. 35, pp. 345-377). Although these findings imply the existence of a large and diverse gene family encoding ligand-gated chloride channels in insects, very little is known about homologous channels of invertebrates. In ffrench-Constant et al., (1991), Proc Natl. Acad. Sci. USA, vol. 88, pp. 7209-7213, a Drosophila melanogaster cDNA having significant predicted amino acid sequence identity to vertebrate ligand-gated chloride channel genes was isolated and mapped to a genetic locus (“Rdl1”) that confers resistance to cyclodiene insecticides and other blockers of GABA-gated chloride channels. Rdl was shown to encode a GABA subunit by the expression of functional homomultimeric GABA in Xenopus oocytes following injection with Rdl mRNA (ffrench-Constant et al., (1993), Nature, vol. 363, pp. 449-451).

One other example of a ligand-gated chloride channel gene from an invertebrate species is a GABA β-like subunit gene isolated from the pond snail, Lymnaea stagnalis (Harvey et al., (1991), EMBO J., vol. 10, pp. 3239-3245). The functional relationship of the product encoded by this gene to vertebrate GABA β subunits was corroborated by the formation of a functional chimeric with properties similar to vertebrate α/β heteromultimers when the gene was co-expressed with a vertebrate α subunit in Xenopus oocytes.

The characterization and isolation of an invertebrate calcium channel subunit gene(s) would be useful in the cloning of calcium channel subunits from other invertebrate preparations of physiological or economic importance for purposes such as screening drugs to identify drugs which specifically interact with, and bind to, the calcium channel on the surface of a cell, such as, for example, organic calcium channel blocking agents, e.g., phenylalkylamines.

BRIEF SUMMARY OF THE INVENTION

The primary object of the present invention is the isolation and characterization of an invertebrate (i.e., insect) calcium channel subunit gene(s).

The present invention provides for the isolation of genomic DNA fragment(s) from insects which encode a conserved amino acid sequence unique to the voltage-dependent calcium channel multigene family. Polymerase chain reaction (“PCR”)-based homology and screening of cDNA libraries with homologous probes were utilized to isolate the genomic DNA fragment(s) of the invention. Using PCR, the first insect calcium channel subunit genes were cloned. The calcium channel α₁ subunit gene was cloned from Drosophila melanogaster, and designated herein as “Dmca1D”. The cDNA clones corresponding to the DNA fragments are designated N1, W8A, SH22C, and SH22D. Likewise the β subunit gene was also cloned from Drosophila melanogaster and designated herein as “2L4”. The cDNA clones corresponding to the DNA fragments are designated B5 and 6-I.

The DNA sequence expressing the corresponding amino acid sequences encoding the calcium channel subunit gene(s) of the invention can be cloned into any suitable expression vector, such as, for example, plasmid DNA, viral DNA including human viruses, animal viruses and insect viruses and bacteriophages to form a recombinant expression system which directs the expression of the calcium channel subunit of the invention. It is understood that this expression system can be expressed in any suitable host cell to form a functional recombinant calcium channel.

In another aspect of the invention, there is provided a method of expressing a functional invertebrate calcium channel comprising (a) transforming a host cell with the gene of the present invention i.e., gene encoding the calcium channel α₁, or β, or other insect subunit, and (b) facilitating expression of the gene(s) in the host cell, thereby forming a functional ion channel which exhibits similar pharmacological properties of calcium channel in insect tissue.

In still another aspect of the invention, there is provided a method of screening a chemical agent for effectiveness as a pesticide, comprising (a) facilitating expression of the gene of the invention i.e., gene encoding the calcium channel α₁, or β, or other insect subunit, in a host thereby forming a functional calcium channel, (b) exposing the host to a chemical agent having pesticidal activity, and (c) evaluating the exposed host to determine if the functional calcium channel is the target site for the pesticidal activity of the chemical agent.

In still a further aspect of the invention, there is provided a method of identifying compositions which specifically interact with, and bind to, the calcium channel on the surface of a cell comprising (a) contacting a cell containing the gene of the invention i.e., gene encoding the calcium channel subunit, with a plurality of said compositions, and (b) determining those compositions which bind to the calcium channel expressed in the cell, thereby identifying drugs which specifically interact with, and bind to, the calcium channel.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic diagram depicting a strategy for cloning and the relationship of cDNA clones encoding the calcium channel α₁ subunit from Drosophila [A, Cartoon showing the general structure of all α₁ subunits known to date. Black boxes labeled 6 & 7, identify the position of primers used for successful amplification of a portion of genomic DNA encoding the Drosophila α₁ sequence. The region extending diagonally from the 3′ end of W8A indicates an alternatively spliced sequence which is not present in clone SH22C. The small open boxes in SH22D indicate positions of the alternative splice regions studied in Table 1. The large rectangular box indicates the open reading frame for the Drosophila α₁ subunit starting with the first possible methionine codon (designated met1 herein). The positions of the repeats (I-IV) are shown as shaded gray boxes within the open reading frame].

FIGS. 2a-2 c illustrate the nucleotide sequence (“SEQ ID NO. 1”) and deduced amino acid sequence (“SEQ. ID. NO. 2”) of the cDNA encoding the Drosophila α₁ subunit of the invention.

FIG. 2a[SEQ. I.D. NOS.: 1&2]—2 sequences aligned.

FIG. 2b—SEQ. I.D. No. 1.

FIG. 2c—SEQ. I.D. NO. 2.

FIG. 3 is a photomicrograph of the chromosome mapping of the α₁ subunit Dmca1D [In situ hybridization to Drosophila salivary gland polytene chromosomes using a biotinylated probe (bases 4252-5795, FIG. 2) mapped this gene to 35EF on the left arm of chromosome 2. Numbered divisions for this section of chromosome 2L are marked and the hybridization signal is indicated by the arrow].

FIG. 4 illustrates the tissue and temporal expression of the Drosophila α₁ subunit mRNA by Northern blotting [A, Message distribution in adult body parts. B, developmental profile of calcium channel α₁ subunit mRNA expression in embryos showing a peak of expression in the late embryonic stages. Lanes 1-7 represent sequentially older embryos collected over 3 hour intervals and then aged approximately at 25° C. (1=0-3 hr, 2=3-6 hr, 3=6-9 hr, 4=9-12 hr, 5=12-15 hr, 6=15-18 hr, 7=18-24 hr)].

FIG. 5. is a photomicrograph of the localization of α₁ subunit mRNA in the embryonic nervous system using in situ hybridization to a whole mount embryo [Dorsal is up and anterior is to the left].

FIG. 6. is a comparison of hydropathy plots for α₁ subunits from rat brain type D [Panel B, with the Drosophila subunit; Panel A, using the first in-frame methionine (met1) as the initiating amino acid in the Drosophila sequence. Up is hydrophobic and down (negative numbers) is hydrophilic].

FIG. 7. [SEQ ID NOS.: 3&4] illustrates the alignment of the deduced amino acid sequences of α₁ subunits from Drosophila (upper) and rabbit skeletal muscle (lower) [The transmembrane domains are shaded in gray and their identity is shown above in bold lettering.

Nonconservative amino acid substitutions in regions of interest are indicated by filled triangles. The hatched bar indicates the phenylalkylamine-binding fragment. The black bars underline dihydropyridine-binding fragments].

FIG. 8 Cloning strategy for the calcium channel β subunit from Drosophila. (A) Degenerate forward (DPF1) and reverse (DPR1) primers were made from regions conserved in mammalian β subunits and used with whole fly cDNA as a template. A 0.35 kb fragment (cloned into pBluescript and designated pBT15) with high similarity to mammalian β subunits was used to probe a Drosophila head cDNA library. Clones B5 and B6 were isolated. Clone B6 was used to reprobe the library and clones 6-I and 6-O were isolated. The 3′ end of 6-I (indicated by cross hatched bar) was used to isolate clone 6-Q. In-frame stop codons in each of these clones are indicated by * and putative initiating methionines are marked with M. To obtain a physiologically significant, full length cDNA, exact match forward (EPF1 and EPF2) and reverse (EPR2) primers were used for reverse transcription coupled PCR (RT-PCR) with poly A selected RNA selected from various body parts (heads, bodies, or legs). Since strongest amplification came from “leg” cDNA, these products were subcloned and sequenced. One of these subclones was 1L4 which carries a complete open reading frame for the Drosophila β subunit. For each clone the thick lines indicate regions with the same sequence as 2L4 while thin lines indicate regions of difference. The open reading frame of 2L4 is shown as an open/hatch rectangle. Within clone 2L4 the three alternative splicing regions are indicated by X, Y and Z (see FIG. 11) while the conserved, putative α-helical domains (see FIG. 9) are shown as cross-hatched areas. (B) Hydropathy plot Kyte et al. (1982), J. Mol. Biol., vol 157, pp. 105-132 for the Drosophila β subunit encoded by clone 2L4. This plot (made with GeneWorks software) indicates hydrophobic (up) and hydrophilic (down, negative numbers) regions. The X-axis is deduced amino acid number.

FIG. 9 (SEQ ID NOS: 5-11 Alignment of deduced amino acid sequence of RT-PCR amplification product 2L4 (encoding a Drosophila β subunit sequence. The PILEUP program was used to align the sequences. Structural features discussed in the text are indicated by symbols below the Drosophila amino acid sequence as follows: Δ protein kinase C (PKC) phosphorylation site ([ST]-x-[RK]); ©casein kinase II phosphorylation site [ST]-x(s)-*DE*; # protein kinase A phosphorylation site [RK](2)-x-[ST]; * in frame stop codon. The PKC site that is present in all the vertebrate β subunits but absent in Drosophila is indicated by a bracketed symbol [Δ]. In Drosophila this site has been replaced with a tyrosine kinase phosphorylation site, [RK]-x-(3)-*DE*-x(2)-Y marked with +. An ATP/GTP-binding site motif (P-loop=[AG]-x-(4)-G-K-[ST]) in the Drosophila sequence is marked by a heavy underline. Four putative α-helix regions are boxed and two PEST domains are shaded. The 3 alternative splice sites in the Drosophila sequence marked and labeled X, Y or Z correspond with the regions indicated in clone 2L4 in FIG. 8. For the sequences shown, the GenBank access number X61394, [Pragnell et al. (1991), FEBS Lett., vol 291, pp. 253-258]), rat-β2=Rtb2 (M80545, [Perez-Reyes et al. (1992), J. Biol. Chem., vol 267, pp. 1792-1797]), rat-β3=Rtb3 (M88751, [Castellano et al. (1993), J. Biol. Chem., vol 268, pp. 3450-3455]), rat-β4=Rtb4 (L02315, [Castellano et al. (1993), J. Biol. Chem., vol 268, pp. 12359-12366]), rabbit-β1=Rbb1 (M25817, [Ruth et al. (1989), Science, vol 245, pp. 1115-1118]). The Drosophila sequence (Dmb1) has been submitted to GenBank (accession #U11074). “con” is the consensus sequence. The numbers above the consensus sequence represent the position number within the deduced amino acid sequence of the Drosophila β subunit (Dmb1).

FIG. 10[SEQ I.D. NOS.: 12-42] Sequences of alternatively spliced forms of the Drosophila β subunit cDNA and portions of the corresponding genomic DNA. Portions of cDNA clones and subcloned PCR amplification products are compared in regions of alternative splicing (X, Y and Z in FIG. 8). Common regions (not alternatively spliced) are boxed. * is an in-frame stop codon. All sequences are from cDNA library phage clones except “gen” which is genomic DNA and those sequences which begin with “2” which are PCR amplification products generated with EPF1 and EPR1 as primers. Those PCR products with E in the name used embryonic cDNA as the template while those with L used leg/antennal cDNA. X shows alignment of the three alternatively spliced forms in the amino-terminus for B5 (same sequence as 2L4), 6-O and 6-I. A PKC site (unique to B5) is shown by Δ and a casein kinase II phosphorylation site (unique to 6-O) is marked by ©. Y shows the alignment of 7 alternatively spliced cDNA forms with a partial genomic (Gen) sequence in the middle region. A PKC site unique to B6 is marked by Δ. Z shows the alignment of 5 alternatively spliced forms in the 3′ region. A possible phosphorylation site for either PKC or casein kinase II is marked with ♦. The bottom left inset summarizes the alternative splice patterns in cDNA clones compared with the genomic sequence in the middle (Y) nonconserved region of the β subunit. Thick regions are exons and thin regions are introns. The inverted v regions have been removed in the individual cDNAs as indicated. The numbers above each region indicate its size in base pairs. The filled boxes are nonvariable regions for all clones analyzed.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides for the characterization and isolation of an invertebrate calcium channel subunit gene(s). The present invention provides the complete sequence of a calcium channel α₁ and β subunit cDNA cloned from a Drosophila head cDNA library. This appears to be the first insect calcium channel subunit cloned using a PCR approach which relied on sequence similarity to previously cloned calcium channels from vertebrate species. The approach used in the present invention allowed for the rapid cloning of related genes from evolutionarily distant organisms and should be applicable for the cloning of subunits from other invertebrate preparations of physiological or economic importance.

The present invention provides for the isolation of genomic DNA fragment(s) from the insect, e.g. Drosophila melanogaster, which encode a conserved amino acid sequence unique to the voltage-dependent calcium channel multigene family. Polymerase chain reaction (“PCR”)-based homology is utilized to isolate genomic DNA fragment(s) which were used to probe a cDNA library. Using these techniques, the first insect calcium channel subunit genes were cloned. More particularly, these techniques yielded four α₁ cDNA clones, designated N1, W8A, SH22C, and SH22D—the open reading frame of the combined cDNA clones (primarily N1, W8A, and SH22C) encompasses the Dmca1D gene sequence of the present invention. PCR using probes based on vertebrate β subunit genes yielded clones designated B5, B6, 6-I, 6-O and 6-Q. Reverse transcription coupled PCR (RT-PCR) was utilized to isolate clone 2L4 which contains the open reading frame for the Drosophila β subunit (Dmb1) gene sequence of the present invention.

It is understood that the cDNAs encoding the clones designated N1, W8A, SH22C, and SH22D (whose combination encompasses the open reading frame of the Dmca1D gene) and B5, B6, 6-l, 6-O, 6-Q, and2L4 are for purposes of illustration only, and the existence of a diverse family of genes in Drosophila melanogaster that are structurally related to the voltage-dependent calcium channel gene family of invertebrates is supported by the present invention.

The genomic sequence of the invention, designated Dmca1D, exhibits the conserved features commonly found in members of the family of voltage-dependent calcium channel genes. More specifically, the Dmca1D genomic sequence encodes a deduced protein estimated to contain 2516 amino acids with a predicted molecular weight of 276,493 kDa. The deduced protein shares many features with vertebrate homologues including: (1) 4 repeat structures each containing 6 transmembrane domains; (2) a conserved ion selectivity filter region between transmembrane domains 5 and 6; and (3) an EF hand in the carboxy tail. The Drosophila subunit is unusual in that the initial amino and terminal carboxy tails are much longer than those of the vertebrate homologues. The region corresponding to the last transmembrane domain (IVS6) and the adjacent cytoplasmic domain have been postulated to form a phenylalkylamine-binding site in vertebrate calcium channels. This region is completely conserved in the Drosophila sequence while domains thought to be involved in dihydropyridine binding show numerous changes. Since the Drosophila subunit of the invention exhibits 78.3% sequence similarity to the type D calcium channel α₁ subunit from rat brain, it has been designated Drosophila melanogaster calcium channel alpha-1 type D subunit (“Dmca1D”). This appears to be the first report of a neuronal calcium channel subunit sequence from an invertebrate species. In situ hybridization using digoxigenin-labeled probes shows that Dmca1D is highly expressed in the embryonic nervous system. Northern analysis shows that Dmca1D cDNA hybridizes to three size classes of mRNA (9.5, 10.2 and 12.5 kb) in heads, but only two classes (9.5 and 12.5 kb) in bodies and legs. PCR analysis of cDNA versus genomic DNA suggests that the Dmca1D message undergoes alternative splicing with more heterogeneity appearing in head and embryonic extracts than in bodies and legs. The genomic sequence of the invention, designated Dmb1, exhibits conserved features found in members of the family of calcium channel β subunits. The Dmbl sequence encodes a deduced protein estimated to contain 432 amino acids with a molecular weight of 47,944 Da. Like β subunits from mammals, this subunit lacks significant transmembrane domains, which is consistent with the model that the β subunit is a cytoplasmic protein interacting with a cytoplasmic domain of alpha-1 subunits (Ruth et al. (1985), Science, vol 245, pp. 1115-1118; Pragnell et al., (1994) Nature, Vol. 368, pp. 67-70).

In accordance with one embodiment of the invention, there is provided an isolated gene and/or gene fragment or portion thereof comprising a DNA molecule encoding a calcium channel α₁ and β subunit from Drosophila melanogaster. Preferably, the DNA molecules of the invention encodes for an amino acid sequence, or mutant thereof, corresponding to Dmca1D, as shown in FIG. 2 (SEQ. ID. NO. 2). The DNA molecule of the invention preferably comprises a nucleotide sequence, or a mutant DNA sequence thereof, corresponding to Dmca1D, as shown in FIG. 2 (SEQ. ID. NO. 1). It is understood that any modifications, e.g., insertions, deletions, mutations, recombinants, etc., of the DNA nucleotide and/or corresponding amino acid sequence(s) are within the scope of the present invention provided that the modified sequence(s) encode for a gene, its homologs or a fragment thereof producing a calcium channel α₁ subunit from Drosophila melanogaster. In addition, this subunit should exhibit pharmacological properties of the native calcium channel α₁ subunit in insect tissue.

In accordance with another embodiment of the invention, there is provided an isolated gene and/or gene fragment or portion thereof comprising a DNA molecule encoding a calcium channel β subunit from Drosophila melanogaster. Preferably, the DNA molecule of the invention encodes for an amino acid sequence, or a mutant DNA sequence thereof, corresponding to Dmb1 as shown in FIG. 9. The DNA molecule of the invention preferably comprises a nucleotide sequence, or a mutant DNA sequence thereof, corresponding to Dmb1, as shown in FIG. 13. It is understood that any modifications, e.g., insertions, deletions, mutations, recombinants, etc., of the DNA nucleotide and/or corresponding amino acid sequence(s) are within the scope of the present invention provided that the modified sequence(s) encode for a gene, its homologs or a fragment thereof producing a calcium channel β subunit from Drosophila melanogaster. In addition, this subunit should exhibit properties of the native calcium channel β subunit in neuronal invertebrate tissue.

Recombinant DNA techniques are used to insert the DNA sequences of the invention (e.g. gene encoding the calcium channel α₁ subunit from Drosophila melanogaster or gene encoding β subunit from Drosophila melanogaster into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequences. A large number of vector systems known in the art can be used, such as, plasmids, bacteriophage virus or other modified viruses. Suitable vectors include, but are not limited to the following viral vectors such as lambda vector system gt11, gtWES.tB, Charon 4, and plasmid vectors such as pBR322, pBR325, pACYC177, pACYC184, pAR series, pKK223-3, pUC8, pUC9, pUC18, pUC19, pLG339, pR290, pKC37, pKC101 and other similar systems. The DNA sequences are cloned into the vector using standard cloning procedures in the art, as described by Sambrook et al., (1989), In: Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Springs Harbor, N.Y., which disclosure is hereby incorporated by reference.

The recombinant DNA molecule (e.g., vector+sequence of invention) can then be introduced into appropriate host cells, including but not limited to bacteria, virus, yeast, vertebrate or invertebrate cells or the like. The vector system must be compatible with the host cell used. The recombinant vectors can be introduced into the host cells via transformation, transfection or infection using standard techniques in the art. A variety of host cell systems can be used to express the calcium channel α₁ and/or β subunit gene of the invention. For example, host cell systems include, but are not limited to the following: bacteria transformed with bacteriophage DNA, plasmid DNA or cosmid DNA such as E. coli JM103, E. coli C600, E. coli CO4, E. coli DH20 and E. coli TB1; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (baculovirus).

In order to obtain efficient expression of the calcium channel α₁ and/or β subunit gene, a promoter must be present in the expression vector. RNA polymerase normally binds to the promoter and initiates transcription of a gene or a group of linked genes and regulatory elements (operon). Promoters vary in their strength, i.e., ability to promote transcription. For the purpose of expressing the gene of the invention, it is desirable to use strong promoters in order to obtain a high level of transcription and, hence, expression of the gene. Depending upon the host cell system utilized, any one of a number of suitable promoters can be used, such as, the lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the P_(R) and P_(L) promoters of coliphage lambda, the copia (Flavell, A. J., Levis, R., Simon, M. A., and Rubin, G. M. (1981) Nucleic Acid Research 9, 6279-6291), heat-shock 70 (Ingolia, T. D., Craig, E. A., and McCarthy, B. J. (1980) cell 21, 669-679) or metallothionein promoters (Maroni, G., Otto, E. and Lastowski-Perry, D. (1986) Genetics 112, 493-504) from Drosophila, and others including but not limited to lacUV5, ompF, bla, lpp and the like, nos promoter, the small subunit ribulose bisphosphate carboxylase genes, the small subunit chlorophyll A/B binding polypeptide, the 35S promoter of cauliflower mosaic virus, and promoters isolated from plant genes, including the Pto promoter itself (Vallejos et al., (1986), Genetics, vol. 112, pp. 93-105, which disclosure is hereby incorporated by reference) to direct high levels of transcription of adjacent DNA segments.

Host cell strains and expression vectors can be chosen which inhibit the action of the promoter unless specifically induced. In certain operons the addition of specific inducers is necessary for efficient transcription of the inserted DNA; for example, the lac operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside). A variety of other operons, such as trp, pro, etc., are under different controls. The trp operon is induced when tryptophan is absent in the growth media; and the P_(L) promoter of lambda can be induced by an increase in temperature in host cells containing a temperature sensitive lambda repressor, e.g., c1857. In this way, greater than 95% of the promoter-directed transcription may be inhibited in uninduced cells. Thus, expression of the gene of the invention can be controlled.

One such promoter/operator system is the so-called “tac” or trp-lac promoter/operator system (Russell and Bennett, (1982), Gene, vol. 20, pp. 231-243, which disclosure is hereby incorporated by reference). This hybrid promoter is constructed by combining the −35 b.p. (−35 region) of the trp promoter and the −10 b.p. (−10 region or Pribnow box) of the lac promoter (the sequences of DNA which are the RNA polymerase binding site). In addition to maintaining the strong promoter characteristics of the tryptophan promoter, tac is also controlled by the lac repressor.

When cloning in a eucaryotic host cell, enhancer sequences (e.g., the 72 bp tandem repeat of SV40 DNA or the retroviral long terminal repeats of LTRs, etc.) may be inserted to increase transcriptional efficiency. Enhancer sequences are a set of eucaryotic DNA elements that appear to increase transcriptional efficiency in a manner relatively independent of their position and orientation with respect to a nearby gene. Unlike the classic promoter elements (e.g., the polymerase binding site and the Goldberg-Hogness “TATA” box) which must be located immediately 5′ to the gene, enhancer sequences have the remarkable ability to function upstream from, within, or downstream from eucaryotic genes. Therefore, the position of the enhancer sequence with respect to the inserted gene is less critical.

Specific initiation signals are also required for efficient gene transcription and translation in procaryotic cells. These transcription and translation initiation signals may vary in “strength” as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promoter, may also contain any combination of various “strong” transcription and/or translation initiation signals. For instance, efficient translation in E. coli requires a Shine-Dalgarno (“SD”) sequence about -9 bases 5′ to the initiation codon (ATG) to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host cell ribosomes can be employed. Such combinations include but are not limited to the SD-ATG combination from the CRO gene or the N gene of coliphage lambda, or from the E. coli tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides can be used.

Any of the conventional cloning methods for insertion of DNA fragments into a vector can be used to ligate the promoter and other control elements into specific sites within the vector. Accordingly, gene sequences containing those regions coding for the calcium channel α₁ subunit of the invention and/or the calcium channel β subunit of the invention can be ligated into an expression vector at a specific site in relation to the vector promoter and control elements so that when the recombinant DNA molecule is introduced into a host cell the foreign genetic sequence can be expressed (i.e., transcribed and translated) by the host cell.

As previously mentioned, the recombinant DNA molecule(s) can be introduced into appropriate host cells (including but not limited to bacteria, virus, yeast, vertebrate and invertebrate cells or the like) by transformation, infection or transfection (depending upon the vector/host cell system). Transformants are selected based upon the expression of one or more appropriate gene markers normally present in the vector, such as ampicillin resistance or tetracycline resistance in pBR322, or thymidine kinase activity in eucaryotic host systems. Expression of such marker genes should indicate that the recombinant DNA molecule is intact and is replicating. Expression vectors may be derived from cloning vectors, which usually contain a marker function. Such cloning vectors may include, but are not limited to the following: SV40 and adenovirus, vaccinia virus vectors, insect viruses such as baculoviruses, yeast vectors, bacteriophage vectors such as lambda gt-WES-lambda BC, lambda gt-1-lambda B, M13mp7, M13mp8, M13mp9, or plasmid DNA vectors such as pBR322, pAC105, pVA51, pACYC177, pKH47, pACYC184, pUB110, pMB9, pBR325, Col E1, pSC101, pBR313, pML21, RSF2124, pCR1, RP4, pBR328 and the like.

The expression vectors containing the foreign gene inserts (i.e., DNA encoding the calcium channel α₁ and/or β subunits of the invention) can be identified by three approaches: (1) DNA-DNA hybridization using probes comprising sequences that are homologous to the gene(s); (2) presence or absence of “marker” gene function and (3) expression of inserted sequences based on physical, immunological or functional properties. Once a recombinant which expresses the gene is identified, the gene product should be analyzed. Immunological analysis is especially important because the ultimate goal is to use the gene(s) or recombinant expression systems that express the gene(s) in assays for screening chemical agents. Once the calcium channel α₁ and/or β subunit is identified, it is cultured under conditions which facilitate growth of the cells and expression of the gene as will be apparent to one skilled in the art, then isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard techniques. In addition, since the amino acid sequence is known from the DNA sequence of the invention, the calcium channel α₁ and/or β subunit can be synthesized by chemical methods according to the procedure of Hunkapiller et al., (1984), Nature, vol. 310, pp. 105-111, which disclosure is hereby incorporated by reference.

The functional calcium channel produced by expression of the calcium channel α₁ and/or β subunit gene of the invention, can be used to screen for pesticides that are effective in the control of insects. It is known that the insect calcium channel forms a particularly attractive site for pesticides due to pronounced differences in its pharmacology with that of vertebrates, as described in Glossman, British Pharmacology, V. 102, pp 446-452 (1991), which disclosure is hereby incorporated by reference. Due to those differences in insect and vertebrate calcium channel pharmacology, cells transformed to include the insect calcium channel formed in accordance with the present invention can be exposed to various potential insecticides and pesticides and evaluated for their susceptibility to the agents to develop and identify insect control agents that will not cause adverse effects to vertebrate species. Exemplary methods of screening are described in Eldefrawi et al., (1987), FASEB J., vol. 1, pp. 262-271; and Rauh et al., (1990), Trends in Pharmacol. Sci., vol. 11, pp. 325-329, which disclosures are hereby incorporated by reference.}

The following Examples are provided to further illustrate the present invention.

EXAMPLE I Methods

1. Polymerase Chain Reaction (“PCR”):

Primer sites were selected by aligning cDNA sequences for α₁ subunits of calcium channels from rabbit skeletal muscle (Tanabe et al., (1987), Nature, vol. 328, pp. 313-318, which disclosure is hereby incorporated by reference), heart (Mikami et al., (1989), Nature, vol. 340, pp. 230-233, which disclosure is hereby incorporated by reference) and brain (Mori et al., (1991), Nature, vol. 350, pp. 398-402, which disclosure is hereby incorporated by reference), rat aorta (Koch et al., (1990), J. Biol. Chem., 265, pp. 17786-17791, which disclosure is hereby incorporated by reference), and fish skeletal muscle (Grabner et al., (1991), Proc. Nati. Acad. Sci. USA, vol. 88, pp. 727-731, which disclosure is hereby incorporated by reference) to identify the most highly conserved regions with the least amount of codon degeneracy. Inosine was used when A, T, G, and C were all a possibility at a given site (Martin et al., (1985), Nucleic Acids Res., vol. 13, p. 8927 and Knoth et al., (1988), Nucleic Acids Res., vol. 16, p. 11932, which disclosures are hereby incorporated by reference). FIGS. 1 and 3 show the positions of a successful primer pair (P6 and P7) in the carboxy portion of the channel. Primer P6 lies within IVS5 and has the sequence: 5′ AT[C/T/A]G[T/C]IATG[C/T]TITT[C/T]TT[CT]ATITA[C/T]GC3′(“SEQ. ID. NO: 44”) Primer P7 lies between IVS6 and the putative EF hand and has the sequence: 5′ TC[G/A]TCIA[G/A][G/A]TG[G/A]TGIGGICCIA-[G/A][G/A/T]AT3′(“SEQ. ID. NO: 45”). FIG. 1 additionally shows that there are 4 repeat units designated I, II, III, and IV which are similar in structure to each other. Within each repeat there are six transmembrane domains designated 1 through 6 (aka S1-S6) which are thought to form α-helical structures through the membrane. The S4 regions have positively charged amino acids every 3 to 4 residues which are thought to align on one side of the α-helix to form the voltage sensor. In addition to the membrane spanning domains, the extracellular region which falls between regions S5 and S6 in each repeat is thought to dip into the membrane forming short segments SS1 and SS2 involved in the ion selectivity filter of the channel. Furthermore, the cDNA clones shown in FIG. 1 were isolated from a head library using as a probe the 499 base pair PCR amplification product from primers shown in A (SH22C) or the 5′ ends of clones SH22C or W8A. The diagram shows the overlap among the clones. FIG. 3 further shows that in situ hybridization to Drosophila salivary gland polytene chromosomes using a biotinylated probe (bases 4252-5795, FIG. 2) mapped this gene to 35EF on the left arm of chromosome 2. This same position was seen using a variety of other probes from W8A and SH22C (data not shown) suggesting that these overlapping cDNAs (FIG. 1) are encoded by the same gene.

2. Reaction Conditions For Cross Species Amplifications:

The template for the polymerase chain reaction was 150 ng of Drosophila genomic DNA prepared from adult flies as described by Jowett, T., (1986), In: Drosophila: A Practical Approach, Roberts, D. B. (ed.), IRL Press (Oxford), which disclosure is hereby incorporated by reference. The 50 μL reaction mixture contained: 0.2 mM of each of the dNTPs, 10 mM Tris (hydroxymethyl) aminomethane (Tris) buffer pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 0.1 μM of each primer, and 1.25 units AmpliTaq™ DNA polymerase from Perkin Elmer Cetus (Norwalk, Conn.). Following an initial 2 minutes at 95° C., the following cycle was repeated 35 times: denaturation 2 minutes at 95° C., annealing 2 minutes at 40° C., extension 2 minutes at 72° C. The final extension was 10 minutes at 72° C. PCR products were analyzed by electrophoresis of 10 μL of reaction mix on a 1% agarose gel.

3. DNA Sequencing:

The band containing the PCR product of interest was extracted from the gel by the phenol/freezing method of Benson, S. A., (1984), Biotechniques, vol. 2, pp. 66-68, which disclosure is hereby incorporated by reference), resuspended in Tris EDTA buffer, ph 8.0 (TE buffer, ph 8.0) (Sambrook et al., (1989), In: Molecular Clonina: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., which disclosure is hereby incorporated by reference) to a concentration of 10-20 ng/μL and 25 ng template was used for reamplification in 100 μL reactions prior to sequencing. The PCR conditions were as described above, except that the annealing temperature was 65° C. Sequencing templates were purified and concentrated using Centricon-100 columns (Amicon, Danvers, Mass.). Double-stranded DNA sequencing was performed on an Applied Biosystems Sequencer Model 373A using the dideoxy chain termination method with fluorescent dye-tagged M13 or SP6 primers according to instructions supplied with a Taq Dye Primer Cycle Sequencing kit (Applied Biosystems, Inc., Foster City, Calif.). Using this approach 300-400 bases were generally read from each template. Each segment of DNA was sequenced at least twice in each direction. For sequencing PCR products without subcdoning or for sequencing phage clones, new tailed primers were synthesized adding an 18 nucleotide M13 or SP6 sequence to the 5′ end of the original PCR primer sequence.

4. Screening For cDNA Clones:

A total of 2×10⁵ plaque-forming units (pfu) of a Drosophila head cDNA library in λgt11 (Itoh et al., (1986), Proc. Natl. Acad. Sci. USA, vol. 83, pp. 4081-4085, which disclosure is hereby incorporated by reference, generously provided by Dr. Paul Salvaterra, Beckman Research Institute, Duarte, Calif.) were screened on Nylon membranes (ICN, Costa Mesa, Calif.) using the 499 base pair amplification product from primer pair P6/P7. The probe was random-prime labeled with ³²P-dCTP using the Multiprime Kit (Amersham Corp., Arlington Heights, Ill.). Standard conditions were used for prehybridization, hybridization, and washing (Sambrook et al., (1989), cited elsewhere herein, which disclosure is hereby incorporated by reference). A 4 kb cDNA clone (SH22C) was isolated initially and further clones (including W8A and SH22D) were obtained using the 5′ end of SH22C. Since W8A did not contain the 5′ end of the open reading frame, rapid amplification of cDNA ends was done with the 5′ rapid amplification of cDNA ends (RACE) kit from Clontech (Palo Alto, Calif.) and a primer from the 5′ end of W8A and extended the sequence 360 bases upstream. Since this extension was still incomplete, the 5′ end of W8A was also used to isolate the N1 cDNA clone (FIG. 1B).

5. In situ Hybridization To Salivary Gland Chromosome Squashes:

The map position of cloned cDNAs was determined as described by Engels et al., (1985), Focus, vol. 8, pp. 6-8 and Murtagh et al., (1993), Biochemistry, vol. 32, pp. 6011-6018, which disclosures are hereby incorporated by reference, using biotinylated probes hybridized to salivary gland chromosomes.

6. Northern Blots:

Heads, bodies and legs were isolated from frozen adult flies as described by Schmidt-Nielsen et al. (1977), J. Neurochem., vol. 29, pp. 1013-1029, which disclosure is hereby incorporated by reference. Total RNA was prepared and poly(A)+ mRNA isolated by the guanidinium isothiocyanate-CsC1 gradient method followed by one passage over oligo (dT)-cellulose columns (Sambrook et al., (1989), cited elsewhere herein, which disclosure is hereby incorporated by reference). 10 μg of poly(A)+ RNA in TE was added to each lane of 0.8% agarose gel containing 6.3% formaldehyde and electrophoresed for 3 hours at 100 V using 1×MOPS buffer [(3-[N-Morpholino]propanesulfonic acid)] according to Sambrook et al. (1989), cited elsewhere herein, which disclosure is hereby incorporated by reference. The gel was capillary blotted onto a nylon membrane (Schleicher & Schuell, Keene, NH) and fixed by UV crosslinking. Prehybridization was for 6 hours at 42° C. in 50% deionized formamide, 5×SSPE, 5×Denhardt's, 0.5% sodium dodecyl sulfate (SDS), 100 μg/ml denatured salmon sperm DNA and then 10⁶ cpm/ml ³²P-labeled cDNA probe was added and the incubation continued for 16 hr at 42° C. The blot was washed 2 times for 15 minutes each at room temperature in 2×SSC, 0.1% SDS followed by 2 more washes for 30 minutes each at 65° C. in 0.1×SSC, 0.1% SDS. The blots were exposed to X-ray film at −70° C. Standard solutions (SSC, SSPE, Denhardt's) are as described by Sambrook et al. (1989), cited elsewhere herein, which disclosure is hereby incorporated by reference.

7. Reverse Transcriptase-Coupled PCR (“RT-PCR”):

First strand cDNA synthesis in 50 μL was conducted at 42° C. for 60 minutes using 1200 units/ml AMV (avian myeloblastosis virus) reverse transcriptase and 80 μg/ml poly(A)+ mRNA as described by Gubler, U. and Hoffman, B J., (1983), Gene, vol. 25, pp. 263-269, which disclosure is hereby incorporated by reference, with the following changes: 40 μg/ml oligo dT primer, 50 mM KCl, 0.5 mM spermidine, 1 mM each dNTP, 800 units/ml RNasin. The reaction was stopped with 1 mM EDTA (ethylenediaminetetraacetic acid) and 0.5 μL of the reaction mix was used for a 50 μL PCR as described for the cross species amplifications above except that 0.005% gelatin was used and the amplification was 35 cycles of: 95° C. 1 minute, 60° C. 1 minute, 72° C. 1 minute, followed by a final 5 minute extension at 72° C. Forty μL of the amplification reaction was electrophoresed and extracted from an agarose gel by the freezing phenol method as described above. DNA pellets were resuspended in 20 μL distilled water and 6 μL was used for each restriction enzyme digestion described in Table 1.

8. In situ Hybridization To Embryo Whole Mounts:

Whole mount in situ hybridization to Drosophila embryos was done as described by Tautz and Pfeifle, (1989), cited elsewhere herein, which disclosure is hereby incorporated by reference, using the formaldehyde fixation method. A single-stranded digoxigenin-labeled cDNA probe was prepared from a PCR product (bases 6488-6777 of the coding region, FIG. 2) which had been extracted from the gel using an Ultrafree-MC filter unit from Millipore Corp. (Bedford, MA), and concentrated using a Centricon-30 spin column. This purified PCR product (200 ng) was used as template to prepare single-stranded antisense DNA in a total volume of 25 μL using 5 μL of the nucleotide solution from vial 6 in the Genius Kit from Boehringer Mannheim (Indianapolis, IN), 2 μL primer stock for the antisense strand (10 μM), and 0.3 μL Taq polymerase (5U/μL). Amplification conditions for the synthesis of this single-stranded probe were: 94° C. 45 seconds, 55° C. 30 seconds, and 72° C. for 60 seconds, for a total of 25 cycles. Labeled probe was stored at −20° C.

EXAMPLE II Strategy For Cloning An α₁ Subunit Of Drosophila Calcium Channels

When these studies were conducted, it was evident that Drosophila had multiple calcium channel subtypes, at least some of which had a different pharmacological specificity from that reported for the cloned dihydropyridine from vertebrate skeletal muscle (Pauron et al., (1987), Biochemistry, vol. 26, pp. 6311-6315; Greenberg et al., (1989), Insect Biochem., vol. 19, pp. 309-322; Pelzer et al., (1989), EMBO J., vol. 8, pp. 2365-2371; Glossmann et al., (1991), Br. J. Pharmacol., vol. 102, pp. 446-452, which disclosures are hereby incorporated by reference). It was not clear, however, how much structural conservation would exist between Drosophila calcium channel subunits and those which had been cloned from vertebrates (Tanabe et al., (1987), Nature, vol. 328, pp. 313-318; Mikami et al., (1989), Nature, vol. 340, pp. 230-233; Koch et al., (1990), J. Biol. Chem., vol. 265, pp. 17786-17791; Mori et al., (1991), Nature, vol. 350, pp. 398-402; and Grabner et al., (1991), Proc. Natl. Acad. Sci. USA, vol. 88, pp. 727-731, which disclosures are hereby incorporated by reference). Since both the Drosophila head binding activity and the cloned vertebrate subunits were known to be phenylalkylamine sensitive, it was reasoned that at least some regions of the sequence were likely to be conserved. Using a polymerase chain reaction (“PCR”) based strategy allowed focus on short regions for primer design which were most likely to be conserved across species. Drosophila genomic DNA was used as a template to avoid assumptions concerning the tissue and stage in development when calcium channels would be expressed. Products approximately the same size as (or larger than) that predicted from vertebrate α₁ subunits were sequenced to identify those which encoded deduced amino acid sequences with structural similarity to the corresponding region of vertebrate calcium channel α₁ subunits. By including products larger than predicted from the vertebrate sequences, it allowed for the occurrence of introns in the genomic DNA used as template.

The product from primer pair P6/P7, spanning the region from IVS5 to a cytoplasmic region following IVS6 (FIG. 1A), had a deduced amino acid sequence very similar to that of vertebrate α₁ subunits except that the 3′ end of the IVS5 coding region and the middle of the IVS6 coding region were disrupted by 59 and 60 base pair introns, respectively. These introns were readily recognized using codon preference analysis from the University of Wisconsin Genetics Computer Group (GCG) software package.

Northern analysis showed that this Drosophila genomic fragment recognized a message that was expressed at a relatively high level in heads as would be expected for a neuronal calcium channel component (Greenberg et al., (1989), Insect Biochem., vol. 19, pp. 309-322, which disclosure is hereby incorporated by reference), so an adult head cDNA library was screened. The two longest cDNA clones, W8A and SH22C, with an overlap of 572 nucleotides were sequenced and combined as shown schematically in FIG. 1B. Although the sequence match between the two clones is excellent within the region of overlap (only 3 nucleotide discrepancies, indicated by open triangles in FIG. 2), there is a region of 149 nucleotides in W8A which shows no sequence similarity with SH22C. This nonmatch region begins in the intracellular loop between IIIS4 and S5 and extends into transmembrane domain IIS5. In situ hybridization to salivary gland chromosomes (FIG. 3) showed that both W8A and SH22C mapped to the same position at 35EF on the left arm of the second chromosome suggesting that the two cDNA clones are derived from the same gene. This was confirmed by sequencing a genomic clone and the SH22D cDNA clone in the regions flanking the non-overlap section. Sequence analysis revealed two alternatively spliced exons in this region.

The 5 end sequence of the cDNA was derived from the N1 clone. In addition, 5′ RACE (rapid amplification of cDNA ends) was done starting with poly (A)+ mRNA from Canton-S and a primer from the 5′ end of W8A. The RACE product extended only 360 bases upstream from the end of W8A whereas N1 clone provided 1116 bases upstream of the 5′ end of W8A. In the 360 bases of overlap between the RACE product and clone N1, there was an exact match except for three bases (indicated by the closed triangles in FIG. 2) within the proposed open reading frame. These differences did not affect the amino acid sequence and most likely represent sequence polymorphisms between DNA from different wild-type sources.

EXAMPLE III Structural Features Of The cDNA Sequence

The complete nucleotide sequence and the deduced amino acid sequence for the Drosophila α₁ subunit are shown in FIG. 2. (SEQ. ID. NO. 1 and SEQ. ID. NO. 2, respectively). Bases are numbered from the first of five possible AUG initiation codons all of which are marked with a *. Three nucleotides which differ in sequence between the N1 clone and the 5′ RACE product using Canton-S poly (A)⁺ mRNA are indicated with a closed triangle above the nucleotide. The sequence shown is from the N1 clone. The 3 nucleotides which differ between cDNA clones W8A and SH22C are indicated with an open triangle above each. The sequence shown is that found in W8A because those nucleotides have also been found in the corresponding genomic DNA sequence (D. Ren and L. M. Hall, unpublished). The deduced amino acid sequence is shown below the DNA sequence and the proposed transmembrane domains are indicated as labeled lines underneath the corresponding amino acid sequences. The position of a proposed calcium binding domain (the EF hand, Babitch, J., (1989), Nature, vol. 346, pp. 321-322, which disclosure is hereby incorporated by reference) is indicated by the heavy labeled line under the amino acids involved. The in-frame stop codons preceding and following the open reading frame are indicated with a dark dot underneath the first base in each codon. The positions of the primers used in the initial PCR amplification of genomic DNA are indicated by the boxed gray areas of the nucleic acid sequence with labels P6and P7 directly above them. This sequence was submitted to GenBank and received Accession No. U00690.

The carboxy terminus of the deduced protein is unambiguously determined by the TAG stop codon at nucleotide position 7549-7551 which is followed by 10 additional in-frame stop codons (indicated by a black dot below the first nucleotide in each triplet). There is no polyadenylation consensus sequence (AAUAAA) in the 3′ untranslated region, so there may be some additional 3′ sequence which was not included in the SH22C clone. The total assembled cDNA sequence (˜8 kb) is about 1.5 kb shorter than the smallest message observed in Northern blotting experiments (FIG. 4). This may be due to missing 5′ and/or 3′ untranslated regions in the cDNA clones sequenced and/or to extensive polyadenylation.

With reference to FIG. 4, there is shown the Northern blot of poly(A)⁺ mRNA (10 μg/lane) isolated from bodies (B), heads (H), or legs (L) was probed with a PCR fragment (bases 6141-7511, FIG. 2) from clone SH22C and washed at high stringency. The tics on the right of the figure indicate positions of bands. The lower inset shows the results of reprobing with ribosomal protein 49 cDNA (rp49) to control for mRNA recovery and gel loading differences since rp49 is expressed uniformly throughout the organism and throughout the different developmental stages (see B below) (O'Connell, P. O. and Rosbash, M., (1984), Nucleic Acids Res., vol. 12, pp. 5495-5513, which disclosure is hereby incorporated by reference). A Northern blot (as in part A) consisting of mRNA isolated from embryos of different ages was hybridized with a ³²P-labeled double-stranded probe from W8A (nucleotides 961 to 2214, FIG. 2).

The most likely start translation start site is in the first methionine marked with a * since it is preceded by 3 in-frame stop codons within the 156 bases upstream as shown in FIG. 2. However, there are 4 additional methionines (also marked with a * underneath the M symbol in FIG. 2) encoded in the region between the first methionine and IS1. The area immediately upstream of each of these methionine codons was compared with the Drosophila translation start site consensus sequence (C/A AA A/C AUG) (Cavener, D. R., (1987), Nucleic Acids Res., vol. 15, pp. 1353-1361, which disclosure is hereby incorporated by reference).

The first methionine shows 0/4 matches. Although it lacks an A at the crucial −3 position, it has the second most commonly used base (G) at this position. The second, third and fifth methionines all have an A in the −3 position. In addition, the second (M494) and fifth (M553) methionines show 3 out of 4 nucleotide matches to the upstream consensus sequence for Drosophila. In Drosophila, the average fit to the 4 nucleotide consensus positions immediately upstream of a start codon is 3.1 matches. On the basis of nucleotide sequence, met494 and met553 could be start site candidates, however there are no upstream in-frame stop codons preceding them. Therefore, it is believed that metl is the start site.

EXAMPLE IV Tissue Distribution And Heteroceneity Of Dmca1D Message Expression

The relative expression of Dmca1D transcripts in different body parts was determined by Northern blot analysis using rp49 (a uniformly expressed ribosomal protein mRNA) (O'Connell, P. O. and Rosbash, M., (1984), Nucleic Acids Res., vol. 12, pp. 5495-5513, which disclosure is hereby incorporated by reference) as a control for amount of RNA loaded into each lane. As shown in FIG. 4A, poly(A)+ RNA from bodies (B), heads (H), and legs (L) were compared following hybridization with a probe from the 3′ end of clone SH22C. This probe contains the coding sequence for the nonconserved carboxy terminus of the α₁ subunit. All three preparations show a major band at 9.5 kb and a minor band at 12.5 kb. The minor band is seen most clearly in the head preparation. In addition, the head preparation shows a second major band at 10.2 kb. A similar result (data not shown) was obtained using a probe derived from W8A. The relationship among the three mRNA size classes is not known. The largest size class (12.5 kb) is a very weak signal in all lanes suggesting that it might be an unprocessed transcript or the product of another gene picked up by sequence similarity. Compared to messages expressed in heads, there is less heterogeneity in the message expressed in the bodies and legs since only one major band (9.5 kb) is visible.

To further investigate the difference in message heterogeneity among heads, bodies and legs, two regions where sequence data from 3 different cDNA clones (W8A, SH22C, and SH22D; see FIG. 1) had shown differences were reviewed. The positions of the regions studied are shown as open boxes in the SH22D clone in FIG. 1B. These differences could be most easily distinguished by RT-PCR (reverse transcriptase coupled PCR) amplification followed by a diagnostic restriction enzyme digestion. It should be noted that the differences in the actual nucleic acid sequences were extensive as expected for alternative splice products and could not be explained by single base changes due to sequence polymorphisms (D. Ren and L. M. Hall, unpublished). As shown in Table 1, in each of the two regions tested for alternative splicing, two different forms were found in heads but only a single form was found in bodies or legs. Embryos (which express this subunit only in the nervous system as shown in FIG. 5 and discussed below) show the same pattern of heterogeneity seen in heads. Taken together, these results again suggest there may be more functional heterogeneity in Dmca1D type calcium channels in neuronal tissue than elsewhere in the fly.

EXAMPLE V Temporal Pattern Of Expression Of Dmca1D

To determine when the Dmca1D message is expressed in Drosophila embryos, a Northern blot (FIG. 4B) containing poly(A)⁺ mRNA from a variety of embryonic stages was probed with two different Dmca1D specific probes: one from W8A (shown in FIG. 4B) and one from SH22C (from nucleotide 5665 in IVS6 to the end, data not shown). Regardless of which probe was used, expression of the 9.5 kb calcium channel message is detected faintly in embryos at 9 to 12 hours corresponding to the time when condensation of the nervous system begins (Kankel et al., (1980), In: The Genetics and Biology of Drosophila, vol. 2, Ashburner, M. and Wright, T. R. F., eds., Academic Press (New York), which disclosure is hereby incorporated by reference). Expression increases rapidly as the nervous system matures within the embryo, peaking just prior to hatching. A second peak of expression of the 9.5 kb message is observed in late pupal stages around 73 to 108 hours post puparium formation when the nervous system is completing a dramatic reorganization (F. Hannan, unpublished observations, which disclosure is hereby incorporated by reference).

EXAMPLE VI Embryonic Whole Mount in situ Hybridization

To determine where the message for this α₁ subunit is expressed, a digoxigenin-labeled antisense probe was used on embryonic whole mounts. As shown in the 13-15 hour embryo in FIG. 5, the Dmca1D subunit was preferentially expressed in the nervous system. A single-stranded, antisense DNA probe labeled with digoxigenin was hybridized to embryo whole mounts and the signal detected as described by Tautz, D. and Pfeifle, C., (1989), Chromosoma, vol. 98, pp. 81-85, which disclosure is hereby incorporated by reference. The dark staining pattern highlights the round, dorsal cerebral hemisphere and the ventral ganglion which comes off the ventral side of the sphere and curves posteriorly on the ventral surface of the embryo.

EXAMPLE VII General Structural Features Of The Deduced Amino Acid Sequence

Using the first in-frame AUG (metl) following a series of in-frame stop codons as the translation start site, FIG. 2 shows that the open reading frame of the combined cDNA clones would encode a protein of 2516 amino acids with an expected molecular weight of 276,493 and a predicted pI of 5.04. The hydrophobicity plot of this complete deduced protein is shown in FIG. 6A where it is compared with the calcium channel type D α₁ subunit from rat brain (FIG. 6B). Hydropathy plots were determined using the method of Kyte, J. and Doolittle, R. F., (1982), J. Mol. Biol., vol. 157, pp. 105-132, which disclosure is hereby incorporated by reference, with the GeneWorks software. If the second AUG is the actual translation start site, the Drosophila protein would consist of 2023 amino acids and have a predicted molecular weight of 224,369 and a pI of 6.49. If it begins with the fifth AUG, the protein would consist of 1964 amino acids with a predicted molecular weight of 218,580 and a predicted pI of 6.78. Just as in the vertebrate calcium channel α₁ subunits, the Drosophila subunit shows four repeat domains (indicated by the bars in FIG. 6 labeled I through IV). Each of these repeats shows 6 hydrophobic domains (labeled 1 through 6) which would be long enough to span the membrane. The resemblance to the vertebrate α₁ hydropathy plots is striking in the hydrophilic as well as the hydrophobic domains. The only places where there are differences are in the cytoplasmic amino and carboxy terminal tails. Both regions are much longer in Drosophila than in the vertebrate homologues. Although there is striking similarity in the region of the carboxy tail closest to transmembrane region IVS6, the similarity falls off after about 163 amino acids from the end of the IVS6 region when the Drosophila sequence is compared with the rat brain D sequence or after 199 amino acids when compared with the rabbit skeletal muscle sequence (comparison not shown). On the amino terminal end the similarity to the vertebrate homologues falls off after about 40 to 50 amino acids upstream of the beginning of IS1.

The repeat structure and the pattern of the hydrophobic domains puts this newly cloned Drosophila protein in the same super family as the voltage-gated sodium and calcium channels. As shown in Table 2, when the deduced protein is compared with available sequences for sodium and calcium channels, in general there is more similarity in amino acid sequence between the Drosophila clone and vertebrate calcium channels (ranging from 63.4 to 78.3%) than between this sequence and sodium channels (57.9 to 58.9%) even if the sodium channel is from Drosophila. These differences are even more striking if amino acid identity is considered (42.7 to 64.2% identity for calcium channels versus 29.6 to 30.5% for sodium channels). Thus, based on overall sequence similarity, the newly cloned gene would be designated as a member of the calcium channel gene family.

Within the calcium channel group, the Drosophila sequence shows the closest relationship to rat brain type D. The next highest scoring channel from rabbit skeletal muscle shows ˜8% less identity and ˜6% less similarity than the rat brain type D channel. Based on this sequence similarity hierarchy and on its expression in the nervous system, the Drosophila channel was designated as Drosophila melanogaster calcium channel alpha 1 subunit type D (“Dmca1D”).

As for other members of the voltage-sensitive cation channel family, each of the S4 transmembrane domains of the newly cloned channel subunit shows positively charged amino acids (R=arginine or K=lysine) every third or fourth amino acid. In a commonly proposed model, this pattern would put all of the positively charged side chains on the same side of an alpha helix so that they sit in the membrane as the voltage-sensor (Stühmer et al., (1989), Nature, vol. 339, pp. 597-603, which disclosure is hereby incorporated by reference). As summarized in Table 3, the Drosophila protein shows the same general pattern as the majority of other calcium channels with 5 positively charged side chains in the S4 helices in domains I, II, and IV and 6 in domain III. Only the rat brain A and B and rabbit brain-1 channels deviate from this pattern.

EXAMPLE VIII Proposed Calcium Binding EF Hand Region

Another feature commonly found in both sodium and calcium channel α₁ subunits is a protein motif known as the EF hand, which consists of two α-helices flanking a calcium binding loop (Babitch, J., (1990), Nature, vol. 346, pp. 321-322, which disclosure is hereby incorporated by reference). As indicated by the heavy underlined region beginning 20 amino acids downstream from the IVS6 region in FIG. 2, an EF hand is found in the Drosophila sequence. As shown in Table 4 (SEQ ID. NOS: 52-65), in the Tufty-Kretsinger test (Tufty, R. M. and Kretsinger, R. H., (1975), Science, vol. 187, pp. 167-169, which disclosure is hereby incorporated by reference) the Dmca1D sequence has 11 matches (out of 16 possibilities) for residues important for calcium binding. The number of matches for Dmca1D can be increased to 14 by allowing conservative amino acid substitutions. Many vertebrate calcium channel α₁ subunits show a similar pattern of matching (Babitch, J., (1990), Nature, vol. 346, pp. 321-322, which disclosure is hereby incorporated by reference). Again, the Drosophila sequence shows more similarity to calcium channels than to sodium channels in this critical area.

EXAMPLE IX Ion Selectivity Filter

A portion of the sodium channel involved in the ion selectivity filter has been identified within short segment 2 (SS2) lying between S5 and S6 in all repeats (Heinemann et al., (1992), Nature, vol. 356, pp. 441-443, which disclosure is hereby incorporated by reference). By changing a single amino acid residue (K1422 in repeat III or A1714 in repeat IV of rat sodium channel II) to a negatively charged glutamic acid (E) (as is found in calcium channels), the ion selectivity of the channel can be changed from that of a sodium channel to resemble that of a calcium channel. Recently, Tang et al., (1993), J. Biol. Chem., vol. 268, pp. 13026-13029, which disclosure is hereby incorporated by reference, have done the reciprocal experiment on cardiac calcium channels and have shown that modification of conserved glutamate residues in the SS2 region of repeats I, II, or IV alters the ion selectivity and permeability of calcium channels. Table 5 (SEQ. ID. NOS: 66-99) compares the SS2 sequences of the newly cloned Dmca1D cDNA with those of other sodium and calcium channels. In general, the new Drosophila sequence resembles the calcium channel sequences more closely than it does the sodium channel sequences. In the crucial region of repeats I, II, III and IV all of the negatively charged glutamic acids (bold E) found in calcium channels have been conserved in the Drosophila sequence, providing further evidence that Dmca1D encodes a calcium channel subunit. The conservation of glutamate residues in all four SS2 regions is consistent with the suggestion of Tang et al. (1993), cited above, which disclosure is hereby incorporated by reference, that these residues form a ring in the pore-lining SS1-SS2 region involved in ion selectivity and permeability.

EXAMPLE X Possible Sites For Posttranslational Modification Of The Protein Encoded By Dmca1D

There are 2 partially overlapping, possible N-linked glycosylation sites (NX[S/T]X) (N644 and N647) (SEQ. ID. NO. 46) in the Drosophila α₁ subunit located in a region of the protein predicted to be external to the plasma membrane. (X generally is any amino acid, but in this site only X refers to any amino acid except P.) These asparagines fall in the loop between IS1 and IS2 which is predicted to be extracellular (see FIGS. 1 and 2). There are 8 possible cAMP-dependent protein kinase phosphorylation sites ([R/K]XX[S/T]) (SEQ. ID. N: 47) lying in predicted cytoplasmic domains. Six are in the amino terminal region; one is in the region between IIS6 and IIIS1, which, in skeletal muscle L-type channels, has been implicated in excitation-contraction coupling processes (Tanabe et al., (1990), Nature, vol. 346, pp. 567-569, which disclosure is hereby incorporated by reference); one is in the carboxy terminus in the cytoplasmic region corresponding to the calcium-binding EF hand. In addition, there are 21 possible protein kinase C phosphorylation sites ([S/T]X[R/K]). Twelve of these are in the amino terminus; 2 are in the region between IIS6 and IIIS1; and 7 are in the carboxy terminal tail. There are also 27 possible casein kinase phosphoration sites ([S/T]XX[D/E]) (SEQ. ID. NO: 48) 12 in the amino terminus, 1 each in the loops IS6/IIS1 and IIIS6/IVS1, 4 in loop IIS6/IIIS1, 1 at the cytoplasmic end of IVS4, and 8 in the carboxy terminal tail. The high concentration of potential phosphorylation sites within several regions (the amino terminus, the II/III cytoplasmic loop and the C terminal tail) suggests that they may play roles in channel modulation by phosphorylation.

EXAMPLE XI Comparison Of Sequences In Region Of The Proposed Phenylalkylamine-Binding Domain

The phenylalkylamines constitute an important class of organic calcium channel blockers. A proposed binding site for phenylalkylamines has been localized to a 42 residue segment extending from E1349 to W1391 in the rabbit skeletal muscle subunit (Striessnig et al., (1990), Proc. Natl. Acad. Sci. USA, vol. 87, pp. 9108-9112, which disclosure is hereby incorporated by reference). This region (shown by hatched underline in FIG. 7) includes transmembrane domain IVS6 and adjacent intracellular and extracellular segments. Since phenylalkvlamines exert their blocking effects from the inner surface of the membrane (Hescheler et al., (1982), Pflügers Arch., vol. 393, pp. 287-291; Affolter, J. and Coronado, R., (1986), Biophys. J., vol. 49, pp. 767-771, which disclosures are hereby incorporated by reference), the binding site for this class of blockers is thought to include the intracellular side of transmembrane segment IVS6 and the adjacent intracellular amino acids (Striessnig et al., (1990), Proc. Natl. Acad. Sci. USA, vol. 87, pp. 9108-9112, which disclosure is hereby incorporated by reference). In FIG. 7, starting with the intracellular amino acids (right end of the hatched underline) and proceeding to the left into the transmembrane region IVS6, it is apparent that this segment is completely conserved between Drosophila (upper line) and rabbit skeletal muscle (lower line) until about halfway through the transmembrane region where there is a weakly conserved change from alanine (A) in the rabbit to serine (S) in Drosophila and a highly conserved change from methionine (M) to valine (V). This high degree of conservation predicts that this Drosophila subunit should bind phenylalkylamines with high affinity.

EXAMPLE XII Sequence Comparisons Relevant To Dihydropyridine Sensitivity

Among the calcium channel α₁ subunits listed in Table 2, the Drosophila subunit is most similar in sequence to those isoforms which have been shown to be dihydropyridine (“DHP”) sensitive (indicated by+in this table). The four isoforms which are known to be insensitive to dihydropyridines (rat brain A and B, rabbit brain-1, and human N-type) show the least similarity to the Drosophila sequence. Another correlation is seen if the length of the cytoplasmic loop between repeats II and III is considered since all the known dihydropyridine-sensitive subunits have a short loop (134 to 150 amino acids in length) whereas the insensitive subunits have a much longer loop, ranging in length from 479 to 539. By this criterion, the Drosophila sequence would also fall into the DHP-sensitive category with a loop length of 129 amino acids.

A model for dihydropyridine-binding sites has been developed using photoaffinity labeling with dihydropyridines and has implicated the extracellular sides of transmembrane segments IIIS6 and IVS6 and the extracellular amino acids immediately adjacent to these transmembrane regions (Nakayama et al, (1991), Proc. Natl. Acad. Sci. USA, vol. 88, 9203-9207; Striessnig et al., (1991), Proc. Natl. Acad. Sci. USA, vol. 88, pp. 10769-10773; Catterall, W. A. and Striessnig, J., (1992), TIPS, vol. 13, pp. 256-262, which disclosures are hereby incorporated by reference). The segments involved are shown by the black underline in FIG. 7. In the portions of those two segments which include the left end (extracellular surface) of both S6 segments and the regions which extend to the left from the shaded transmembrane region, there are many amino acid differences (filled triangles above point to the changes) including: 8 nonconserved amino acid substitutions in the region adjacent to IIIS6 and extending into the extracellular side of S6. In region IVS6 and the adjacent extracellular amino acids, there are three nonconserved substitutions and two deletions (involving one and two amino acids) in the Drosophila sequence compared with the rabbit. The functional significance of these changes can be addressed by expression of this new subunit. The large number of changes in this region are consistent with the cloned channel being the dihydropyridine-insensitive, phenylalkylamine-binding activity which predominates in Drosophila head membranes (Greenberg et al., (1989), Insect Biochem., vol. 19, pp. 309-322, which disclosure is hereby incorporated by reference) even though the cloned channel falls into the same structural category as vertebrate dihydropyridine-sensitive subunits.

RESULTS

1. Invertebrate voltage-dependent calcium channels belong to the same multigene family as those in mammals:

It was clear that Drosophila had calcium channels in both neurons and muscles, but the pharmacological specificity of these channels was apparently different from that described for the vertebrate L-type channel from skeletal muscle (Pauron et al., (1987), Biochemistry, vol. 26, pp. 6311-6315; Greenberg et al., (1989), Insect Biochem., vol. 19, pp. 309-322; Pelzer et al., (1989), EMBO J., vol. 8, pp. 2365-2371; Glossman et al., (1991), Br. J. Pharmacol., vol. 102, pp. 446-452, which disclosures are hereby incorporated by reference) since the predominant channel in Drosophila heads was phenylalkylamine sensitive and dihydropyridine insensitive. In addition, other pharmacological differences were apparent in side-by-side comparisons of guinea pig skeletal muscle with Drosophila head extracts (Glossmann et al., (1991), Br. J. Pharmacol., vol. 102, pp. 446-452, which disclosure is hereby incorporated by reference). Using PCR with degenerate primers, we were able to rapidly cross species to isolate the first invertebrate calcium channel α₁ subunit using information from vertebrate homologues. Our results indicate that despite pharmacological differences across species, insect calcium channel α₁ subunits belong to the same multigene family as mammalian α₁ subunits. The subunit described here shows the same 4 repeat structure, each containing 6 transmembrane segments, that is the characteristic pattern for voltage-dependent calcium channels. This Drosophila sequence highlights regions of α₁ subunits which have been conserved across large evolutionary distances and therefore will facilitate the design of primer pairs for cloning homologous subunits from other invertebrate preparations of physiological importance or for cloning this subunit from pest insects.

2. Analysis Of Dmca1D Suggests Heterogeneity Of Neuronal α₁ Subunits:

In the tissues tested, the size of the mRNA on Northern blots is larger (9.5, 10.2, or 12.5 kb) than the cDNA sequence which we report here (8.0 kb). One possible explanation for this difference is that some untranslated regions are missing from the 5′ and 3′ ends. Indeed, we have not found a polyadenylation site on the 3′ end. The finding of multiple in-frame stop codons in both the 5′ and 3′ untranslated regions provides strong evidence that the sequence presented here contains the full length open reading frame. The predominant forms seen on the Northern blot (FIG. 4) may represent major differences due to alternative splicing. Preliminary comparisons between genomic and cDNA using PCR have demonstrated the presence of at least 22 introns ranging in size from 55 base pairs to 3 kb (D. F. Eberl and D. Ren, unpublished observations, which are hereby incorporated by reference). We demonstrate here that alternative splicing occurs in at least two of these intron regions, but there are still many additional regions to be characterized. Depending on how the alternative splicing is done, it is possible to generate a large variety of mRNAs which will encode subunit forms with potentially different properties. Preliminary results suggest that this calcium channel subunit will show much heterogeneity due to alternative splicing. Indeed, the Drosophila sodium channel a subunit has the potential to express more than 48 different splice variants and at least 19 of which have been identified to date (J. R. Thackery and B. Ganetzky, 1994, J. Neurosci, 14:2569-2578.

In view of the wide variety of potential alternative splice forms, it should be emphasized that the cDNA sequence shown in FIG. 2 represents the synthetic fusion of sequence information from two cDNA clones joined in a region of overlap within repeat III. Because of the large size of the full length message, it has not been possible to isolate a single cDNA clone that contains a complete open reading frame. One challenge of future work on this calcium channel subunit will be to identify physiologically relevant forms and define functional differences resulting from alternative splicing.

Using the Dmca1D cDNA as a probe in Northern blot analysis, there is more α₁ subunit heterogeneity in heads than in bodies and legs since a prominent band at 10.2 kb is seen in heads and is not detected in bodies and legs. Only the 9.5 kb band is seen in all preparations. The heads would be enriched for nervous system compared to bodies and legs so the heterogeneity which we see in size of mRNA from heads could, in part, be due to functional diversity of channels expressed in neurons. This is interesting because it mirrors the greater heterogeneity observed by Leung, H. T. and Byerly, L., (1991), J. Neurosci., vol. 11, pp. 3047-3059, which is hereby incorporated by reference, in the physiological properties of neuronal compared to muscle calcium channels in primary cultures of neurons and muscle from Drosophila embryos.

Indeed, there could be much more heterogeneity than reflected by our Northern analysis with respect to the Dmca1D gene since alternatively spliced messages close in size would not be readily distinguished by Northern blot analysis of a message of this large size. PCR analysis of cDNA using strategically placed primers is a more sensitive approach. In the preliminary PCR experiment summarized in Table 1 we again see more heterogeneity in heads than in bodies and legs. Pelzer et al., (1989), EMBO J., vol. 8, 2365-2371, which disclosure is hereby incorporated by reference, found 8 different conductance levels for calcium channels when Drosophila head membranes were reconstituted into lipid bilayers. These conductances were found in single channel activity records and did not interconvert suggesting that each activity results from a different type of channel molecule. It is possible that these functionally distinct, nonconverting channel subtypes reflect, in part, the alternative splicing which we observe in Dmca1D expressed in Drosophila head mRNA. Functional expression of different splice variants of this cloned calcium channel subunit will allow us to define the molecular basis of these biophysically and pharmacologically distinct channel subtypes.

3. Relationship of Dmca1D To Previously Studied Calcium Channel Activities In Drosophila:

The clones used to construct the full length Dmca1D cDNA were all isolated from a head cDNA library. Thus, Dmca1D is a candidate for encoding the predominant phenylalkylamine-sensitive, dihydropyridine-insensitive binding activity found in Drosophila head membranes. The complete conservation of the phenylalkylamine-binding site in the Dmca1D deduced protein coupled with the numerous changes in the proposed dihydropyridine-binding domains are consistent with this suggestion. There is, however, one difficulty in equating Dmca1D with the previously characterized phenylalkylamine-binding activity in heads and that is that there is a substantial size difference between the deduced amino acid sequence of Dmca1D (219-276 kDa) and the photoaffinity labeled phenylalkylamine-binding components (136 and 27 kDa) (Greenberg et al., (1989), Insect Biochem., vol. 19, pp. 309-322; Pauron et al. (1987), Biochemistry, vol. 26, pp. 6311-6315, which disclosures are hereby incorporated by reference). Even if the two photoaffinity labeled components are actually part of the same protein, they still add up to only 166 kDa. There are several possible explanations for this size discrepancy. It could be due to alternative splicing and the predominantly expressed form of Dmca1D might be a different splice variant from the one presented here. Alternatively, it could be caused by a physiologically relevant proteolysis required for the maturation/activation of the subunit. The deduced Drosophila protein seems to be much larger in size than its vertebrate counterparts and it will be interesting to determine whether the long amino and carboxy tails are required for physiological function. The size difference might also be an artefact reflecting anomalous electrophoretic mobility of a large membrane protein on SDS gels or an artefact reflecting proteolysis during and/or following photoaffinity labeling. Indeed, the carboxy tail of the deduced protein sequence of Dmca1D contains a motif resembling the active site of thiol (cysteine) proteases. Thus, this subunit might catalyze its own cleavage. A final possibility is that the cloned subunit might be the product of a different gene from the one encoding the product seen by phenylalkylamine-photoaffinity labeling in head extracts. Although this seems unlikely in light of the high degree of conservation of the phenylalkylamine-binding site in Dmca1D, there is preliminary evidence for a distinct gene encoding another calcium channel α₁ subunit in Drosophila (L. A. Smith and J. C. Hall, personal communication, which disclosure is hereby incorporated by reference).

Determination of the pharmacological properties of Dmca1D will have to await functional expression. Regardless of its pharmacological specificity, as the first insect calcium channel subunit, the Drosophila α₁ remains the evolutionarily most distant of the sequences described to date. Sequence comparisons coupled with functional studies of chimeric molecules should provide useful information concerning the nature of drug binding sites.

4. Using Genetics To Define Subunit Properties In The Organism:

One of the primary motivating factors in extending calcium channel molecular biology studies to Drosophila is the abilhty to use genetics to inactivate subunit genes singly and in combination in order to define functional roles within the organism. The chromosome mapping studies described here show that the newly cloned Dmca1D gene falls within a well-studied region of the Drosophila genome (see Ashburner et al., (1990), Genetics, vol. 126, pp. 679-694, which disclosure is hereby incorporated by reference). This region includes several lethal mutations. Recently, we have demonstrated that one of these embryonic lethal mutations causes a premature stop codon within the open reading frame of the Dmca1D gene (D. F. Eberl, D. Ren, G. Feng and L. M. Hall, unpublished observations, which disclosures are hereby incorporated by reference). Genetic analysis of double mutants from this and other calcium channel subunits will allow us to define which subunits actually interact in vivo. Transformation rescue experiments (Spradling, A. C., (1986), In: Drosophila: A Practical Approach, Roberts, D. B., ed., IRL Press, Washington, D.C., pp. 175-197, which disclosure is hereby incorporated by reference) using this α₁ subunit will allow us to test whether there is functional overlap among the different genes encoding homologous subunits and to determine the role in vivo of the different splice variants of this gene.

EXAMPLE XIII Cloning of a Drosophila β Subunit

The Drosophila β subunit was cloned using reduced stringency PCR with degenerate primers to amplify a conserved fragment using whole fly cDNA as the template. The degenerate primers were designed from conserved regions of the available $ subunits from: rabbit [Ruth et al. (1985), Science, vol 245, pp. 1115-1118; Hullin et al. (1992) EMBO J. vol 11, pp 885-890], rat [Perez-Reyes. et al. (1992), J. Biol. Chem., vol 267, pp. 1792-1797; Pragnell et al. (1991) FEBS Lett. vol 291, pp 253-258], and human [Harpold et al. (1992), Neuron, vol 8, pp. 71-84]. The forward primer, corresponding to rabbit β1 amino acids 141-146 (SEQ ID NO: 100) (NNDWWI) [Ruth et al. (1985), Science, vol 245, pp. 1115-1118], had the nucleotide sequence (SEQ ID NO: 49): 5′GTGGATCCAA(CT)AA(CT)GA(CT)TGGTGGAT3′. The reverse primer, corresponding to amino acids 291-296 (SEQ ID. NO: 101) 9DMMQKA) of rabbit β1 [Ruth et al. (1985), Science, vol 245, pp. 1115-1118] plus a 5′ BamHI site, had the nucleotide sequence (SEQ ID. NO: 50): 5′ACGGATCCGC(TC)TT(TC)TGCATCAT(GA)TC3′. To prepare the cDNA template, first strand cDNA was synthesized from whole fly poly(A)⁺ selected mRNA [Gubler et al. (1983), Gene, vol 25, pp. 263-269] with modifications described by Zheng et al. [Zheng et al. (1994), J. Neurosci (in press)]. First strand cDNA (0.1 μL) was used as template in a 50 μL PCR reaction containing: 0.2 mM each DNTP, 10 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 0.14M each primer and 1.25 units AmpliTaq DNA polymerase (Perkin Elmer Cetus, Norwalk, Conn.). Amplification involved 35 cycles of: 94° C. 30 sec, 50° C. 30 sec., 72° C. 60 sec, followed extension at 72° C. 10 min and storage at 40° C. After this amplification, a second 25 cycle amplification was done using 5 ul of the product as template in a 100 μL reaction. PCR products were separated by agarose gel electrophoresis, purified by the freezing phenol method, and subcloned into the EcoRV site of pBluescript II™ (Stratagene, Calif.) using T-A subcloning [Ausubel, 1987 #1452].

Clone B6 which had the highest sequence similarity to vertebrate β subunits was used for subsequent high stringency library screening [Sambrook et al. (1989), Molecular Cloning: A laboratory manual. 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.] following labelling with ³²P-dCTP by the random primer method (Megaprime DNA labeling system™, Amersham Corp., Arlington Heights, Ill.). Approximately 6×10⁵ plaque-forming units from a Drosophila head cDNA library in λgt11 (provided by Dr. Paul Salvaterra, Beckman Research Institute, Duarte, CA [Itoh et al. (1985), PNAS, vol 83, pp. 4081-4085]) were screened to isolate the clones summarized in FIG. 8.

EXAMPLE XIV DNA Sequencing

Plasmid DNAs prepared by a mini-preparation protocol [Sambrook et al. (1989), Molecular Cloning. A laboratory manual. 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.] or PCR products generated in a 100 ul reaction as described above (using instead 0.05 mM of each DNTP and 0.05 uM of each primer) were used as sequencing templates. Amplification involved 35 cycles of 94° C. 1 min, 65° C. (or 60° C. for some reactionys) 1 min, 72° C. for 1 min, followed by a final 10 min extension at 72° C. and storage at 4° C. PCR primers for sequencing samples were tagged with M13, M13 reverse or SP6 primer sequences. Prior to sequencing PCR products were purified with the Magic PCR™ DNA purification kit (Promega). Sequencing was by the dideoxy chain termination method (Sanger et al. (1977), PNAS, vol 74, pp. 5463-5467) using Taq Dye Primer Cycle Sequencing kits (Applied Biosystems, Inc., Foster City, Calif.) and an Applied Biosystems Sequencer (Model 373A).

Whole mount in situ hybridization to Drosophila embryos followed the protocol of [Tautz et al. (1989), Chromosoma, vol 98, pp 81-85] using formaldehyde fixation and a single-stranded digoxigenin-labeled probe (nucleotides 848 to 1167, prepared as described in Zheng et al [Zheng et al. (1994), J. Neurosci (in press)].

RESULTS

Using degenerate PCR primers (DPF1 and DPR1) from two highly conserved regions, we were able to amplify a cDNA fragment with high similarity to vertebrate β subunits. Additional clones were isolated. To avoid assembling an incomplete or physiologically irrelevant chimeric sequence exact match primer pairs are used as describe in FIG. 8 with reverse-transcription coupled PCR (RT/PCR) to isolate a “full length” clone (2L4). The sequence of2L4 is shown in FIG. 9. To correct any artifacts introduced by PCR amplification, the sequence of2L4 from nucleotide-32 to 1273 was checked against sequences from phage cDNA clones B5 and 6-I and no differences were found. The sequence from nucleotides 1274 to 1299 was not covered by any available phage clone but was identical in several independent subclones.

The translation initiation site for2L4 was defined as the first ATG downstream of two in-frame stop codons (TGA) at nucleotides-24 to -22 and -6to -4. No polyadenylation consensus signal sequence (AAUAAA) was found in the 3′ untranslated region nor was a poly(A) tract found.

The deduced protein sequence for the Drosophila β subunit (Dmb1) (FIG. 9) consists of 432 amino acids with a pI of 10.31 and a calculated molecular mass of 47,944. Its hydropathy profile is shown in FIG. 8B. Like β subunits from mammals, this subunit lacks significant transmembrane domains, which is consistent with the model that the β subunit is a cytoplasmic protein interacting with a cytoplasmic domain of α₁ subunits [Ruth et al. (1985), Science, vol 245, pp. 1115-1118]; Pragnell et al., 1994).

To compare the evolutionary relationships, the Drosophila β subunit and 5 representative vertebrate β subunits were aligned (FIG. 9). In constructing a phylogenetic tree from these and 5 other mammalian sequences it is apparent that the Drosophila sequence is a distinct branch representing an evolutionary precursor of the existing vertebrate subunits.

In general, many aspects of β subunit structure have been highly conserved across long evolutionary distances. For example, in the rabbit skeletal muscle β subunit (Rbb1, [Ruth et al. (1985), Science, vol 245, pp. 1115-1118]), there are four α-helical domains, each having 8 amino acids starting and ending with leucine and isoleucine and interspersed with negatively charged residues. These domains are thought to play roles in binding of divalent cations [Ruth et al. (1985), Science, vol 245, pp. 1115-1118]. Three of these domains are well conserved in the Drosophila β subunit. (See boxed areas in FIG. 9 labeled αH#) One (αH2) is absent because of a deletion in the Drosophila sequence. A similar deletion has also been reported for some other vertebrate β subunits such as the rat β 1, 3, and 4 shown in FIG. 9. The physiological significance of this deletion is not known.

In skeletal muscle β1, there are two regions which are rich in proline (P), glutamine (E), serine (S) and threonine (T) [Ruth et al. (1985), Science, vol 245, pp. 1115-1118]. Those PEST motifs are common in rapidly degraded proteins (Rogers et al.(1986) Science vol 284pp. 364-368, and are thought to modulate the sensitivity of the β subunits to protease degradation. The first PEST motif is conserved in all the β subunits shown in FIG. 9 including the Drosophila. The second one is less well conserved even among the mammalian subunits and is absent in the Drosophila sequence in 2L4.

The Drosophila sequence shown in FIG. 9 has 2 consensus sites for phosphorylation by protein kinase A (#) and 7 for PKC phosphorylation (Δ). The protein kinase A sites are not conserved in the mammalian subunits shown. Three of the PKC sites (filled triangles) are conserved among all the vertebrate β subunits. A fourth site in the amino terminus is conserved in all mammalian subunits (bracketed, filled triangle), but is absent in the fly β subunit in a corresponding position. This site in the fly β subunit is replaced by a tyrosine phosphorylation site. In addition, clone 2L4 has two PKC sites (at amino acids 14 and 46) flanking this position (FIG. 9), which may substitute for the function of the PKC site conserved among vertebrate β subunits. The abundance of phosphorylation sites in this region suggest a role in modulation by phosphorylation.

Although the two remaining PKC consensus sites at position 264 and 273 in the Drosophila subunit are not conserved in all mammalian forms shown, it is interesting to note that they have been separately conserved in the rat β4 and rat β3 subunits, respectively. Perhaps as an ancestral form, the Drosophila subunit has a double function which has been divided during evolution among different subunit subtypes in higher organisms.

An ATP/GTP-binding site motif A (P-loop) is found in the N-terminal of the Drosophila β subunit (amino acids 7-13). Among all the vertebrate β subunits, this motif is present in only rat β4 although in this subunit it is found in a different region (a nonconserved region following the position of primer B6F1.

The Drosophila β subunit shows temporal and spatial regulation of expression. To study the pattern of expression of the Drosophila β subunit, we used semi-quantitative PCR to examine expression throughout development and in different adult body parts. A fragment of ribosomal protein RP49 (O'Connell and Rosbash (1984), Nucleic Acids Res., vol 12, pp. 5495-5513) was amplified simultaneously as an internal control. The primers (B6F1 and B6RP1) were chosen to span regions which are conserved in all cDNA forms of Dmb1 sequenced to date. The genomic sequence in this region contains an intron of ˜180 base pairs which allowed us to demonstrate that none of the amplification is attributable to contaminating genomic DNA. As can be seen from FIG. 10, the β subunit can first be detected by PCR in 9-12 hour embryos when the neuronal differentiation is beginning (Hartenstein (1993), Atlas of Drosophila Development. Cold Spring Harbor Laboratory Press, Plainview, N.Y.). Expression increases through the embryonic development as the nervous system matures. The message can be detected throughout the larval stages although the levels are somewhat lower than during the peak embryonic period. A second increase in message levels occurs during the pupal phase when the nervous system is undergoing growth and reorganization. In the adult expression is highest in the heads and the “leg” fraction which also contains antennal fragments. A lower level of message was detected in bodies.

To determine the spatial expression of the β subunit in embryonic tissues where muscle versus neuronal expression can be readily distinguished, we used a digoxigenin-labeled antisense probe from the region flanking Y and containing ˜300 base pairs, 260 of which are found in all of the cDNA forms sequenced to date. As shown in FIG. 4B, the β message expression is localized in the nervous system.

Alternative splicing—FIG. 10 shows that calcium channel β subunit in Drosophila undergoes extensive alternative splicing in at least three regions: the amino terminus, the middle and the carboxy terminus. We show three different splice forms for the amino terminal region (X) aligned by their common 3′ end nucleotide sequence. Clone B5 has the same sequence as the full length 2L4. The N-terminus of form 6-O is 16 amino acids longer than that of form B5. Form B5 has a PKC site, and ATP/GTP binding domain and a tyrosine phosphorylation site that are not present in form 6-O, while-form 6-O has a unique casein kinase II phosphorylation site. Although the function of the amino terminus of the β subunit is unknown, it is interesting to note that the amino terminus of potassium channels [Li et al. (1992), Science, vol 257, pp. 1225-1230] and nicotinic acetylcholine (Yu(1991 Nature vol 352, pp. 65-67 Verall, 1992), Cell, vol 68, pp 23-31) are involved in subunit assembly. Perhaps alternative splicing of the amino terminus can determine the α₁ subunit targets for β subunit isoforms.

Forms B6 and 6-I are unusual since they have an in-frame stop codon 21 nucleotides upstream of the X splice site, but no methionine start codon close to this stop codon (cf. FIGS. 8 and 10). Indeed, the first methionine is at position 136. If this methionine is used as start codon, the entire conserved Box A would be absent in the resulting protein.

In the middle region (Y) where sequences diversify among different vertebrate β subunits, 7 different forms have been sequenced in Drosophila and compared with the genomic sequence. There are at least 5 exons (sizes of 18 bp, 21 bp, 36 bp, 12 bp and 15 bp). Alternative use of different splice donors and acceptors [McKeown et al. (1992), Annu. Rev. Cell Biol., vol 8, pp. 133-155] generates multiple protein forms. Form B5 would give rise to a truncated protein which would include conserved Box A, but not Box B (FIG. 8). Although the other 6 forms utilize different combinations of the 5 exons, all 5 exons have size of multiples of 3 so that no frame shift would be introduced by any combinations. Form B6 has a unique PKC consensus sequence in this region. It is interesting to note that forms 2E2, 2E5, and B5 have an exon encoding (SEQ ID NO: 51) STPPTPPTD which is likely a PEST domain which would provide a second such domain as found in the rabbit skeletal muscle β1 subunit [Ruth et al. (1985), Science, vol 245, pp. 1115-1118], but missing in the form 2L4. In this case, alternative splicing generates isoforms with or without a PEST domain thus providing a possible means to alter the stability of the various isoforms.

FIG. 10 shows 12 isoforms in the C-terminal region (Z in FIG. 8) which diverge downstream of a consensus splice site (CAG). Four of the 5 isoforms have common upstream and downstream sequences. Form2L4 and 2E7 have inserts that encode 7 and 14 amino acids, respectively, before stop codons. On the other hand, forms 6-Q, 2E5, and 6-P give rise to longer C-terminal regions of undetermined length (but at least 100 amino acids longer than 2L4) since we have not identified stop codons in the sequence available.

Chromosome mapping—Using in situ hybridization, we have mapped the Dmb1 subunit to salivary gland chromosome region 32DE on the left arm of chromosome 2. Additional deletion mapping in progress will allow us to determine whether any of the existing mutants in that general area are candidates for altered β subunits. These mapping studies are a first step toward similar studies for β subunits. Functional expression studies have shown that the four rat β subunits encoded by 4 different genes are all able to functionally interact with the cardiac α₁ subunits [Castellano et al. (1993), J. Biol. Chem., vol 268, pp. 12359-12366].

REFERENCES

1. Tsien, R. W. and Tsien, R. Y. (1990) Annu. Rev. Cell Biol. 6, 715-760.

2. Tsien, R. W., Ellinor, P. T., and Horne, W. A. (1991) Trends Pharmacol. Sci. 12, 349-354.

3. Hofmann, F., Biel, M., and Flockerzi, V. (1994) Annu. Rev. Neurosci. 17, 399-418.

4. Campbell, K. P., Leung, A. T., and Sharp, A. H. (1988) Trends Neurosci. 11, 425-430.

5. Catterall, W. A. (1988) Science 242, 50-61.

6. Catterall, W. A. and Striessnig, J. (1992) Trends Pharmacol. Sci. 13, 256-262.

7. De Jongh, K. S., Warner, C., and Catterall, W. A. (1990) J. Biol. Chem. 265, 14738-14741.

8. Tanabe, T., Takeshima, H., Mikami, A., Flockerzi, V., Takahashi, H., Kangawa, K., Kojima, M., MATSUO, H., HIROSE, T., and Numa, S. (1987) Nature 328, 313-318.

9. Mikami, A., Imoto, K., Tanabe, T., Niidome, T., Mori, Y., Takeshima, H., Nurumiya, S., and Numa, S. (1989) Nature 340, 230-233.

10. Snutch, T. P., Leonard, J. P., Gilbert, M. M., Lester, H. A., and Davidson, N. (1990) Proc. Natl. Acad. Sci. USA 87, 3391-3395.

11. Mori, Y., Friedrich, T., Kim, M. S., Mikami, A., Nakai, J., Ruth, P., Bosse, E., Hofmann, F., Flockerzi, V., and Furuichi, T. (1991) Nature 350, 398-402.

12. Williams, M. E. Feldman, D. H., McCue, A. F., Brenner, R., Velicelebi, G., Ellis, S. B., and Harpold, M. M. (1992) NEURON 8, 71-84.

13. Williams, M. E., Brust, P. F., Feldman, D. H., Patthi, S., Simerson, S., Maroufi, A. McCue, A. F., Velicelebi, G., Ellis, S. B., and Harpold, M. M. (1992) SCIENCE 257, 389-395.

14. Niidome, T., Kim, M. S., Friedrich, T., and Mori, Y. (1992) FEBS Lett. 308, 7-13.

15. Ruth, P., Rohrkasten, A., Biel, M., Bosse, E., Regulla, S., Meyer, H. E., Flockerzi, V., and Hofmann, F. (1989) SCIENCE 245, 1115-1118.

16. Perez-Reyes, E., Castellano, A., Kim, H. S., Bertrand, P., Baggstrom, E., Lacerda, A. E., Wei, X. Y., and Birnbaumer, L. (1992) J. Biol. Chem. 267, 1792-1797.

17. Castellano, A., Wei, X., Birnbaumer, L., and Perez-Reyes, E. (1993) J. Biol. Chem. 268, 3450-3455.

18. Castellano, A., Wei, X., Birnbaumer, L., and Perez-Reyes, E. (1993) J. Biol. Chem. 268, 12359-12366.

19. Lacerda, A. E., Kim, H. S., Ruth, P., Perez-Reyes, E., Flockerzi, V., Hofmann, F., Birnbaumer, L., and Brown, A. M. (1991) Nature 352, 527-530.

20. Varadi, G., Lory, P., Schultz, D., Varadi, M., and Schwartz, A. (1991) Nature 352, 159-162.

21. Neely, A., Wei, X., Olcese, R., Birnbaumer, L., and Stefani, E. (1993) Science 262, 575-578.

22. Singer, L. D., Gershon, E., Lotan, I., Hullin, R., Biel, M., Flockerzi, V., Hofmann, F., and Dascal, N. (1992) FEBS Lett. 306, 113-118.

23. Hullin, R., Singer-Lahat, D., Freichel, M., Biel, M., Dascal, N., Hofmann, F., and Flockerzi, V. (1992) EMBO J. 11, 885-890.

24. Pragnell, M., Sakamoto, J., Jay, S. D., and Campbell, K. P. (1991) FEBS Lett. 291, 253-258.

25. Harpold, M. M., Ellis, S. B., Velicelebi, G., Brenner, R., McCue, A. F., Feldman, D. H., and Williams, M. E. (1992) Neuron 8, 71-84.

26. Gubler, U. and Hoffman, B. J. (1983) Gene 25, 263-269.

27. Zheng, W., Feng, G., Ren, D., Eberl, D. F. Hannan, F., Dubald, M., and Hall, L. M. (1994) J. Neurosci (in press).

28. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Smith, J. A., Seidman, F. G., Struhl, K., Albright, L. M., Coen, D. M., and Varki, A. (1994) Current Protocols in Molecular Biology, Current Protocols, ???, Wiley Interscience, New York.

29. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular cloning: A laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

30. Itoh, N., Slemmon, J. R., Hawke, D. H., Williamson, R., Morita, E., Itakura, K., Roberts, E., Shively, J. E., Crawford, G. D., and Salvaterra, P. M. (1986) Proc. Natl. Acad. Sci. USA 83, 4081-4085.

31. Sanger, F., Nicklen, S., and Coulsen, A. R. (1977) Proc. Natl. Acad. Sci. USA 74, 5463-5467.

32. Tautz, D. and Pfeifle, C. (1989) Chromosoma 98, 81-85.

33. Grabner, M., Wang, Z., Mittendorfer, J., Rosenthal, F., Charnet, P., Savchenko, A., Hering, S., Ren, D., Hall, L. M., and Glossmann, H. (1994) J. Biol. chem. (in press).

34. Kuhl, D. P. and Caskey, C. T. (1993) Curr. Op. Genetics Develop. 3, 404-407.

35. Pragnell, M., De Waard, M., Mori, Y., Tanabe, T., Snutch, T. P., and Campbell, K. P. (1904) Nature 368, 67-70.

36. Rogers, S., Wells, R., and Rechsteiner, M. (1986) Science 234, 364-368.

37. O'Connell, P. O. and Rosbash, M. (1984) Nucleic Acids Res. 12, 5495-5513.

38. Hartenstein, V. (1993) Atlas of Drosophila development, Cold Spring Harbor Laboratory Press, Plainview, N.Y.

39. Li, M., Jan, Y. N., and Jan, L. Y. (1992) Science 257, 12251230.

40. Yu, X.-M and Hall, Z. W. (1991) Nature 352, 64-67.

41. Verrall, S. and Hall, Z. W. (1992) Cell 68, 23-31.

42. McKeown, M. (1992) Annu. Rev. Cell Biol. 8, 133-155.

43. Beam, K. G., Knudson, C. M., and Powell, J. A. (1986) Nature 320, 168-170.

44. Kyte, J. and Doolittle, R. F. (1982) J. Mol. Biol. 157, 105132.

45. Ashburner, M. and Thompson, J., J. N. (1978) in: The Genetics and Biology of Drosophila (Ashburner, M. and Wright, T. R. F. eds) Vol. 2a, pp. 1-109, Academic Press: New York.

46. Engels, W. R., Preston, C. R., Thompson, P., and Eggleston, W. B. (1985) Focus 8, 6-8.

47. Murtagh, J., J. J., Lee, F.-J. S., Deak, P., Hall, L. M., Monaco, L., Lee, C. M., Stevens, L. A., Moss, J., and Vaughan, M. (1993) Biochemistry 32, 6011-6018.

48. Thackery, J. R., Ganetzky, B., 1994, J. Neurosci, 14:2569-2578.

Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is described by the following claims.

TABLE 1 RT-PCR followed by restriction enzyme digestion reveals more DmcaID message heterogeneity in heads than in bodies or legs Region Diagnostic amplified by mRNA isoforms restriction RT-PCR Source of mRNA present enzyme Cytoplasmic loop Heads ⁽¹⁾A, D Hinf I between II & III Bodies A Hinf I (bases 3830- Legs A Hinf I 4033) IIIS3 to Loop Heads C, D Pst I or RSA I between 111S5 & Bodies C Pst I or Rsa I S6 Legs D Pst I or Rsa I (bases 4251- 4635) ⁽¹⁾A, C, D refer to splice forms found in different cDNA clones (A = W8A, C = SH22C, D = SH22D) in the regions indicated by open boxes in the SH22D diagram in FIG. 1B. Although the alternative forms were similar in size, they could be distinguished in the PCR amplification products following digestion with the indicated restriction enzymes.

TABLE 2 Comparison of a Drosophila calcium channel α₁ subunit with the vertebrate α₁ subunits at amino acid level. Sim- Iden- ilarity tity Loop DHP Sensitivity (%) (%) II/III* References +Rat Brain-D 78.3 64.2 134 Hui et al., 1991 +Rabbit Skeletal 72.4 56.1 138 Tambe et al., 1987 Muscle +Human Brain 71.3 55.5 134 Williams et al, 1992b +Rabbit Lung 70.2 54.1 125 Biel et al., 1990 +Carp Skeletal Muscle 70.0 51.7 139 Grabner et al., 1991 +Rat Brain-C 69.9 54.1 150 Snutch et al., 1991 +Rat Heart 69.6 53.3 147 Mikami et al., 1989 +Rat Aorta 68.7 53.0 147 Koch et al., 1990 −Rat Brain-A 65.2 45.1 479 Starr et al., 1991 −Rabbit Brain-1 64.5 44.2 539 Mori et al., 1991 −Rat Brain-B 63.4 43.7 438 Dubel et al., 1992 −Human N-type 63.4 42.7 451 Williams et al., 1992a Na⁺ channel 58.9 30.5 Loughney et al., 1989 (Drosophila) Na⁺ channel 57.9 29.6 Trimmer et al., 1989 (Rat skel. muscle) *This is the cytoplasmic loop between IIS6 and IIS1. In DmcalD the length of this loop is 129 amino acids.

TABLE 3 Comparison of alternating positive charges in S4 transmembrane domains in calcium channel α₁ subunits. Numbers of positively charged amino acids in S4 domain Clone Source† #KRT KRT KRT KRT Drosophila head (DmcalD) 145 235 156 235 Carp skeletal muscle 145 145 156 145 Rabbit skeletal muscle 145 235 156 145 Human brain 145 145 156 145 Rat brain-D 145 145 156 145 Rat brain-C 145 145 156 145 Rat aorta 145 145 156 145 Rabbit heart 145 145 156 145 Rat brain-B 101 213 235  123* Rabbit brain-1 145 235 246  134* Rat brain-A 145 235 246  134* †The references for sequences used in this comparison are given in Table 2. #K = lysine; R - arginine; T - total positively charged side chains placed every 3-4 residues. *For this domain, these α₁ sununits have a glutamine (Q) in the position occupied by arginine (R) or lysine (K) in other species. This position is the fourth amino acid from the previous positively charged amino acid and falls near the cytoplasmic end of this transmembrane α-helix. There is an arginine residue in the immediately preceding position for each of these proteins.

TABLE 4 Tufty-Kretsinger (TK) test for EF hand: Comparison of the Drosophila sequence with vertebrate sodium and calcium channel α1 subunits (taken, in part, from Babitch, 1990).† Vertices: TK TEST: Na⁺ channel α₁ subunit upstream sequences Eel 1588 M FD E T WH K F DV H G TQ F LD Y N D LP R F VN A L 1616  9(12) Rat BrI 1607 M FY E V WE K F DP DA TQ F M EF E K LS Q F AA A L 1535 10(13) Rat BRII 1797 M FY E V WE K F DP DA TQ F I EF C K LS D F AA A L 1825 11(13) Rat BRIII 1743 M FY E V WE K F DP DA TQ F I EF C K LS D F AA A L 1771 11(13) Rat Heart M FY E I WE K F DP EA TQ F I EY L A LS D F AD A L 11(13) Rat μ1 1612 M FY E T WE K F DP DA T Q F I DY S R LS D F VT D L 1840 11(12) Na⁺ channel α₁ subunit downstream sequences: Eel 1642 K IS Y LD V L L AV TQ EV L G DT T E ME A MR L S I 1670 10(11) Rat μl 1666 K IH C LD I L F AL TK EV L G DS G E MD A LK Q T M 1694 10(11) Ca2+ channel α1 subunit sequences: Rat Brain-C E FK R I WA E Y DP EA K GR IK H L D VV T L LR R I 11(14) Carp Skel. E FK K I WA E Y DP EA T GR IK H L D VV T L LR R I 11(14) Human Brain E FK R I WS E Y DP EA K GR IK H L D VV T L LR R I 11(14) Rabbit Skel. E FK A I WA E Y DP EA K GR IK H L D VV T L LR R I 11(14) Rat Brain-D E FK R I WS E Y DP EA K GR IK H L D VV T L LR R I 11(14) DmcalD 1946 E FI R L WS E Y DP DA K GR IK H L D VV T L LR K I 1974 11(14) †Footnotes for Table 4 are on the following page: †Footnotes for Table 4 The X, Y, Z, −Y, −X, −Z in the “Vertices” row refer to the vertices of the calcium coordination octahedron in the EF hand. These positions are often occupied by amino acids containing an oxygen atom. The TK TEST row indicates the positions of the 16 test residues where E is glutamic acid, n is a hydrophobic residue (F, phenylalanine; I, isoleucine; L, leucine; M, methionine; V, valine) and * is an oxygen containing residue (D, aspartic acid; N, asparagine; E, glutamic acid; Q, glutamine; S, serine; T, threonine). Each sequence is scored 1 for the presence and 0 for the absence of a test residue with 16 matches being the highest possible score. In the “Scores” column the first number is the raw score (and is the sum of the single underlined amino acids). The number within the parentheses is the score if conservative substitutions are allowed (and is the sum of the single and double underlined amino acids). The references for calcium channel sequences are given in Table 2. The sodium channel references are: eel (Noda et al, 1984), rat brain I and II (Noda et al., 1986), rat brain III (Kayano et al., 1988), rat heart (Rogart et al., 1989), rat skeletal μl (Trimmer et al., 1989). Br = brain; Skel = skeletal muscle

TABLE 5 Ion selectivity filter of ion channels† Repeat I Repeat II Calcium Consensus QCiTmEgWTDvLY Consensus QilTGEdWnsvMY channel Drosophila QCVTLEGWTDVLY Drosophila QIMTGEDWNAVMY Carp Skel QCITTESWTDVLY Carp Skel QVLTGEEWDSIMY Rab. Skel QVLTGEDWNSVMY Rab. Skel QCITMEGWTDVLY Human Br QCITMEGWTDVLY Human Br QILTGEDWNAVMY Rat Br-D QCITMEGWTDVLY Rat Br-D QILTGEDWNAVMY Rat Br-C QCITMEGWTDVLY Rat Br-C QILTGEDWNSVMY Rat Aorta QCITMEGWTDVLY Rat Aorta QILTGEDWNSVMY Rab. Heart QCITMEGWTDVLY Rab. Heart QILTGEDWNSVMY Rat Br-B QCITMEGWTDVLY Rat Br-B QILTGEDWNSVMY Rab. Br-1 QCITMEGWTDVLY Rab. Br-1 QILTGEDWNSVMY Rat Br-A QCITMEGWTDVLY Rat Br-A QILTGEDWNSVMY Sodium Consensus RLMTQDyWEnLYQ Consensus RvLCGEWIEtMWD channel para RLMTQDFWEDLYQ para RVLCGEWIESMWD Rat BrII RLMTQDFWEDLYQ Rat BrII RVLCGEWIESMWD Rat BrIII RLMTQDFWEDLYQ Rat BrIII RVLCGEWIESMWD Rat Heart RLMTQDFWEDLYQ Rat Heart RILCGEWIESMWD Rat Skel μ1 RLMTQDFWEDLYQ Rat Skel μ1 RILCGEWIESMWD Eel RLMTQDFWEDLYQ Eel RALCGEWIESMWD SS1 SS2 SS1 SS2 Repeat III Repeat IV Calcium Consensus TvSTfEGWPelLY Consensus RcATGEaWqeiml channel Drosophila TVSTFEGWPGLLY Drosophila RSATGEAWEIMM Carp Skel TISTFEGWPEILY Carp Skel RVATGEQWPKVIL Rab. Skel TVISTFEGWPEILY Rab. Skel RCATGEQWPKVIL Human Br TVISTFEGWPEILY Human Br RCATGEQWPKVIL Rat Br-D TVISTFEGWPEILY Rat Br-D RCATGEQWPKVIL Rat Br-C TVISTFEGWPEILY Rat Br-C RCATGEQWPKVIL Rat Aorta TVISTFEGWPEILY Rat Aorta RCATGEQWPKVIL Rab. Heart TVISTFEGWPEILY Rab. Heart RCATGEQWPKVIL Rat Br-B TVISTFEGWPEILY Rat Br-B RSATGEQWPKVIL Rab. Br-1 TVISTFEGWPEILY Rab. Br-1 RSATGEQWPKVIL Rat Br-A TVISTFEGWPEILY Rat Br-A RSATGEQWPKVIL Sodium Consensus QVaTFKGWMdIMy Consensus qitTSAGWDGILa para QVATFKGWIQIMN para QMSTSAGWDGVLD Rat BrII QVATFKGWIQIMN Rat BrII QISTSAGWDGVLD Rat BrIII QVATFKGWIQIMN Rat BrIII QISTSAGWDGVLD Rat Heart QVATFKGWIQIMN Rat Heart QISTSAGWDGVLD Rat Skel μ1 QVATFKGWMDIMY Rat Skel μ1 EITTSAGWDGLLN Eel QVSTFKGWMDIMY Eel EITTSAGWDGLLL SS1 SS2 SS1 SS2

                   #             SEQUENCE LISTING (1) GENERAL INFORMATION:    (iii) NUMBER OF SEQUENCES: 101 (2) INFORMATION FOR SEQ ID NO:1:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 8075 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 157..7704     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: GGTCATCATT GGCTCTCAGA GGATTCTCTG CTGCCAACAT AGCCGATGAA AA #CATAATGC     60 AACACAGAAT AATGTTGCCG AAATTGCTGT GATTGCAAAG CCTCGACCTC GA #CCTCAACC    120 TCGACCTCCG CCTCCACCAC CACCACGAAT ACTGTG ATG GGT GGC  #GGG GAG CTG      174                    #                   #    Met Gly Gly Gly Glu Leu                    #                   #      1             #   5 GTG AAC TGT ATA GCC TAC GAT GAC AAC ACC CT #G GTC ATC GAG AGG AAA      222 Val Asn Cys Ile Ala Tyr Asp Asp Asn Thr Le #u Val Ile Glu Arg Lys              10      #             15      #             20 CCC TCG CCC TCC TCC CCG TCC ACC AGC CGG CG #T TAT CTG AAG GCC GAA      270 Pro Ser Pro Ser Ser Pro Ser Thr Ser Arg Ar #g Tyr Leu Lys Ala Glu          25          #         30          #         35 ACG CCG ACG CGT GGC AGT CGA AAG TAC AAC CG #C AAG TCA TCG GCT AAA      318 Thr Pro Thr Arg Gly Ser Arg Lys Tyr Asn Ar #g Lys Ser Ser Ala Lys      40              #     45              #     50 AGT GAT TTG GAA GTG GTC GTT GTC AAG CCG GA #A CAC CAT CAT CAG CAT      366 Ser Asp Leu Glu Val Val Val Val Lys Pro Gl #u His His His Gln His  55                  # 60                  # 65                  # 70 CGA TCT CCG ACG ATA ACG CTT CCG GTT CCG GC #T AAC CCA CTA ACC ACA      414 Arg Ser Pro Thr Ile Thr Leu Pro Val Pro Al #a Asn Pro Leu Thr Thr                  75  #                 80  #                 85 TCG GCA TCG GCG GGA TCC TCG CCC ACG GGA GC #G GGA TTG GCA GCC GGA      462 Ser Ala Ser Ala Gly Ser Ser Pro Thr Gly Al #a Gly Leu Ala Ala Gly              90      #             95      #            100 TTG GGA ACT GCC TCG GGA ACG GTC CTG CAA CA #A AGC TGC AGT GCA CTT      510 Leu Gly Thr Ala Ser Gly Thr Val Leu Gln Gl #n Ser Cys Ser Ala Leu         105           #       110           #       115 GAT CCG CCC GAG GAT TCG AAT CAG CCC AGC GG #G ACC AGG AGG CGA GCC      558 Asp Pro Pro Glu Asp Ser Asn Gln Pro Ser Gl #y Thr Arg Arg Arg Ala     120               #   125               #   130 ACC AGC ACC GAG CTC GCC CTC AGC AAC GTC AC #C AGT CAG ATT GTG AAC      606 Thr Ser Thr Glu Leu Ala Leu Ser Asn Val Th #r Ser Gln Ile Val Asn 135                 1 #40                 1 #45                 1 #50 AAT GCC ACC TAC AAG CTA GAC TTC AAG CAA CG #T CGT CAC AAA AGC AAC      654 Asn Ala Thr Tyr Lys Leu Asp Phe Lys Gln Ar #g Arg His Lys Ser Asn                 155   #               160   #               165 AAC GGA GGC AGT GAG TCA GGA TCT CTA ACC GG #A ATA GCC ACA GGA CCG      702 Asn Gly Gly Ser Glu Ser Gly Ser Leu Thr Gl #y Ile Ala Thr Gly Pro             170       #           175       #           180 GCG ACA AGT CCC GCA GGA CCA ACA GGA CCA AC #C AGT TCC AGC GGC AAG      750 Ala Thr Ser Pro Ala Gly Pro Thr Gly Pro Th #r Ser Ser Ser Gly Lys         185           #       190           #       195 CGG CGC AAG TCC AGT TGC ACA TCC TGC GGC GG #A GGT GGC ATC AGT GCC      798 Arg Arg Lys Ser Ser Cys Thr Ser Cys Gly Gl #y Gly Gly Ile Ser Ala     200               #   205               #   210 CCA CCC CCG AGA CTA ACG CCC GAG GAG GCG TG #G CAA CTG CAA CCA CAG      846 Pro Pro Pro Arg Leu Thr Pro Glu Glu Ala Tr #p Gln Leu Gln Pro Gln 215                 2 #20                 2 #25                 2 #30 AAC AGT GTT ACC AGT GCC GGC AGC ACA AAT AG #T AGT TTC AGC AGC GGC      894 Asn Ser Val Thr Ser Ala Gly Ser Thr Asn Se #r Ser Phe Ser Ser Gly                 235   #               240   #               245 GGC GGA CGC GAC GAT AAT AGT AGT TAC AGT GC #C GTC GGC GGC GAT AGC      942 Gly Gly Arg Asp Asp Asn Ser Ser Tyr Ser Al #a Val Gly Gly Asp Ser             250       #           255       #           260 AGC AGC AGC AAT AGT TGC AAC TGC GAT ATC AC #C GGT GAT AAC AGT ACA      990 Ser Ser Ser Asn Ser Cys Asn Cys Asp Ile Th #r Gly Asp Asn Ser Thr         265           #       270           #       275 TTG CAT GGT TTG GGC GTC GGC GAC GTT TGT AG #T TTC ATC GCC GAT TGT     1038 Leu His Gly Leu Gly Val Gly Asp Val Cys Se #r Phe Ile Ala Asp Cys     280               #   285               #   290 GAC GAC AAT AGC GAG GAC GAC GAC GGC GAT CC #G AAT AAC CAG GAT CTC     1086 Asp Asp Asn Ser Glu Asp Asp Asp Gly Asp Pr #o Asn Asn Gln Asp Leu 295                 3 #00                 3 #05                 3 #10 AGC TCG CAA ACC CTG CGC ACA GCG GCC ATC GT #A GCG GCA GTT GCG GCA     1134 Ser Ser Gln Thr Leu Arg Thr Ala Ala Ile Va #l Ala Ala Val Ala Ala                 315   #               320   #               325 GCA GCC AAG GAA CAG GCC CAG GAG CAA TCG CT #C GCC GAC TGC GAG AGC     1182 Ala Ala Lys Glu Gln Ala Gln Glu Gln Ser Le #u Ala Asp Cys Glu Ser             330       #           335       #           340 TTC AGC GAT CGC CGG CAG GAT GCC GAT GAG GA #C GTC CGC ATC ATT CAG     1230 Phe Ser Asp Arg Arg Gln Asp Ala Asp Glu As #p Val Arg Ile Ile Gln         345           #       350           #       355 GAT TGC TGC GGC GGC AAC AAC GAC TCA CTC GA #A GAC GTT GGC GAG GTG     1278 Asp Cys Cys Gly Gly Asn Asn Asp Ser Leu Gl #u Asp Val Gly Glu Val     360               #   365               #   370 GAC GAC AAC GCC GAC GTT GTC GTG AGA AAG AA #C TCA AGG AAT CGT CCC     1326 Asp Asp Asn Ala Asp Val Val Val Arg Lys As #n Ser Arg Asn Arg Pro 375                 3 #80                 3 #85                 3 #90 TCG ATC AGA AGG ACA TGC AGG ATA ACC GAG GA #G GAC GAC GAC GAG GAC     1374 Ser Ile Arg Arg Thr Cys Arg Ile Thr Glu Gl #u Asp Asp Asp Glu Asp                 395   #               400   #               405 GAG AAC GCG GAC TAC GGT GAT TTC GAT CGG GA #G GAT CAA GAG CTA GAC     1422 Glu Asn Ala Asp Tyr Gly Asp Phe Asp Arg Gl #u Asp Gln Glu Leu Asp             410       #           415       #           420 GAC GAG GAG CCC GAG GGC ACC ACC ATT GAC AT #T GAT GAG CAG GAA CAG     1470 Asp Glu Glu Pro Glu Gly Thr Thr Ile Asp Il #e Asp Glu Gln Glu Gln         425           #       430           #       435 CAG CAC GAC CAA GGT GAT TCC GCT GAA GAG GA #A GAC CAC GAC GAG GAC     1518 Gln His Asp Gln Gly Asp Ser Ala Glu Glu Gl #u Asp His Asp Glu Asp     440               #   445               #   450 GTC GAC GAG TAC TTT GAG GAG GAG GAG GAC GA #C ACG CAG GCC TTT TCG     1566 Val Asp Glu Tyr Phe Glu Glu Glu Glu Asp As #p Thr Gln Ala Phe Ser 455                 4 #60                 4 #65                 4 #70 CCA TTC TAC TCC AGT TCC GCG GAG CTA ATT GA #T AAT TTT GGT GGC GGT     1614 Pro Phe Tyr Ser Ser Ser Ala Glu Leu Ile As #p Asn Phe Gly Gly Gly                 475   #               480   #               485 GCG GGC AAG TTC TTC AAC ATA ATG GAC TTC GA #G CGT GGA GCC TCC GGC     1662 Ala Gly Lys Phe Phe Asn Ile Met Asp Phe Gl #u Arg Gly Ala Ser Gly             490       #           495       #           500 GAG GGA GGC TTT TCG CCA AAC GGC AAC GGT GG #T CCC GGC AGC GGT GAT     1710 Glu Gly Gly Phe Ser Pro Asn Gly Asn Gly Gl #y Pro Gly Ser Gly Asp         505           #       510           #       515 GTT TCC CGT ACG GCG AGA TAC GAC TCC GGG GA #G GGG GAT CTG GGC GGC     1758 Val Ser Arg Thr Ala Arg Tyr Asp Ser Gly Gl #u Gly Asp Leu Gly Gly     520               #   525               #   530 GGC AAC AAT ATC ATG GGC ATC GAT TCT ATG GG #C ATT GCA AAC ATT CCG     1806 Gly Asn Asn Ile Met Gly Ile Asp Ser Met Gl #y Ile Ala Asn Ile Pro 535                 5 #40                 5 #45                 5 #50 GAA ACC ATG AAC GGC ACC ACA ATT GGA CCA AG #T GGA GCC GGT GGC CAA     1854 Glu Thr Met Asn Gly Thr Thr Ile Gly Pro Se #r Gly Ala Gly Gly Gln                 555   #               560   #               565 AAA GGT GGT GCT GCT GCA GGT GCC GCT GGC CA #A AAG AGA CAA CAA CGC     1902 Lys Gly Gly Ala Ala Ala Gly Ala Ala Gly Gl #n Lys Arg Gln Gln Arg             570       #           575       #           580 CGT GGA AAA CCG CAA CCA GAC AGA CCA CAA CG #A GCA TTA TTT TGC CTG     1950 Arg Gly Lys Pro Gln Pro Asp Arg Pro Gln Ar #g Ala Leu Phe Cys Leu         585           #       590           #       595 AGC GTC AAG AAT CCC CTG CGA GCC CTG TGC AT #T CGC ATT GTG GAG TGG     1998 Ser Val Lys Asn Pro Leu Arg Ala Leu Cys Il #e Arg Ile Val Glu Trp     600               #   605               #   610 AAA CCA TTT GAG TTC CTT ATT TTG TTA ACC AT #T TTT GCC AAC TGT ATT     2046 Lys Pro Phe Glu Phe Leu Ile Leu Leu Thr Il #e Phe Ala Asn Cys Ile 615                 6 #20                 6 #25                 6 #30 GCC TTG GCG GTT TAC ACC CCT TAT CCG GGA AG #C GAT TCA AAC GTG ACG     2094 Ala Leu Ala Val Tyr Thr Pro Tyr Pro Gly Se #r Asp Ser Asn Val Thr                 635   #               640   #               645 AAT CAA ACC TTG GAA AAA GTT GAA TAT GTA TT #C CTA GTT ATA TTC ACA     2142 Asn Gln Thr Leu Glu Lys Val Glu Tyr Val Ph #e Leu Val Ile Phe Thr             650       #           655       #           660 GCG GAA TGT GTT ATG AAA ATT TTA GCA TAT GG #T TTT GTG TTA CAT GAT     2190 Ala Glu Cys Val Met Lys Ile Leu Ala Tyr Gl #y Phe Val Leu His Asp         665           #       670           #       675 GGT GCA TAT CTG GGA AAT GGA TGG AAT TTA TT #A GAT TTT ACA ATT GTA     2238 Gly Ala Tyr Leu Gly Asn Gly Trp Asn Leu Le #u Asp Phe Thr Ile Val     680               #   685               #   690 GTT ATG GGG GCG ATA AGT ACT GCA CTC TCC CA #A TTG ATG AAG GAC GCC     2286 Val Met Gly Ala Ile Ser Thr Ala Leu Ser Gl #n Leu Met Lys Asp Ala 695                 7 #00                 7 #05                 7 #10 TTT GAT GTG AAG GCT CTA CGT GCC TTT CGA GT #G CTA CGT CCA CTG CGA     2334 Phe Asp Val Lys Ala Leu Arg Ala Phe Arg Va #l Leu Arg Pro Leu Arg                 715   #               720   #               725 CTT GTA TCG GGT GTA CCA AGT CTA CAG GTT GT #G CTG AAT TCA ATT TTA     2382 Leu Val Ser Gly Val Pro Ser Leu Gln Val Va #l Leu Asn Ser Ile Leu             730       #           735       #           740 AAG GCC ATG GTG CCA CTG TTT CAC ATT GCA CT #C CTG GTC CTA TTC GTA     2430 Lys Ala Met Val Pro Leu Phe His Ile Ala Le #u Leu Val Leu Phe Val         745           #       750           #       755 ATC ATA ATC TAT GCG ATA ATT GGC CTA GAG CT #C TTC TCT GGC AAA TTG     2478 Ile Ile Ile Tyr Ala Ile Ile Gly Leu Glu Le #u Phe Ser Gly Lys Leu     760               #   765               #   770 CAC AAG GCG TGT CGC GAT GAG ATC ACA GGT GA #A TAC GAG GAA AAC ATC     2526 His Lys Ala Cys Arg Asp Glu Ile Thr Gly Gl #u Tyr Glu Glu Asn Ile 775                 7 #80                 7 #85                 7 #90 CGG CCC TGC GGA GTG GGC TAC CAG TGT CCG CC #G GGC TAC AAG TGC TAC     2574 Arg Pro Cys Gly Val Gly Tyr Gln Cys Pro Pr #o Gly Tyr Lys Cys Tyr                 795   #               800   #               805 GGC GGA TGG GAT GGA CCA AAC GAC GGC ATC AC #C AAC TTC GAC AAC TTT     2622 Gly Gly Trp Asp Gly Pro Asn Asp Gly Ile Th #r Asn Phe Asp Asn Phe             810       #           815       #           820 GGC CTG GCC ATG TTG ACG GTG TTC CAG TGC GT #C ACC CTT GAG GGC TGG     2670 Gly Leu Ala Met Leu Thr Val Phe Gln Cys Va #l Thr Leu Glu Gly Trp         825           #       830           #       835 ACT GAT GTC CTT TAT AGC ATC CAA GAT GCA AT #G GGC AGC GAT TGG CAG     2718 Thr Asp Val Leu Tyr Ser Ile Gln Asp Ala Me #t Gly Ser Asp Trp Gln     840               #   845               #   850 TGG ATG TAC TTC ATT TCC ATG GTT ATC CTG GG #T GCC TTC TTC GTG ATG     2766 Trp Met Tyr Phe Ile Ser Met Val Ile Leu Gl #y Ala Phe Phe Val Met 855                 8 #60                 8 #65                 8 #70 AAT CTG ATT CTC GGT GTG TTG TCC GGT GAG TT #C TCC AAG GAG CGT AAC     2814 Asn Leu Ile Leu Gly Val Leu Ser Gly Glu Ph #e Ser Lys Glu Arg Asn                 875   #               880   #               885 AAG GCC AAA AAC CGC GGT GAC TTC CAG AAG CT #G CGC GAG AAG CAG CAG     2862 Lys Ala Lys Asn Arg Gly Asp Phe Gln Lys Le #u Arg Glu Lys Gln Gln             890       #           895       #           900 ATC GAA GAG GAT CTG CGG GGC TAT CTC GAT TG #G ATT ACC CAA GCC GAG     2910 Ile Glu Glu Asp Leu Arg Gly Tyr Leu Asp Tr #p Ile Thr Gln Ala Glu         905           #       910           #       915 GAC ATT GAA CCA GAC GCC GTG GGA GGT CTG AT #A TCC GAT GGC AAG GGC     2958 Asp Ile Glu Pro Asp Ala Val Gly Gly Leu Il #e Ser Asp Gly Lys Gly     920               #   925               #   930 AAG CAG CCC AAC GAA ATG GAT TCC ACC GAG AA #T CTG GGC GAA GAA ATG     3006 Lys Gln Pro Asn Glu Met Asp Ser Thr Glu As #n Leu Gly Glu Glu Met 935                 9 #40                 9 #45                 9 #50 CCC GAG GTC CAA ATG ACT GAA TCA CGA TGG CG #C AAA ATG AAG AAG GAC     3054 Pro Glu Val Gln Met Thr Glu Ser Arg Trp Ar #g Lys Met Lys Lys Asp                 955   #               960   #               965 TTC GAT CGA GTC AAT CGT CGA ATG CGA AGA GC #C TGT CGC AAG GCA GTC     3102 Phe Asp Arg Val Asn Arg Arg Met Arg Arg Al #a Cys Arg Lys Ala Val             970       #           975       #           980 AAG TCG CAG GCC TTC TAT TGG CTC ATC ATC GT #T TTG GTG TTT CTC AAT     3150 Lys Ser Gln Ala Phe Tyr Trp Leu Ile Ile Va #l Leu Val Phe Leu Asn         985           #       990           #       995 ACG GGT GTC TTG GCC ACG GAG CAT TAT GGC CA #A CTT GAT TGG CTA GAT     3198 Thr Gly Val Leu Ala Thr Glu His Tyr Gly Gl #n Leu Asp Trp Leu Asp     1000              #   1005               #  1010 AAC TTC CAG GAG TAC ACC AAC GTG TTC TTC AT #C GGA CTG TTC ACC TGC     3246 Asn Phe Gln Glu Tyr Thr Asn Val Phe Phe Il #e Gly Leu Phe Thr Cys 1015                1020 #                1025  #               1030 GAA ATG TTG TTG AAG ATG TAC AGC TTG GGC TT #T CAG GGC TAC TTC GTT     3294 Glu Met Leu Leu Lys Met Tyr Ser Leu Gly Ph #e Gln Gly Tyr Phe Val                 1035  #               1040   #              1045 TCG CTG TTC AAT CGT TTT GAT TGT TTT GTG GT #G ATT GGC AGC ATT ACG     3342 Ser Leu Phe Asn Arg Phe Asp Cys Phe Val Va #l Ile Gly Ser Ile Thr             1050      #           1055       #          1060 GAA ACC CTG CTA ACA AAC ACG GGA ATG ATG CC #G CCA TTG GGT GTC TCC     3390 Glu Thr Leu Leu Thr Asn Thr Gly Met Met Pr #o Pro Leu Gly Val Ser         1065          #       1070           #      1075 GTG CTG CGT TGT GTA CGT CTC CTG AGA GTC TT #T AAA GTA ACT AAG TAC     3438 Val Leu Arg Cys Val Arg Leu Leu Arg Val Ph #e Lys Val Thr Lys Tyr     1080              #   1085               #  1090 TGG CGG TCT CTC TCA AAT CTC GTC GCT TCC CT #A TTG AAC TCT ATA CAA     3486 Trp Arg Ser Leu Ser Asn Leu Val Ala Ser Le #u Leu Asn Ser Ile Gln 1095                1100 #                1105  #               1110 TCG ATT GCT TCA CTT TTG TTA CTG CTC TTC CT #A TTT ATT GTG ATA TTT     3534 Ser Ile Ala Ser Leu Leu Leu Leu Leu Phe Le #u Phe Ile Val Ile Phe                 1115  #               1120   #              1125 GCT TTG CTG GGC ATG CAA GTT TTT GGC GGT AA #A TTT AAT TTT GAT GGC     3582 Ala Leu Leu Gly Met Gln Val Phe Gly Gly Ly #s Phe Asn Phe Asp Gly             1130      #           1135       #          1140 AAA GAG GAG AAG TAT CGA ATG AAC TTC GAC TG #C TTC TGG CAG GCT CTA     3630 Lys Glu Glu Lys Tyr Arg Met Asn Phe Asp Cy #s Phe Trp Gln Ala Leu         1145          #       1150           #      1155 CTC ACA GTG TTT CAG ATC ATG ACT GGC GAG GA #T TGG AAT GCT GTG ATG     3678 Leu Thr Val Phe Gln Ile Met Thr Gly Glu As #p Trp Asn Ala Val Met     1160              #   1165               #  1170 TAT GTG GGC ATC AAT GCC TAT GGC GGT GTG TC #C TCC TAT GGT GCC TTG     3726 Tyr Val Gly Ile Asn Ala Tyr Gly Gly Val Se #r Ser Tyr Gly Ala Leu 1175                1180 #                1185  #               1190 GCC TGT ATT TAC TTT ATT ATT TTG TTC ATA TG #C GGT AAC TAC ATC CTG     3774 Ala Cys Ile Tyr Phe Ile Ile Leu Phe Ile Cy #s Gly Asn Tyr Ile Leu                 1195  #               1200   #              1205 CTA AAC GTG TTC TTG GCC ATT GCT GTG GAT AA #T TTG GCC GAT GCC GAC     3822 Leu Asn Val Phe Leu Ala Ile Ala Val Asp As #n Leu Ala Asp Ala Asp             1210      #           1215       #          1220 TCG CTC TCT GAG GTC GAA AAA GAA GAG GAA CC #T CAC GAT GAA TCT GCT     3870 Ser Leu Ser Glu Val Glu Lys Glu Glu Glu Pr #o His Asp Glu Ser Ala         1225          #       1230           #      1235 CAG AAA AAG TCA CAT AGT CCG ACT CCA ACA AT #T GAT GGC ATG GAT GAT     3918 Gln Lys Lys Ser His Ser Pro Thr Pro Thr Il #e Asp Gly Met Asp Asp     1240              #   1245               #  1250 CAC CTC AGC ATA GAT ATC GAT ATG GAG CAA CA #G GAA CTG GAT GAC GAA     3966 His Leu Ser Ile Asp Ile Asp Met Glu Gln Gl #n Glu Leu Asp Asp Glu 1255                1260 #                1265  #               1270 GAC AAA ATG GAC CAT GAA ACA TTA TCA GAC GA #G GAA GTT CGT GAA ATG     4014 Asp Lys Met Asp His Glu Thr Leu Ser Asp Gl #u Glu Val Arg Glu Met                 1275  #               1280   #              1285 TGC GAG GAG GAA GAG GAA GTG GAT GAA GAA GG #C ATG ATT ACA GCA CGA     4062 Cys Glu Glu Glu Glu Glu Val Asp Glu Glu Gl #y Met Ile Thr Ala Arg             1290      #           1295       #          1300 CCC CGA CGT ATG TCT GAG GTT AAT ACG GCA AC #G AAA ATT CTA CCC ATA     4110 Pro Arg Arg Met Ser Glu Val Asn Thr Ala Th #r Lys Ile Leu Pro Ile         1305          #       1310           #      1315 CCG CCG GGC ACA TCA TTT TTT CTT TTC TCA CA #A ACG AAC AGA TTT CGC     4158 Pro Pro Gly Thr Ser Phe Phe Leu Phe Ser Gl #n Thr Asn Arg Phe Arg     1320              #   1325               #  1330 GTC TTC TGC CAC TGG CTT TGC AAT CAC AGC AA #T TTC GGC AAC ATT ATT     4206 Val Phe Cys His Trp Leu Cys Asn His Ser As #n Phe Gly Asn Ile Ile 1335                1340 #                1345  #               1350 CTG TGT TGC ATT ATG TTT TCA TCG GCT ATG TT #G GCA GCA GAG AAT CCT     4254 Leu Cys Cys Ile Met Phe Ser Ser Ala Met Le #u Ala Ala Glu Asn Pro                 1355  #               1360   #              1365 CTG AGA GCC AAT GAT GAC CTG AAT AAA GTG CT #C AAT AAA TTT GAT TAT     4302 Leu Arg Ala Asn Asp Asp Leu Asn Lys Val Le #u Asn Lys Phe Asp Tyr             1370      #           1375       #          1380 TTT TTC ACG GCA GTT TTC ACA ATG GAA CTG AT #T CTG AAA TTG ATT TCA     4350 Phe Phe Thr Ala Val Phe Thr Met Glu Leu Il #e Leu Lys Leu Ile Ser         1385          #       1390           #      1395 TAC GGC TTC GTA TTA CAC GAC GGA GCC TTT TG #C AGA TCC GCA TTT AAT     4398 Tyr Gly Phe Val Leu His Asp Gly Ala Phe Cy #s Arg Ser Ala Phe Asn     1400              #   1405               #  1410 CTA TTA GAT TTA CTT GTG GTC TGC GTG TCA TT #G ATT TCT CTA GTG TCC     4446 Leu Leu Asp Leu Leu Val Val Cys Val Ser Le #u Ile Ser Leu Val Ser 1415                1420 #                1425  #               1430 AGT TCG GAT GCG ATT TCA GTC GTG AAA ATT CT #A CGT GTG CTC CGT GTT     4494 Ser Ser Asp Ala Ile Ser Val Val Lys Ile Le #u Arg Val Leu Arg Val                 1435  #               1440   #              1445 TTA AGG CCA CTC AGA GCC ATT AAT CGT GCC AA #G GGA CTG AAG CAT GTT     4542 Leu Arg Pro Leu Arg Ala Ile Asn Arg Ala Ly #s Gly Leu Lys His Val             1450      #           1455       #          1460 GTT CAA TGT GTC ATA GTC GCT GTT AAG ACT AT #C GGA AAT ATT GTG CTC     4590 Val Gln Cys Val Ile Val Ala Val Lys Thr Il #e Gly Asn Ile Val Leu         1465          #       1470           #      1475 GTC ACA TGC CTA CTG CAG TTC ATG TTT GCC GT #A ATA GGA GTC CAA TTG     4638 Val Thr Cys Leu Leu Gln Phe Met Phe Ala Va #l Ile Gly Val Gln Leu     1480              #   1485               #  1490 TTT AAG GGC AAA TTT TTC AAG TGC ACT GAT GG #T TCC AAA ATG ACT CAA     4686 Phe Lys Gly Lys Phe Phe Lys Cys Thr Asp Gl #y Ser Lys Met Thr Gln 1495                1500 #                1505  #               1510 GAT GAA TGC TAC GGA ACC TAT CTG GTC TAT GA #T GAT GGC GAT GTT CAT     4734 Asp Glu Cys Tyr Gly Thr Tyr Leu Val Tyr As #p Asp Gly Asp Val His                 1515  #               1520   #              1525 AAG CCG CGA CTC AGG GAA CGG GAA TGG AGT AA #C AAT CGC TTC CAC TTC     4782 Lys Pro Arg Leu Arg Glu Arg Glu Trp Ser As #n Asn Arg Phe His Phe             1530      #           1535       #          1540 GAT GAT GTG GCC AAG GGC ATG TTG ACT TTG TT #C ACG GTG TCC ACA TTT     4830 Asp Asp Val Ala Lys Gly Met Leu Thr Leu Ph #e Thr Val Ser Thr Phe         1545          #       1550           #      1555 GAG GGC TGG CCA GGT TTG CTG TAT GTT TCA AT #T GAT TCG AAT AAG GAA     4878 Glu Gly Trp Pro Gly Leu Leu Tyr Val Ser Il #e Asp Ser Asn Lys Glu     1560              #   1565               #  1570 AAC GGC GGT CCA ATA CAC AAC TTC CGT CCG AT #C GTA GCT GCC TAC TAT     4926 Asn Gly Gly Pro Ile His Asn Phe Arg Pro Il #e Val Ala Ala Tyr Tyr 1575                1580 #                1585  #               1590 ATA ATC TAC ATT ATT ATT ATT GCC TTC TTC AT #G GTG AAC ATA TTC GTC     4974 Ile Ile Tyr Ile Ile Ile Ile Ala Phe Phe Me #t Val Asn Ile Phe Val                 1595  #               1600   #              1605 GGT TTC GTT ATC GTC ACT TTC CAA AAT GAG GG #T GAA CAG GAA TAT AAG     5022 Gly Phe Val Ile Val Thr Phe Gln Asn Glu Gl #y Glu Gln Glu Tyr Lys             1610      #           1615       #          1620 AAT TGT GAT CTG GAT AAG AAT CAG CGC AAT TG #C ATA GAA TTT GCC TTG     5070 Asn Cys Asp Leu Asp Lys Asn Gln Arg Asn Cy #s Ile Glu Phe Ala Leu         1625          #       1630           #      1635 AAA GCG AAA CCC GTT AGA CGC TAT ATA CCA AA #G CAT GGT ATA CAA TAT     5118 Lys Ala Lys Pro Val Arg Arg Tyr Ile Pro Ly #s His Gly Ile Gln Tyr     1640              #   1645               #  1650 AAG GTC TGG TGG TTC GTC ACG TCG TCA TCC TT #C GAG TAC ACA ATA TTC     5166 Lys Val Trp Trp Phe Val Thr Ser Ser Ser Ph #e Glu Tyr Thr Ile Phe 1655                1660 #                1665  #               1670 ATA CTG ATC ATG ATA AAC ACG GTA ACG CTG GC #T ATG AAG TTT TAC AAT     5214 Ile Leu Ile Met Ile Asn Thr Val Thr Leu Al #a Met Lys Phe Tyr Asn                 1675  #               1680   #              1685 CAG CCG CTG TGG TAC ACG GAA CTT TTA GAT GC #C TTG AAT ATG ATA TTT     5262 Gln Pro Leu Trp Tyr Thr Glu Leu Leu Asp Al #a Leu Asn Met Ile Phe             1690      #           1695       #          1700 ACG GCG GTG TTT GCT TTG GAA TTT GTC TTT AA #A TTA GCC GCG TTT CGA     5310 Thr Ala Val Phe Ala Leu Glu Phe Val Phe Ly #s Leu Ala Ala Phe Arg         1705          #       1710           #      1715 TTT AAG AAC TAC TTT GGA GAT GCT TGG AAC GT #A TTC GAT TTT ATC ATC     5358 Phe Lys Asn Tyr Phe Gly Asp Ala Trp Asn Va #l Phe Asp Phe Ile Ile     1720              #   1725               #  1730 GTT TTA GGC AGT TTC ATT GAC ATT GTC TAC TC #T GAA ATT AAG AGC AAG     5406 Val Leu Gly Ser Phe Ile Asp Ile Val Tyr Se #r Glu Ile Lys Ser Lys 1735                1740 #                1745  #               1750 GAT ACT TCT CAG ATA GCA GAA TGT GAC ATT GT #A GAG GGC TGC AAA TCC     5454 Asp Thr Ser Gln Ile Ala Glu Cys Asp Ile Va #l Glu Gly Cys Lys Ser                 1755  #               1760   #              1765 ACC AAG AAA TCA GCT GGT TCA AAT TTA ATA TC #C ATC AAT TTC TTC CGA     5502 Thr Lys Lys Ser Ala Gly Ser Asn Leu Ile Se #r Ile Asn Phe Phe Arg             1770      #           1775       #          1780 CTG TTC CGA GTT ATG CGA CTC GTC AAG CTT CT #C AGC AAA GGC GAG GGC     5550 Leu Phe Arg Val Met Arg Leu Val Lys Leu Le #u Ser Lys Gly Glu Gly         1785          #       1790           #      1795 ATT CGA ACA TTA CTG TGG ACT TTT ATC AAA TC #C TTC CAG GCA CTG CCC     5598 Ile Arg Thr Leu Leu Trp Thr Phe Ile Lys Se #r Phe Gln Ala Leu Pro     1800              #   1805               #  1810 TAC GTA GCC CTG CTA ATT GTG CTT CTA TTT TT #C ATT TAT GCG GTT GTG     5646 Tyr Val Ala Leu Leu Ile Val Leu Leu Phe Ph #e Ile Tyr Ala Val Val 1815                1820 #                1825  #               1830 GGG ATG CAA GTG TTC GGC AAA ATT GCT CTA GA #T GGT GGA AAC GCC ATC     5694 Gly Met Gln Val Phe Gly Lys Ile Ala Leu As #p Gly Gly Asn Ala Ile                 1835  #               1840   #              1845 ACG GCC AAT AAC AAT TTC CAA ACG TTC CAG CA #G GCT GTT TTA GTA CTC     5742 Thr Ala Asn Asn Asn Phe Gln Thr Phe Gln Gl #n Ala Val Leu Val Leu             1850      #           1855       #          1860 TTC CGA TCG GCC ACC GGA GAA GCT TGG CAG GA #A ATT ATG ATG TCC TGC     5790 Phe Arg Ser Ala Thr Gly Glu Ala Trp Gln Gl #u Ile Met Met Ser Cys         1865          #       1870           #      1875 TCG GCG CAA CCG GAT GTG AAG TGC GAT ATG AA #T TCA GAT ACG CCG GGA     5838 Ser Ala Gln Pro Asp Val Lys Cys Asp Met As #n Ser Asp Thr Pro Gly     1880              #   1885               #  1890 GAA CCA TGC GGT TCC TCA ATA GCC TAT CCG TA #C TTT ATT TCC TTC TAT     5886 Glu Pro Cys Gly Ser Ser Ile Ala Tyr Pro Ty #r Phe Ile Ser Phe Tyr 1895                1900 #                1905  #               1910 GTT CTC TGC TCG TTT TTG ATT ATT AAT CTT TT #C GTG GCC GTC ATT ATG     5934 Val Leu Cys Ser Phe Leu Ile Ile Asn Leu Ph #e Val Ala Val Ile Met                 1915  #               1920   #              1925 GAC AAC TTT GAC TAT CTG ACT CGT GAT TGG TC #G ATT TTG GGT CCC CAC     5982 Asp Asn Phe Asp Tyr Leu Thr Arg Asp Trp Se #r Ile Leu Gly Pro His             1930      #           1935       #          1940 CAC TTG GAC GAG TTT ATT CGC CTT TGG AGC GA #A TAC GAT CCG GAT GCC     6030 His Leu Asp Glu Phe Ile Arg Leu Trp Ser Gl #u Tyr Asp Pro Asp Ala         1945          #       1950           #      1955 AAG GGA CGC ATC AAA CAC TTG GAT GTG GTC AC #A TTG CTG AGA AAG ATC     6078 Lys Gly Arg Ile Lys His Leu Asp Val Val Th #r Leu Leu Arg Lys Ile     1960              #   1965               #  1970 TCC CCA CCA CTT GGC TTC GGC AAA CTG TGT CC #A CAT AGA ATG GCC TGC     6126 Ser Pro Pro Leu Gly Phe Gly Lys Leu Cys Pr #o His Arg Met Ala Cys 1975                1980 #                1985  #               1990 AAG CGA CTG GTT TCC ATG AAC ATG CCC CTC AA #C TCA GAT GGA ACG GTT     6174 Lys Arg Leu Val Ser Met Asn Met Pro Leu As #n Ser Asp Gly Thr Val                 1995  #               2000   #              2005 CTC TTC AAT GCC ACA CTG TTT GCT GTG GTC CG #C ACT TCG CTG AGC ATC     6222 Leu Phe Asn Ala Thr Leu Phe Ala Val Val Ar #g Thr Ser Leu Ser Ile             2010      #           2015       #          2020 AAA ACT GAC GGT AAT ATC GAT GAT GCC AAC TC #C GAG CTG CGC GCC ACT     6270 Lys Thr Asp Gly Asn Ile Asp Asp Ala Asn Se #r Glu Leu Arg Ala Thr         2025          #       2030           #      2035 ATC AAG CAG ATC TGG AAG CGT ACC AAT CCG AA #G CTT CTG GAT CAG GTT     6318 Ile Lys Gln Ile Trp Lys Arg Thr Asn Pro Ly #s Leu Leu Asp Gln Val     2040              #   2045               #  2050 GTT CCA CCG CCG GGC AAC GAT GAC GAG GTG AC #C GTC GGC AAG TTC TAC     6366 Val Pro Pro Pro Gly Asn Asp Asp Glu Val Th #r Val Gly Lys Phe Tyr 2055                2060 #                2065  #               2070 GCC ACA TAT CTA ATT CAG GAC TAC TTC CGG CG #C TTC AAG AAG CGC AAG     6414 Ala Thr Tyr Leu Ile Gln Asp Tyr Phe Arg Ar #g Phe Lys Lys Arg Lys                 2075  #               2080   #              2085 GAA CAG GAG GGC AAG GAG GGT CAT CCG GAC AG #C AAT ACA GTC ACG CTG     6462 Glu Gln Glu Gly Lys Glu Gly His Pro Asp Se #r Asn Thr Val Thr Leu             2090      #           2095       #          2100 CAG GCC GGC TTG CGA ACC TTA CAC GAA GTG TC #C CCA GCT CTA AAG AGA     6510 Gln Ala Gly Leu Arg Thr Leu His Glu Val Se #r Pro Ala Leu Lys Arg         2105          #       2110           #      2115 GCC ATC TCC GGC AAT CTC GAC GAG CTG GAC CA #G GAG CCG GAG CCC ATG     6558 Ala Ile Ser Gly Asn Leu Asp Glu Leu Asp Gl #n Glu Pro Glu Pro Met     2120              #   2125               #  2130 CAT CGT CGT CAT CAT ACG CTT TTC GGC AGC GT #G TGG TCA TCG ATC CGC     6606 His Arg Arg His His Thr Leu Phe Gly Ser Va #l Trp Ser Ser Ile Arg 2135                2140 #                2145  #               2150 CGA CAT GGA AAC GGA ACC TTC AGG CGA AGT GC #C AAG GCA ACT GCT TCG     6654 Arg His Gly Asn Gly Thr Phe Arg Arg Ser Al #a Lys Ala Thr Ala Ser                 2155  #               2160   #              2165 CAG AGC AAC GGA GCC TTG GCG ATC GGT GGA TC #C GCG TCC GCG GCC TTG     6702 Gln Ser Asn Gly Ala Leu Ala Ile Gly Gly Se #r Ala Ser Ala Ala Leu             2170      #           2175       #          2180 GGT GTG GGC GGT AGC TCG CTG GTC CTG GGA AG #C AGC GAT CCC GCT GGC     6750 Gly Val Gly Gly Ser Ser Leu Val Leu Gly Se #r Ser Asp Pro Ala Gly         2185          #       2190           #      2195 GGG GAT TAT CTG TAC GAC ACT CTG AAC CGC AG #C GTA GCC GAC GGA GTG     6798 Gly Asp Tyr Leu Tyr Asp Thr Leu Asn Arg Se #r Val Ala Asp Gly Val     2200              #   2205               #  2210 AAC AAT ATA ACG CGG AAC ATA ATG CAG GCC CG #T TTG GCG GCA GCC GGA     6846 Asn Asn Ile Thr Arg Asn Ile Met Gln Ala Ar #g Leu Ala Ala Ala Gly 2215                2220 #                2225  #               2230 AAG CTG CAG GAC GAA CTG CAG GGG GCA GGA AG #T GGC GGA GAG CTA AGG     6894 Lys Leu Gln Asp Glu Leu Gln Gly Ala Gly Se #r Gly Gly Glu Leu Arg                 2235  #               2240   #              2245 ACA TTC GGC GAG AGC ATA TCC ATG CGA CCG CT #G GCC AAA AAT GGA GGC     6942 Thr Phe Gly Glu Ser Ile Ser Met Arg Pro Le #u Ala Lys Asn Gly Gly             2250      #           2255       #          2260 GGA GCG GCC ACT GTG GCC GGA ACA CTG CCG CC #T GAG GCG AAT GCC ATT     6990 Gly Ala Ala Thr Val Ala Gly Thr Leu Pro Pr #o Glu Ala Asn Ala Ile         2265          #       2270           #      2275 AAC TAT GAC AAC CGC AAT CGT GGT ATT TTA TT #G CAT CCA TAT AAC AAT     7038 Asn Tyr Asp Asn Arg Asn Arg Gly Ile Leu Le #u His Pro Tyr Asn Asn     2280              #   2285               #  2290 GTC TAC GCA CCC AAT GGT GCT CTT CCT GGC CA #C GAA CGC ATG ATC CAA     7086 Val Tyr Ala Pro Asn Gly Ala Leu Pro Gly Hi #s Glu Arg Met Ile Gln 2295                2300 #                2305  #               2310 TCG ACA CCA GCT AGT CCC TAC GAT CAG CGT CG #T TTA CCA ACT TCA TCT     7134 Ser Thr Pro Ala Ser Pro Tyr Asp Gln Arg Ar #g Leu Pro Thr Ser Ser                 2315  #               2320   #              2325 GAT ATG AAC GGT CTA GCC GAA TCA TTG ATT GG #A GGG GTA CTC GCC GCT     7182 Asp Met Asn Gly Leu Ala Glu Ser Leu Ile Gl #y Gly Val Leu Ala Ala             2330      #           2335       #          2340 GAA GGG ATG GGT AAA TAC TGC GAC TCC GAG TT #C GTG GGG ACT GCT GCA     7230 Glu Gly Met Gly Lys Tyr Cys Asp Ser Glu Ph #e Val Gly Thr Ala Ala         2345          #       2350           #      2355 CGG GAG ATG CGC GAA GCG CTG GAC ATG ACG CC #C GAG GAA ATG AAC CTG     7278 Arg Glu Met Arg Glu Ala Leu Asp Met Thr Pr #o Glu Glu Met Asn Leu     2360              #   2365               #  2370 GCC GCC CAC CAG ATC CTC TCC AAC GAG CAC TC #G CTG AGT CTG ATC GGC     7326 Ala Ala His Gln Ile Leu Ser Asn Glu His Se #r Leu Ser Leu Ile Gly 2375                2380 #                2385  #               2390 AGT AGC AAT GGT AGC ATC TTC GGT GGA TCC GC #C GGT GGC CTG GGA GGG     7374 Ser Ser Asn Gly Ser Ile Phe Gly Gly Ser Al #a Gly Gly Leu Gly Gly                 2395  #               2400   #              2405 GCT GGA TCT GGA GGT GTG GGT GGA TTG GGC GG #T AGT AGC AGC ATT CGC     7422 Ala Gly Ser Gly Gly Val Gly Gly Leu Gly Gl #y Ser Ser Ser Ile Arg             2410      #           2415       #          2420 AAC GCT TTC GGC GGA AGC GGA AGT GGA CCG TC #C TCG CTG TCG CCG CAA     7470 Asn Ala Phe Gly Gly Ser Gly Ser Gly Pro Se #r Ser Leu Ser Pro Gln         2425          #       2430           #      2435 CAT CAG CCT TAC TCG GGC ACT CTG AAC TCA CC #A CCG ATT CCG GAT AAT     7518 His Gln Pro Tyr Ser Gly Thr Leu Asn Ser Pr #o Pro Ile Pro Asp Asn     2440              #   2445               #  2450 CGT CTG AGA CGT GTT GCC ACA GTC ACG ACC AC #A AAC AAT AAC AAT AAG     7566 Arg Leu Arg Arg Val Ala Thr Val Thr Thr Th #r Asn Asn Asn Asn Lys 2455                2460 #                2465  #               2470 TCC CAA GTT AGC CAA AAC AAT TCG AGT AGC TT #A AAT GTT AGG GCT AAT     7614 Ser Gln Val Ser Gln Asn Asn Ser Ser Ser Le #u Asn Val Arg Ala Asn                 2475  #               2480   #              2485 GCC AAT AGC CAA ATG AAC ATG TCA CCA ACT GG #A CAA CCA GTG CAG CAA     7662 Ala Asn Ser Gln Met Asn Met Ser Pro Thr Gl #y Gln Pro Val Gln Gln             2490      #           2495       #          2500 CAA TCG CCG CTA AGA GGA CAG GGC AAT CAG AC #T TAC TCC TCA              #7704 Gln Ser Pro Leu Arg Gly Gln Gly Asn Gln Th #r Tyr Ser Ser         2505          #       2510           #      2515 TAGCACCCAC ATTGTAAGCT ATACATACAG AATGTCTTCT TGATGGAACT TT #AAATGTGC   7764 ATTCAGCGCA AGCTGAGGTT TATTGGCTAA TTTATTTGTT ATTTTTAGCG AA #GAAAAACA   7824 CATTAGTCTT AGCATCGGGA ATTGTTATAT TTGAATTGTT CGCACACACA CA #AGCGGGAA   7884 CCAAACCAAC AAAACTTGTA TAACTTGTAT AAAGAAAATC AGCTAATTGT AT #ATGTATAA   7944 ATATATTAAT GTTTTTGCCT TTTTGAGAAA TCTATCGTGG GCCTTCGTCC TC #TAACGAGC   8004 CAGAAAACCA AAAAACCAAC AACACTAAAC TGAACAAATT AAGGAAAAAT GT #ATATTTTT   8064 GGATAAAAAA A                #                   #                   #     8075 (2) INFORMATION FOR SEQ ID NO:2:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 2516 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Gly Gly Gly Glu Leu Val Asn Cys Ile Al #a Tyr Asp Asp Asn Thr   1               5  #                 10  #                 15 Leu Val Ile Glu Arg Lys Pro Ser Pro Ser Se #r Pro Ser Thr Ser Arg              20      #             25      #             30 Arg Tyr Leu Lys Ala Glu Thr Pro Thr Arg Gl #y Ser Arg Lys Tyr Asn          35          #         40          #         45 Arg Lys Ser Ser Ala Lys Ser Asp Leu Glu Va #l Val Val Val Lys Pro      50              #     55              #     60 Glu His His His Gln His Arg Ser Pro Thr Il #e Thr Leu Pro Val Pro  65                  # 70                  # 75                  # 80 Ala Asn Pro Leu Thr Thr Ser Ala Ser Ala Gl #y Ser Ser Pro Thr Gly                  85  #                 90  #                 95 Ala Gly Leu Ala Ala Gly Leu Gly Thr Ala Se #r Gly Thr Val Leu Gln             100       #           105       #           110 Gln Ser Cys Ser Ala Leu Asp Pro Pro Glu As #p Ser Asn Gln Pro Ser         115           #       120           #       125 Gly Thr Arg Arg Arg Ala Thr Ser Thr Glu Le #u Ala Leu Ser Asn Val     130               #   135               #   140 Thr Ser Gln Ile Val Asn Asn Ala Thr Tyr Ly #s Leu Asp Phe Lys Gln 145                 1 #50                 1 #55                 1 #60 Arg Arg His Lys Ser Asn Asn Gly Gly Ser Gl #u Ser Gly Ser Leu Thr                 165   #               170   #               175 Gly Ile Ala Thr Gly Pro Ala Thr Ser Pro Al #a Gly Pro Thr Gly Pro             180       #           185       #           190 Thr Ser Ser Ser Gly Lys Arg Arg Lys Ser Se #r Cys Thr Ser Cys Gly         195           #       200           #       205 Gly Gly Gly Ile Ser Ala Pro Pro Pro Arg Le #u Thr Pro Glu Glu Ala     210               #   215               #   220 Trp Gln Leu Gln Pro Gln Asn Ser Val Thr Se #r Ala Gly Ser Thr Asn 225                 2 #30                 2 #35                 2 #40 Ser Ser Phe Ser Ser Gly Gly Gly Arg Asp As #p Asn Ser Ser Tyr Ser                 245   #               250   #               255 Ala Val Gly Gly Asp Ser Ser Ser Ser Asn Se #r Cys Asn Cys Asp Ile             260       #           265       #           270 Thr Gly Asp Asn Ser Thr Leu His Gly Leu Gl #y Val Gly Asp Val Cys         275           #       280           #       285 Ser Phe Ile Ala Asp Cys Asp Asp Asn Ser Gl #u Asp Asp Asp Gly Asp     290               #   295               #   300 Pro Asn Asn Gln Asp Leu Ser Ser Gln Thr Le #u Arg Thr Ala Ala Ile 305                 3 #10                 3 #15                 3 #20 Val Ala Ala Val Ala Ala Ala Ala Lys Glu Gl #n Ala Gln Glu Gln Ser                 325   #               330   #               335 Leu Ala Asp Cys Glu Ser Phe Ser Asp Arg Ar #g Gln Asp Ala Asp Glu             340       #           345       #           350 Asp Val Arg Ile Ile Gln Asp Cys Cys Gly Gl #y Asn Asn Asp Ser Leu         355           #       360           #       365 Glu Asp Val Gly Glu Val Asp Asp Asn Ala As #p Val Val Val Arg Lys     370               #   375               #   380 Asn Ser Arg Asn Arg Pro Ser Ile Arg Arg Th #r Cys Arg Ile Thr Glu 385                 3 #90                 3 #95                 4 #00 Glu Asp Asp Asp Glu Asp Glu Asn Ala Asp Ty #r Gly Asp Phe Asp Arg                 405   #               410   #               415 Glu Asp Gln Glu Leu Asp Asp Glu Glu Pro Gl #u Gly Thr Thr Ile Asp             420       #           425       #           430 Ile Asp Glu Gln Glu Gln Gln His Asp Gln Gl #y Asp Ser Ala Glu Glu         435           #       440           #       445 Glu Asp His Asp Glu Asp Val Asp Glu Tyr Ph #e Glu Glu Glu Glu Asp     450               #   455               #   460 Asp Thr Gln Ala Phe Ser Pro Phe Tyr Ser Se #r Ser Ala Glu Leu Ile 465                 4 #70                 4 #75                 4 #80 Asp Asn Phe Gly Gly Gly Ala Gly Lys Phe Ph #e Asn Ile Met Asp Phe                 485   #               490   #               495 Glu Arg Gly Ala Ser Gly Glu Gly Gly Phe Se #r Pro Asn Gly Asn Gly             500       #           505       #           510 Gly Pro Gly Ser Gly Asp Val Ser Arg Thr Al #a Arg Tyr Asp Ser Gly         515           #       520           #       525 Glu Gly Asp Leu Gly Gly Gly Asn Asn Ile Me #t Gly Ile Asp Ser Met     530               #   535               #   540 Gly Ile Ala Asn Ile Pro Glu Thr Met Asn Gl #y Thr Thr Ile Gly Pro 545                 5 #50                 5 #55                 5 #60 Ser Gly Ala Gly Gly Gln Lys Gly Gly Ala Al #a Ala Gly Ala Ala Gly                 565   #               570   #               575 Gln Lys Arg Gln Gln Arg Arg Gly Lys Pro Gl #n Pro Asp Arg Pro Gln             580       #           585       #           590 Arg Ala Leu Phe Cys Leu Ser Val Lys Asn Pr #o Leu Arg Ala Leu Cys         595           #       600           #       605 Ile Arg Ile Val Glu Trp Lys Pro Phe Glu Ph #e Leu Ile Leu Leu Thr     610               #   615               #   620 Ile Phe Ala Asn Cys Ile Ala Leu Ala Val Ty #r Thr Pro Tyr Pro Gly 625                 6 #30                 6 #35                 6 #40 Ser Asp Ser Asn Val Thr Asn Gln Thr Leu Gl #u Lys Val Glu Tyr Val                 645   #               650   #               655 Phe Leu Val Ile Phe Thr Ala Glu Cys Val Me #t Lys Ile Leu Ala Tyr             660       #           665       #           670 Gly Phe Val Leu His Asp Gly Ala Tyr Leu Gl #y Asn Gly Trp Asn Leu         675           #       680           #       685 Leu Asp Phe Thr Ile Val Val Met Gly Ala Il #e Ser Thr Ala Leu Ser     690               #   695               #   700 Gln Leu Met Lys Asp Ala Phe Asp Val Lys Al #a Leu Arg Ala Phe Arg 705                 7 #10                 7 #15                 7 #20 Val Leu Arg Pro Leu Arg Leu Val Ser Gly Va #l Pro Ser Leu Gln Val                 725   #               730   #               735 Val Leu Asn Ser Ile Leu Lys Ala Met Val Pr #o Leu Phe His Ile Ala             740       #           745       #           750 Leu Leu Val Leu Phe Val Ile Ile Ile Tyr Al #a Ile Ile Gly Leu Glu         755           #       760           #       765 Leu Phe Ser Gly Lys Leu His Lys Ala Cys Ar #g Asp Glu Ile Thr Gly     770               #   775               #   780 Glu Tyr Glu Glu Asn Ile Arg Pro Cys Gly Va #l Gly Tyr Gln Cys Pro 785                 7 #90                 7 #95                 8 #00 Pro Gly Tyr Lys Cys Tyr Gly Gly Trp Asp Gl #y Pro Asn Asp Gly Ile                 805   #               810   #               815 Thr Asn Phe Asp Asn Phe Gly Leu Ala Met Le #u Thr Val Phe Gln Cys             820       #           825       #           830 Val Thr Leu Glu Gly Trp Thr Asp Val Leu Ty #r Ser Ile Gln Asp Ala         835           #       840           #       845 Met Gly Ser Asp Trp Gln Trp Met Tyr Phe Il #e Ser Met Val Ile Leu     850               #   855               #   860 Gly Ala Phe Phe Val Met Asn Leu Ile Leu Gl #y Val Leu Ser Gly Glu 865                 8 #70                 8 #75                 8 #80 Phe Ser Lys Glu Arg Asn Lys Ala Lys Asn Ar #g Gly Asp Phe Gln Lys                 885   #               890   #               895 Leu Arg Glu Lys Gln Gln Ile Glu Glu Asp Le #u Arg Gly Tyr Leu Asp             900       #           905       #           910 Trp Ile Thr Gln Ala Glu Asp Ile Glu Pro As #p Ala Val Gly Gly Leu         915           #       920           #       925 Ile Ser Asp Gly Lys Gly Lys Gln Pro Asn Gl #u Met Asp Ser Thr Glu     930               #   935               #   940 Asn Leu Gly Glu Glu Met Pro Glu Val Gln Me #t Thr Glu Ser Arg Trp 945                 9 #50                 9 #55                 9 #60 Arg Lys Met Lys Lys Asp Phe Asp Arg Val As #n Arg Arg Met Arg Arg                 965   #               970   #               975 Ala Cys Arg Lys Ala Val Lys Ser Gln Ala Ph #e Tyr Trp Leu Ile Ile             980       #           985       #           990 Val Leu Val Phe Leu Asn Thr Gly Val Leu Al #a Thr Glu His Tyr Gly         995           #       1000           #      1005 Gln Leu Asp Trp Leu Asp Asn Phe Gln Glu Ty #r Thr Asn Val Phe Phe     1010              #   1015               #  1020 Ile Gly Leu Phe Thr Cys Glu Met Leu Leu Ly #s Met Tyr Ser Leu Gly 1025                1030 #                1035  #               1040 Phe Gln Gly Tyr Phe Val Ser Leu Phe Asn Ar #g Phe Asp Cys Phe Val                 1045  #               1050   #              1055 Val Ile Gly Ser Ile Thr Glu Thr Leu Leu Th #r Asn Thr Gly Met Met             1060      #           1065       #          1070 Pro Pro Leu Gly Val Ser Val Leu Arg Cys Va #l Arg Leu Leu Arg Val         1075          #       1080           #      1085 Phe Lys Val Thr Lys Tyr Trp Arg Ser Leu Se #r Asn Leu Val Ala Ser     1090              #   1095               #  1100 Leu Leu Asn Ser Ile Gln Ser Ile Ala Ser Le #u Leu Leu Leu Leu Phe 1105                1110 #                1115  #               1120 Leu Phe Ile Val Ile Phe Ala Leu Leu Gly Me #t Gln Val Phe Gly Gly                 1125  #               1130   #              1135 Lys Phe Asn Phe Asp Gly Lys Glu Glu Lys Ty #r Arg Met Asn Phe Asp             1140      #           1145       #          1150 Cys Phe Trp Gln Ala Leu Leu Thr Val Phe Gl #n Ile Met Thr Gly Glu         1155          #       1160           #      1165 Asp Trp Asn Ala Val Met Tyr Val Gly Ile As #n Ala Tyr Gly Gly Val     1170              #   1175               #  1180 Ser Ser Tyr Gly Ala Leu Ala Cys Ile Tyr Ph #e Ile Ile Leu Phe Ile 1185                1190 #                1195  #               1200 Cys Gly Asn Tyr Ile Leu Leu Asn Val Phe Le #u Ala Ile Ala Val Asp                 1205  #               1210   #              1215 Asn Leu Ala Asp Ala Asp Ser Leu Ser Glu Va #l Glu Lys Glu Glu Glu             1220      #           1225       #          1230 Pro His Asp Glu Ser Ala Gln Lys Lys Ser Hi #s Ser Pro Thr Pro Thr         1235          #       1240           #      1245 Ile Asp Gly Met Asp Asp His Leu Ser Ile As #p Ile Asp Met Glu Gln     1250              #   1255               #  1260 Gln Glu Leu Asp Asp Glu Asp Lys Met Asp Hi #s Glu Thr Leu Ser Asp 1265                1270 #                1275  #               1280 Glu Glu Val Arg Glu Met Cys Glu Glu Glu Gl #u Glu Val Asp Glu Glu                 1285  #               1290   #              1295 Gly Met Ile Thr Ala Arg Pro Arg Arg Met Se #r Glu Val Asn Thr Ala             1300      #           1305       #          1310 Thr Lys Ile Leu Pro Ile Pro Pro Gly Thr Se #r Phe Phe Leu Phe Ser         1315          #       1320           #      1325 Gln Thr Asn Arg Phe Arg Val Phe Cys His Tr #p Leu Cys Asn His Ser     1330              #   1335               #  1340 Asn Phe Gly Asn Ile Ile Leu Cys Cys Ile Me #t Phe Ser Ser Ala Met 1345                1350 #                1355  #               1360 Leu Ala Ala Glu Asn Pro Leu Arg Ala Asn As #p Asp Leu Asn Lys Val                 1365  #               1370   #              1375 Leu Asn Lys Phe Asp Tyr Phe Phe Thr Ala Va #l Phe Thr Met Glu Leu             1380      #           1385       #          1390 Ile Leu Lys Leu Ile Ser Tyr Gly Phe Val Le #u His Asp Gly Ala Phe         1395          #       1400           #      1405 Cys Arg Ser Ala Phe Asn Leu Leu Asp Leu Le #u Val Val Cys Val Ser     1410              #   1415               #  1420 Leu Ile Ser Leu Val Ser Ser Ser Asp Ala Il #e Ser Val Val Lys Ile 1425                1430 #                1435  #               1440 Leu Arg Val Leu Arg Val Leu Arg Pro Leu Ar #g Ala Ile Asn Arg Ala                 1445  #               1450   #              1455 Lys Gly Leu Lys His Val Val Gln Cys Val Il #e Val Ala Val Lys Thr             1460      #           1465       #          1470 Ile Gly Asn Ile Val Leu Val Thr Cys Leu Le #u Gln Phe Met Phe Ala         1475          #       1480           #      1485 Val Ile Gly Val Gln Leu Phe Lys Gly Lys Ph #e Phe Lys Cys Thr Asp     1490              #   1495               #  1500 Gly Ser Lys Met Thr Gln Asp Glu Cys Tyr Gl #y Thr Tyr Leu Val Tyr 1505                1510 #                1515  #               1520 Asp Asp Gly Asp Val His Lys Pro Arg Leu Ar #g Glu Arg Glu Trp Ser                 1525  #               1530   #              1535 Asn Asn Arg Phe His Phe Asp Asp Val Ala Ly #s Gly Met Leu Thr Leu             1540      #           1545       #          1550 Phe Thr Val Ser Thr Phe Glu Gly Trp Pro Gl #y Leu Leu Tyr Val Ser         1555          #       1560           #      1565 Ile Asp Ser Asn Lys Glu Asn Gly Gly Pro Il #e His Asn Phe Arg Pro     1570              #   1575               #  1580 Ile Val Ala Ala Tyr Tyr Ile Ile Tyr Ile Il #e Ile Ile Ala Phe Phe 1585                1590 #                1595  #               1600 Met Val Asn Ile Phe Val Gly Phe Val Ile Va #l Thr Phe Gln Asn Glu                 1605  #               1610   #              1615 Gly Glu Gln Glu Tyr Lys Asn Cys Asp Leu As #p Lys Asn Gln Arg Asn             1620      #           1625       #          1630 Cys Ile Glu Phe Ala Leu Lys Ala Lys Pro Va #l Arg Arg Tyr Ile Pro         1635          #       1640           #      1645 Lys His Gly Ile Gln Tyr Lys Val Trp Trp Ph #e Val Thr Ser Ser Ser     1650              #   1655               #  1660 Phe Glu Tyr Thr Ile Phe Ile Leu Ile Met Il #e Asn Thr Val Thr Leu 1665                1670 #                1675  #               1680 Ala Met Lys Phe Tyr Asn Gln Pro Leu Trp Ty #r Thr Glu Leu Leu Asp                 1685  #               1690   #              1695 Ala Leu Asn Met Ile Phe Thr Ala Val Phe Al #a Leu Glu Phe Val Phe             1700      #           1705       #          1710 Lys Leu Ala Ala Phe Arg Phe Lys Asn Tyr Ph #e Gly Asp Ala Trp Asn         1715          #       1720           #      1725 Val Phe Asp Phe Ile Ile Val Leu Gly Ser Ph #e Ile Asp Ile Val Tyr     1730              #   1735               #  1740 Ser Glu Ile Lys Ser Lys Asp Thr Ser Gln Il #e Ala Glu Cys Asp Ile 1745                1750 #                1755  #               1760 Val Glu Gly Cys Lys Ser Thr Lys Lys Ser Al #a Gly Ser Asn Leu Ile                 1765  #               1770   #              1775 Ser Ile Asn Phe Phe Arg Leu Phe Arg Val Me #t Arg Leu Val Lys Leu             1780      #           1785       #          1790 Leu Ser Lys Gly Glu Gly Ile Arg Thr Leu Le #u Trp Thr Phe Ile Lys         1795          #       1800           #      1805 Ser Phe Gln Ala Leu Pro Tyr Val Ala Leu Le #u Ile Val Leu Leu Phe     1810              #   1815               #  1820 Phe Ile Tyr Ala Val Val Gly Met Gln Val Ph #e Gly Lys Ile Ala Leu 1825                1830 #                1835  #               1840 Asp Gly Gly Asn Ala Ile Thr Ala Asn Asn As #n Phe Gln Thr Phe Gln                 1845  #               1850   #              1855 Gln Ala Val Leu Val Leu Phe Arg Ser Ala Th #r Gly Glu Ala Trp Gln             1860      #           1865       #          1870 Glu Ile Met Met Ser Cys Ser Ala Gln Pro As #p Val Lys Cys Asp Met         1875          #       1880           #      1885 Asn Ser Asp Thr Pro Gly Glu Pro Cys Gly Se #r Ser Ile Ala Tyr Pro     1890              #   1895               #  1900 Tyr Phe Ile Ser Phe Tyr Val Leu Cys Ser Ph #e Leu Ile Ile Asn Leu 1905                1910 #                1915  #               1920 Phe Val Ala Val Ile Met Asp Asn Phe Asp Ty #r Leu Thr Arg Asp Trp                 1925  #               1930   #              1935 Ser Ile Leu Gly Pro His His Leu Asp Glu Ph #e Ile Arg Leu Trp Ser             1940      #           1945       #          1950 Glu Tyr Asp Pro Asp Ala Lys Gly Arg Ile Ly #s His Leu Asp Val Val         1955          #       1960           #      1965 Thr Leu Leu Arg Lys Ile Ser Pro Pro Leu Gl #y Phe Gly Lys Leu Cys     1970              #   1975               #  1980 Pro His Arg Met Ala Cys Lys Arg Leu Val Se #r Met Asn Met Pro Leu 1985                1990 #                1995  #               2000 Asn Ser Asp Gly Thr Val Leu Phe Asn Ala Th #r Leu Phe Ala Val Val                 2005  #               2010   #              2015 Arg Thr Ser Leu Ser Ile Lys Thr Asp Gly As #n Ile Asp Asp Ala Asn             2020      #           2025       #          2030 Ser Glu Leu Arg Ala Thr Ile Lys Gln Ile Tr #p Lys Arg Thr Asn Pro         2035          #       2040           #      2045 Lys Leu Leu Asp Gln Val Val Pro Pro Pro Gl #y Asn Asp Asp Glu Val     2050              #   2055               #  2060 Thr Val Gly Lys Phe Tyr Ala Thr Tyr Leu Il #e Gln Asp Tyr Phe Arg 2065                2070 #                2075  #               2080 Arg Phe Lys Lys Arg Lys Glu Gln Glu Gly Ly #s Glu Gly His Pro Asp                 2085  #               2090   #              2095 Ser Asn Thr Val Thr Leu Gln Ala Gly Leu Ar #g Thr Leu His Glu Val             2100      #           2105       #          2110 Ser Pro Ala Leu Lys Arg Ala Ile Ser Gly As #n Leu Asp Glu Leu Asp         2115          #       2120           #      2125 Gln Glu Pro Glu Pro Met His Arg Arg His Hi #s Thr Leu Phe Gly Ser     2130              #   2135               #  2140 Val Trp Ser Ser Ile Arg Arg His Gly Asn Gl #y Thr Phe Arg Arg Ser 2145                2150 #                2155  #               2160 Ala Lys Ala Thr Ala Ser Gln Ser Asn Gly Al #a Leu Ala Ile Gly Gly                 2165  #               2170   #              2175 Ser Ala Ser Ala Ala Leu Gly Val Gly Gly Se #r Ser Leu Val Leu Gly             2180      #           2185       #          2190 Ser Ser Asp Pro Ala Gly Gly Asp Tyr Leu Ty #r Asp Thr Leu Asn Arg         2195          #       2200           #      2205 Ser Val Ala Asp Gly Val Asn Asn Ile Thr Ar #g Asn Ile Met Gln Ala     2210              #   2215               #  2220 Arg Leu Ala Ala Ala Gly Lys Leu Gln Asp Gl #u Leu Gln Gly Ala Gly 2225                2230 #                2235  #               2240 Ser Gly Gly Glu Leu Arg Thr Phe Gly Glu Se #r Ile Ser Met Arg Pro                 2245  #               2250   #              2255 Leu Ala Lys Asn Gly Gly Gly Ala Ala Thr Va #l Ala Gly Thr Leu Pro             2260      #           2265       #          2270 Pro Glu Ala Asn Ala Ile Asn Tyr Asp Asn Ar #g Asn Arg Gly Ile Leu         2275          #       2280           #      2285 Leu His Pro Tyr Asn Asn Val Tyr Ala Pro As #n Gly Ala Leu Pro Gly     2290              #   2295               #  2300 His Glu Arg Met Ile Gln Ser Thr Pro Ala Se #r Pro Tyr Asp Gln Arg 2305                2310 #                2315  #               2320 Arg Leu Pro Thr Ser Ser Asp Met Asn Gly Le #u Ala Glu Ser Leu Ile                 2325  #               2330   #              2335 Gly Gly Val Leu Ala Ala Glu Gly Met Gly Ly #s Tyr Cys Asp Ser Glu             2340      #           2345       #          2350 Phe Val Gly Thr Ala Ala Arg Glu Met Arg Gl #u Ala Leu Asp Met Thr         2355          #       2360           #      2365 Pro Glu Glu Met Asn Leu Ala Ala His Gln Il #e Leu Ser Asn Glu His     2370              #   2375               #  2380 Ser Leu Ser Leu Ile Gly Ser Ser Asn Gly Se #r Ile Phe Gly Gly Ser 2385                2390 #                2395  #               2400 Ala Gly Gly Leu Gly Gly Ala Gly Ser Gly Gl #y Val Gly Gly Leu Gly                 2405  #               2410   #              2415 Gly Ser Ser Ser Ile Arg Asn Ala Phe Gly Gl #y Ser Gly Ser Gly Pro             2420      #           2425       #          2430 Ser Ser Leu Ser Pro Gln His Gln Pro Tyr Se #r Gly Thr Leu Asn Ser         2435          #       2440           #      2445 Pro Pro Ile Pro Asp Asn Arg Leu Arg Arg Va #l Ala Thr Val Thr Thr     2450              #   2455               #  2460 Thr Asn Asn Asn Asn Lys Ser Gln Val Ser Gl #n Asn Asn Ser Ser Ser 2465                2470 #                2475  #               2480 Leu Asn Val Arg Ala Asn Ala Asn Ser Gln Me #t Asn Met Ser Pro Thr                 2485  #               2490   #              2495 Gly Gln Pro Val Gln Gln Gln Ser Pro Leu Ar #g Gly Gln Gly Asn Gln             2500      #           2505       #          2510 Thr Tyr Ser Ser         2515 (2) INFORMATION FOR SEQ ID NO:3:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 785 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Met Ser Glu Val Asn Thr Ala Thr Lys Ile Le #u Pro Ile Pro Pro Gly 1               5    #                10   #                15 Thr Ser Phe Phe Leu Phe Ser Gln Thr Asn Ar #g Phe Arg Val Phe Cys             20       #            25       #            30 His Trp Leu Cys Asn His Ser Asn Glu Gly As #n Met Val Gly Gly Gly         35           #        40           #        45 Ile Met Glu Ser Ser Ala Met Glu Ala Ala Gl #u Asn Pro Leu Arg Ala     50               #    55               #    60 Asn Asp Asp Leu Asn Lys Val Leu Asn Lys Gl #u Asp Tyr Phe Glu Thr 65                   #70                   #75                   #80 Ala Val Phe Asp Pro Glu Leu Ile Leu Lys As #p Ile Ser Tyr Gly Phe                 85   #                90   #                95 Val Leu His Asp Gly Ala Phe Cys Arg Ser Al #a Arg Asn Glu Leu Asp             100       #           105       #           110 Leu Leu Val Val Cys Val Ser Ile Leu Ser Le #u Val Ser Ser Ser Asn         115           #       120           #       125 Ala Ile Ser Val Val Lys Ile Leu Arg Val Le #u Arg Val Leu Arg Pro     130               #   135               #   140 Asx Arg Ala Ile Asn Arg Ala Lys Gly Leu Ly #s His Val Val Gln Cys 145                 1 #50                 1 #55                 1 #60 Ile Val Ala Val Thr Lys Thr Ile Gly Asn Il #e Val Leu Val Ile Gly                 165   #               170   #               175 Leu Leu Gln Phe Met Glu Ala Val Ile Gly Va #l Leu Phe Lys Gly Lys             180       #           185       #           190 Phe Phe Lys Cys Thr Asp Gly Ser Lys Met Th #r Gln Asp Glu Cys Tyr         195           #       200           #       205 Gly Thr Tyr Leu Val Tyr Asp Asp Gly Asp Va #l His Lys Pro Arg Leu     210               #   215               #   220 Arg Glu Arg Glu Trp Ser Asn Asn Arg Phe Hi #s Phe Asp Asp Val Ala 225                 2 #30                 2 #35                 2 #40 Lys Gly Met Leu Thr Leu Phe Thr Val Ser Th #r Phe Glu Gly Trp Pro                 245   #               250   #               255 Gly Leu Leu Tyr Val Ser Ile Asp Ser Asn Ly #s Glu Asn Gly Gly Pro             260       #           265       #           270 Ile His Asn Phe Arg Pro Ile Val Ala Ala Ty #r Tyr Asp Ile Tyr Ile         275           #       280           #       285 Ile Ile Tyr Ala Phe Phe Met Val Asn Ile Gl #u Val Gly Arg Val Ile     290               #   295               #   300 Val Thr Phe Gln Asn Glu Gly Glu Gln Glu Ty #r Lys Asn Cys Asp Leu 305                 3 #10                 3 #15                 3 #20 Asp Lys Asn Gln Arg Asn Cys Ile Glu Phe Al #a Leu Lys Ala Lys Pro                 325   #               330   #               335 Val Arg Arg Tyr Ile Pro Lys His Gly Ile Gl #n Tyr Lys Val Trp Trp             340       #           345       #           350 Phe Val Thr Ser Ser Ser Glu Glu Tyr Thr Il #e Glu Ile Leu Ile Met         355           #       360           #       365 Ile Asn Thr Val Thr Leu Ala Met Lys Phe Ty #r Asn Gln Pro Leu Trp     370               #   375               #   380 Tyr Thr Glu Leu Leu Asp Ala Leu Asn Met Il #e Glu Ile Ala Val Glu 385                 3 #90                 3 #95                 4 #00 Ala Leu Glu Glu Val Glu Lys Leu Ala Ala Ph #e Arg Phe Lys Asn Tyr                 405   #               410   #               415 Phe Gly Asp Ala Trp Asn Val Glu Asp Glu Il #e Leu Val Leu Gly Ser             420       #           425       #           430 Phe Ile Asp Leu Val Tyr Ser Glu Ile Lys Se #r Lys Asp Thr Ser Gln         435           #       440           #       445 Ile Ala Glu Cys Asp Ile Val Glu Gly Cys Ly #s Ser Thr Lys Lys Ser     450               #   455               #   460 Ala Gly Ser Asn Leu Ile Ser Ile Asn Phe Ph #e Arg Leu Glu Arg Val 465                 4 #70                 4 #75                 4 #80 Met Arg Leu Val Lys Leu Leu Ser Lys Gly Gl #u Gly Ile Arg Thr Leu                 485   #               490   #               495 Leu Trp Thr Phe Ile Lys Ser Phe Gln Ala Le #u Pro Tyr Val Ala Leu             500       #           505       #           510 Leu Ile Val Leu Leu Glu Glu Ile Tyr Ala Va #l Val Gly Met Val Glu         515           #       520           #       525 Gly Lys Ile Ala Leu Asp Gly Gly Asn Ala Il #e Thr Ala Asn Asn Asn     530               #   535               #   540 Phe Gln Thr Phe Gln Gln Ala Val Leu Val Le #u Phe Arg Ser Ala Thr 545                 5 #50                 5 #55                 5 #60 Gly Glu Ala Trp Gln Glu Ile Met Met Ser Cy #s Ser Ala Gln Pro Asp                 565   #               570   #               575 Val Lys Cys Asp Met Asn Ser Asp Thr Pro Gl #y Glu Pro Cys Gly Ser             580       #           585       #           590 Ser Ile Ala Tyr Arg Tyr Glu Ile Ser Glu Ty #r Val Leu Cys Ser Phe         595           #       600           #       605 Leu Leu Ile Asn Leu Glu Val Ala Val Ile Me #t Asp Asn Phe Asp Tyr     610               #   615               #   620 Leu Thr Arg Asp Trp Ser Ile Leu Gly Pro Hi #s His Leu Asp Glu Phe 625                 6 #30                 6 #35                 6 #40 Ile Arg Leu Trp Ser Glu Tyr Asp Pro Asp Al #a Lys Gly Arg Ile Lys                 645   #               650   #               655 His Leu Asp Val Val Thr Leu Leu Arg Lys Il #e Ser Pro Pro Leu Gly             660       #           665       #           670 Phe Gly Lys Leu Cys Pro His Arg Met Ala Cy #s Lys Arg Leu Val Ser         675           #       680           #       685 Met Asn Met Pro Leu Asn Ser Asp Gly Thr Va #l Leu Phe Asn Ala Thr     690               #   695               #   700 Leu Phe Ala Val Val Arg Thr Ser Leu Ser Il #e Lys Thr Asp Gly Asn 705                 7 #10                 7 #15                 7 #20 Ile Asp Asp Ala Asn Ser Glu Leu Arg Ala Th #r Ile Lys Gln Ile Trp                 725   #               730   #               735 Lys Arg Thr Asn Pro Lys Leu Leu Asp Gln Va #l Val Pro Pro Pro Gly             740       #           745       #           750 Asn Asp Asp Glu Val Thr Val Gly Lys Phe Ty #r Ala Thr Tyr Leu Ile         755           #       760           #       765 Gln Asp Tyr Phe Arg Arg Phe Lys Lys Arg Ly #s Glu Gln Glu Gly Lys     770               #   775               #   780 Glu 785 (2) INFORMATION FOR SEQ ID NO:4:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 793 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Glu Ile Pro Val Ser Pro Arg Pro Arg Pro Le #u Ala Glu Leu Gln Leu 1               5    #                10   #                15 Lys Glu Lys Ala Val Pro Ile Pro Glu Ala Se #r Ser Phe Phe Ile Phe             20       #            25       #            30 Ser Pro Thr Asn Lys Val Arg Val Leu Cys Hi #s Arg Ile Val Asn Ala         35           #        40           #        45 Thr Trp Glu Ile Asn Glu Ile Leu Leu Phe Il #e Leu Leu Ser Ser Ala     50               #    55               #    60 Ala Asp Ala Ala Glu Asp Pro Ile Arg Ala Gl #u Ser Val Arg Asn Gln 65                   #70                   #75                   #80 Ile Leu Gly Tyr Glu Asp Ile Ala Phe Ile Se #r Val Glu Thr Val Glu                 85   #                90   #                95 Leu Val Leu Arg Met Ile Ser Tyr Gly Ala Ph #e Leu His Lys Gly Phe             100       #           105       #           110 Ser Cys Arg Asn Leu Lys Asn Asn Ile Asp Al #a Leu Leu Val Val Ala         115           #       120           #       125 Val Gly Ile Arg Lys Met Ile Glu Ser Ser Th #r Ile Ser Val Val Lys     130               #   135               #   140 Ile Ile Arg Met Leu Arg Val Met Leu Arg Hi #s His Arg Ala Val Asn 145                 1 #50                 1 #55                 1 #60 Arg Ala Lys Gly Leu Lys His Val Val Gln Cy #s Phe Val Ala Ile Arg                 165   #               170   #               175 Thr Ile Gly Asn Ile Val Ile Val Ile Thr Le #u Leu Gln Glu Met Glu             180       #           185       #           190 Ala Gln Ile Gln Val Gln Leu Glu Lys Gly Ly #s Phe Phe Ser Cys Asn         195           #       200           #       205 Asp Leu Ser Lys Met Thr Glu Glu Glu Cys Ar #g Gly Tyr Tyr Tyr Val     210               #   215               #   220 Tyr Lys Asp Gly Asp Pro Thr Gln Met Glu Le #u Arg Pro Arg Trp Ile 225                 2 #30                 2 #35                 2 #40 His Asn Asp Phe His Phe Asp Asn Val Leu Se #r Ala Met Met Ser Leu                 245   #               250   #               255 Phe Thr Val Ser Thr Phe Glu Gly Trp Pro Gl #n Leu Leu Tyr Arg Ala             260       #           265       #           270 Ile Asp Ser Asn Glu Glu Asp Met Gly Pro Va #l Tyr Asn Asn Arg Val         275           #       280           #       285 Glu Met Ala Ile Phe Phe Ile Ile Tyr Ile Il #e Leu Ile Ala Lys Glu     290               #   295               #   300 Met Met Asn Gln Phe Val Gly Ile Ala Ala Va #l Thr Phe Gln Glu Gln 305                 3 #10                 3 #15                 3 #20 Gly Glu Thr Glu Tyr Lys Asn Cys Glu Leu As #p Lys Asn Gln Arg Gln                 325   #               330   #               335 Cys Val Gln Tyr Ala Leu Lys Ala Arg Pro Le #u Arg Cys Tyr Ile Pro             340       #           345       #           350 Lys Asn Pro Tyr Gln Tyr Gln Val Trp Tyr Va #l Val Thr Ser Ser Tyr         355           #       360           #       365 Glu Glu Tyr Leu Met Glu Ala Leu Ile Met Le #u Asn Thr Ile Gly Leu     370               #   375               #   380 Gly Met Gln His Tyr His Gln Ser Glu Glu Me #t Asn His Ile Ser Asp 385                 3 #90                 3 #95                 4 #00 Ile Leu Asn Val Ala Arg Asp Leu Glu Arg Il #e Leu Glu Met Ile Asp                 405   #               410   #               415 Lys Asn Asn Ala Phe Lys Ala Arg Gly Tyr Ph #e Gly Asp Arg Trp Asn             420       #           425       #           430 Val Leu Asp Glu Leu Ile Trp Leu Gly Ser Il #e Ile Asp Val Ile Leu         435           #       440           #       445 Ser Glu Ile Asp Thr Phe Leu Ala Ser Ser Gl #y Gly Leu Tyr Cys Leu     450               #   455               #   460 Gly Gly Gly Cys Gly Asn Val Asp Pro Asp Gl #u Ser Ala Arg Ile Ser 465                 4 #70                 4 #75                 4 #80 Ser Ala Leu Lys Arg Leu Glu Arg Val Met Ar #g Leu Ile Lys Leu Asp                 485   #               490   #               495 Ser Arg Ala Glu Gly Val Arg Thr Leu Leu Tr #p Thr Phe Ile Lys Ser             500       #           505       #           510 Phe Gln Ala Leu Pro Tyr Ile Ala Leu Leu Le #u Val Met Leu Glu Glu         515           #       520           #       525 Ile Tyr Ala Val Ile Gly Met Met Phe Gly Ly #s Ile Ala Leu Val Asp     530               #   535               #   540 Gly Thr Gln Ile Asn Arg Asn Asn Asn Phe Gl #n Thr Phe Pro Gln Ala 545                 5 #50                 5 #55                 5 #60 Val Leu Leu Leu Phe Arg Cys Ala Thr Gly Gl #u Ala Trp Gln Glu Ile                 565   #               570   #               575 Leu Leu Ala Cys Ser Tyr Gly Lys Leu Cys As #p Pro Glu Ser Asp Tyr             580       #           585       #           590 Ala Pro Gly Glu Glu Tyr Thr Cys Gly Thr As #n Phe Ala Tyr Tyr Tyr         595           #       600           #       605 Phe Ile Ser Phe Tyr Met Leu Cys Ala Leu Ph #e Ile Ile Asn Leu Phe     610               #   615               #   620 Val Ala Val Phe Met Asp Asn Phe Asp Tyr Le #u Thr Arg Asp Trp Ser 625                 6 #30                 6 #35                 6 #40 Ile Leu Gly Pro His His Leu Asp Glu Phe Ly #s Ala Ile Trp Ala Glu                 645   #               650   #               655 Tyr Asp Pro Glu Ala Lys Gly Arg Ile Lys Hi #s Leu Asp Val Val Thr             660       #           665       #           670 Leu Leu Arg Arg Ile Gln Pro Pro Leu Gly Ph #e Gly Lys Phe Cys Pro         675           #       680           #       685 His Arg Val Ala Cys Lys Arg Leu Val Gly Me #t Asn Met Pro Leu Asn     690               #   695               #   700 Ser Asp Gly Thr Val Thr Phe Asn Ala Thr Le #u Phe Ala Leu Val Arg 705                 7 #10                 7 #15                 7 #20 Thr Ala Leu Lys Ile Lys Thr Glu Gly Asn Ph #e Glu Gln Ala Asn Glu                 725   #               730   #               735 Glu Leu Arg Ala Ile Ile Lys Ile Trp Lys Ly #s Arg Thr Ser Met Lys             740       #           745       #           750 Leu Leu Asp Gln Val Ile Pro Pro Ile Gly As #p Asp Glu Val Thr Val         755           #       760           #       765 Gly Lys Phe Tyr Ala Thr Phe Leu Ile Gln Gl #u His Phe Arg Lys Phe     770               #   775               #   780 Met Lys Arg Gln Glu Glu Tyr Tyr Gly 785                 7 #90 (2) INFORMATION FOR SEQ ID NO:5:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 526 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Arg Ser Asp Gly Ser Thr Ser Ser Asp Thr Th #r Ser Asn Xaa Xaa Val 1               5    #                10   #                15 Arg Gln Gly Ser Ala Asp Ser Tyr Thr Ser Ar #g Pro Gly Xaa Asp Ser             20       #            25       #            30 Asp Val Ser Leu Glu Glu Asp Arg Glu Ala Le #u Arg Arg Glu Ala Glu         35           #        40           #        45 Arg Gln Ala Xaa Ala Gln Leu Glu Lys Ala Ly #s Thr Lys Pro Val Ala     50               #    55               #    60 Phe Ala Val Arg Thr Asn Val Ser Tyr Xaa Gl #y Xaa Xaa Asp Asp Glu 65                   #70                   #75                   #80 Val Pro Val Gln Gly Val Ala Ile Xaa Phe Gl #u Ala Lys Asp Phe Leu                 85   #                90   #                95 His Ile Lys Glu Lys Tyr Asn Asn Asp Trp Tr #p Ile Gly Arg Leu Val             100       #           105       #           110 Lys Glu Gly Cys Glu Ile Gly Phe Ile Pro Se #r Pro Val Lys Leu Glu         115           #       120           #       125 Ser Ile Arg Leu Xaa Gln Glu Gln Xaa Xaa Ly #s Gln Xaa Arg Leu Xaa     130               #   135               #   140 Ser Ser Lys Ser Gly Gly Asn Ser Ser Ser Se #r Leu Gly Asp Ile Val 145                 1 #50                 1 #55                 1 #60 Thr Gly Thr Arg Arg Ser Thr Pro Pro Ser Se #r Ala Lys Gln Lys Gln                 165   #               170   #               175 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa             180       #           185       #           190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa         195           #       200           #       205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Lys Lys Thr     210               #   215               #   220 Glu His Val Pro Pro Tyr Asp Val Val Pro Se #r Met Arg Pro Val Val 225                 2 #30                 2 #35                 2 #40 Leu Val Gly Pro Ser Leu Lys Gly Tyr Glu Va #l Thr Asp Met Met Gln                 245   #               250   #               255 Lys Ala Leu Phe Asp Phe Leu Lys His Arg Ph #e Asp Gly Arg Ile Ser             260       #           265       #           270 Ile Thr Arg Val Thr Ala Asp Ile Ser Leu Al #a Lys Arg Ser Val Leu         275           #       280           #       285 Asn Asn Pro Ser Lys His Xaa Ile Ile Glu Ar #g Ser Asn Thr Arg Ser     290               #   295               #   300 Xaa Ser Leu Ala Glu Val Gln Ser Glu Ile Gl #u Arg Ile Phe Glu Leu 305                 3 #10                 3 #15                 3 #20 Ala Arg Thr Leu Gln Leu Val Val Leu Asp Al #a Asp Thr Ile Asn His                 325   #               330   #               335 Pro Ala Gln Leu Ser Lys Thr Ser Leu Ala Pr #o Ile Ile Val Tyr Val             340       #           345       #           350 Lys Ile Ser Ser Pro Lys Val Leu Gln Arg Le #u Ile Lys Ser Arg Gly         355           #       360           #       365 Lys Ser Gln Ser Lys His Leu Asn Val Gln Me #t Xaa Ala Xaa Asp Lys     370               #   375               #   380 Leu Ala Gln Cys Pro Pro Xaa Glu Met Phe As #p Val Ile Leu Asp Glu 385                 3 #90                 3 #95                 4 #00 Asn Gln Leu Glu Asp Ala Cys Glu His Leu Al #a Glu Tyr Leu Glu Ala                 405   #               410   #               415 Tyr Trp Lys Ala Thr His Pro Pro Ser Ser Th #r Pro Pro Asn Pro Leu             420       #           425       #           430 Leu Xaa Asn Thr Met Ala Thr Ala Ala Leu Xa #a Xaa Ser Pro Ala Xaa         435           #       440           #       445 Xaa Ser Asn Xaa Gln Xaa Xaa Gln Xaa Xaa Xa #a Gly Xaa Val Leu Thr     450               #   455               #   460 Xaa Xaa Ser Pro Xaa Xaa Arg Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Glu Xaa 465                 4 #70                 4 #75                 4 #80 Xaa Xaa Xaa Xaa Gly Ser Ser Gln Arg Ser Xa #a Arg His Gly Xaa Xaa                 485   #               490   #               495 Val Glu Glu Asp Tyr Xaa Asp Ala Tyr Gln Xa #a Xaa Xaa Gln Xaa Xaa             500       #           505       #           510 Arg Xaa Xaa Xaa Xaa Xaa Xaa Pro Xaa Xaa Xa #a Xaa Xaa Asp         515           #       520           #       525 (2) INFORMATION FOR SEQ ID NO:6:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 566 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Tyr Asp Asp Ser Tyr Val Pro Gly Phe Gl #u Asp Xaa Xaa Xaa Ser 1               5    #                10   #                15 Glu Ala Gly Ser Ala Asp Ser Tyr Thr Ser Ar #g Pro Ser Leu Asp Ser             20       #            25       #            30 Asp Val Ser Leu Glu Glu Asp Arg Glu Ser Al #a Arg Arg Glu Val Glu         35           #        40           #        45 Ser Gln Ala Gln Gln Gln Leu Glu Arg Ala Ly #s His Lys Pro Val Ala     50               #    55               #    60 Phe Ala Val Arg Thr Asn Val Ser Tyr Cys Gl #y Val Leu Asp Glu Glu 65                   #70                   #75                   #80 Cys Pro Val Gln Gly Ser Gly Val Asn Phe Gl #u Ala Lys Asp Phe Leu                 85   #                90   #                95 His Ile Lys Glu Lys Tyr Ser Asn Asp Trp Tr #p Ile Gly Arg Leu Val             100       #           105       #           110 Lys Glu Gly Gly Asp Ile Ala Phe Ile Pro Se #r Pro Gln Arg Leu Glu         115           #       120           #       125 Ser Ile Arg Leu Lys Gln Glu Gln Xaa Xaa Ly #s Xaa Xaa Xaa Xaa Xaa     130               #   135               #   140 Xaa Ala Arg Arg Ser Gly Asn Xaa Pro Ser Se #r Leu Ser Asp Ile Xaa 145                 1 #50                 1 #55                 1 #60 Xaa Gly Asn Arg Arg Ser Pro Pro Pro Ser Le #u Ala Lys Gln Lys Gln                 165   #               170   #               175 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa             180       #           185       #           190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa         195           #       200           #       205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Lys Gln Ala     210               #   215               #   220 Glu His Val Pro Pro Tyr Asp Val Val Pro Se #r Met Arg Pro Val Val 225                 2 #30                 2 #35                 2 #40 Leu Val Gly Pro Ser Leu Lys Gly Tyr Glu Va #l Thr Asp Met Met Gln                 245   #               250   #               255 Lys Ala Leu Phe Asp Phe Leu Lys His Arg Ph #e Asp Gly Arg Ile Ser             260       #           265       #           270 Ile Thr Arg Val Thr Ala Asp Leu Ser Leu Al #a Lys Arg Ser Val Leu         275           #       280           #       285 Asn Asn Pro Gly Lys Arg Thr Ile Ile Glu Ar #g Ser Ser Ala Arg Ser     290               #   295               #   300 Xaa Ser Ile Ala Glu Val Gln Ser Glu Ile Gl #u Arg Ile Phe Glu Leu 305                 3 #10                 3 #15                 3 #20 Ala Lys Ser Leu Gln Leu Val Val Leu Asp Al #a Asp Thr Ile Asn His                 325   #               330   #               335 Pro Ala Gln Leu Ala Lys Thr Ser Leu Ala Pr #o Ile Ile Val Phe Val             340       #           345       #           350 Lys Val Ser Ser Pro Lys Val Leu Gln Arg Le #u Ile Arg Ser Arg Gly         355           #       360           #       365 Lys Ser Gln Met Lys His Leu Thr Val Gln Me #t Met Ala Tyr Asp Lys     370               #   375               #   380 Leu Val Gln Cys Pro Pro Xaa Glu Ser Phe As #p Val Ile Leu Asp Glu 385                 3 #90                 3 #95                 4 #00 Asn Gln Leu Asp Asp Ala Cys Glu His Leu Al #a Glu Tyr Leu Glu Val                 405   #               410   #               415 Tyr Trp Arg Ala Thr His His Pro Ala Pro Gl #y Pro Xaa Xaa Gly Met             420       #           425       #           430 Leu Gly Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Pro Ser Ala         435           #       440           #       445 Ile Pro Gly Leu Gln Asn Gln Gln Leu Xaa Le #u Gly Glu Arg Gly Glu     450               #   455               #   460 Glu His Ser Pro Leu Glu Arg Asp Ser Leu Me #t Pro Ser Asp Glu Ala 465                 4 #70                 4 #75                 4 #80 Xaa Xaa Xaa Xaa Xaa Ser Glu Ser Ser Arg Gl #n Ala Trp Thr Gly Ser                 485   #               490   #               495 Ser Gln Arg Ser Ser Arg His Xaa Xaa Xaa Le #u Glu Glu Asp Tyr Ala             500       #           505       #           510 Asp Ala Tyr Gln Asp Leu Tyr Gln Pro His Ar #g Gln His Thr Ser Gly         515           #       520           #       525 Leu Pro Ser Ala Asn Gly His Asp Pro Gln As #p Arg Leu Leu Ala Gln     530               #   535               #   540 Asp Ser Glu His Asp His Asn Asp Arg Asn Tr #p Gln Arg Asn Arg Pro 545                 5 #50                 5 #55                 5 #60 Trp Pro Lys Asp Ser Tyr                 565 (2) INFORMATION FOR SEQ ID NO:7:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 574 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Met Ser Ser Ser Tyr Ala Lys Asn Gly Ala Al #a Asp Gly Pro His Ser 1               5    #                10   #                15 Pro Ser Ser Gln Val Ala Arg Gly Thr Thr Th #r Arg Arg Ser Arg Leu             20       #            25       #            30 Lys Arg Ser Asp Gly Ser Thr Thr Ser Thr Se #r Phe Ile Xaa Xaa Xaa         35           #        40           #        45 Leu Arg Gln Gly Ser Ala Asp Ser Tyr Thr Se #r Arg Pro Ser Xaa Asp     50               #    55               #    60 Xaa Ser Asp Val Ser Leu Glu Glu Asp Arg Gl #u Ala Ile Arg Gln Glu 65                   #70                   #75                   #80 Arg Glu Gln Gln Ala Ala Ile Gln Leu Glu Ar #g Ala Lys Ser Lys Pro                 85   #                90   #                95 Val Ala Phe Ala Val Lys Thr Asn Val Ser Ty #r Cys Gly Ala Leu Asp             100       #           105       #           110 Glu Asp Val Pro Val Pro Ser Thr Ala Ile Se #r Phe Asp Ala Lys Asp         115           #       120           #       125 Phe Leu His Ile Lys Glu Lys Tyr Asn Asn As #p Trp Trp Ile Gly Arg     130               #   135               #   140 Leu Val Lys Glu Gly Cys Ile Glu Gly Phe Il #e Pro Ser Pro Leu Arg 145                 1 #50                 1 #55                 1 #60 Leu Glu Asn Ile Arg Ile Gln Gln Glu Gln Xa #a Xaa Lys Arg Gly Arg                 165   #               170   #               175 Phe His Gly Gly Lys Ser Ser Gly Asn Ser Se #r Ser Ser Leu Gly Glu             180       #           185       #           190 Met Val Ser Gly Thr Phe Arg Ala Thr Pro Th #r Thr Thr Ala Lys Gln         195           #       200           #       205 Lys Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa     210               #   215               #   220 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa 225                 2 #30                 2 #35                 2 #40 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Lys                 245   #               250   #               255 Val Thr Glu His Ile Pro Pro Tyr Asp Val Va #l Pro Ser Met Arg Pro             260       #           265       #           270 Val Val Leu Val Gly Pro Ser Leu Lys Gly Ty #r Glu Val Thr Asp Met         275           #       280           #       285 Met Gln Lys Ala Leu Phe Asp Phe Leu Lys Hi #s Arg Phe Asp Gly Arg     290               #   295               #   300 Ile Ser Ile Thr Arg Val Thr Ala Lys Ile Se #r Leu Ala Lys Arg Ser 305                 3 #10                 3 #15                 3 #20 Val Leu Asn Asn Pro Ser Lys Arg Ala Ile Il #e Glu Arg Ser Asn Thr                 325   #               330   #               335 Arg Ser Xaa Ser Leu Ala Glu Val Gln Ser Gl #u Ile Glu Arg Ile Phe             340       #           345       #           350 Glu Leu Ala Arg Ser Leu Gln Leu Val Val Le #u Asp Ala Asp Thr Ile         355           #       360           #       365 Asn His Pro Ala Gln Leu Ile Lys Thr Ser Le #u Ala Pro Ile Ile Val     370               #   375               #   380 His Val Lys Val Ser Ser Pro Lys Val Leu Gl #n Arg Leu Ile Lys Ser 385                 3 #90                 3 #95                 4 #00 Arg Gly Lys Ser Gln Ser Lys His Leu Asn Va #l Gln Leu Val Ala Ala                 405   #               410   #               415 Asp Lys Leu Ala Gln Cys Pro Pro Glu Met Ph #e Asp Val Ile Leu Asp             420       #           425       #           430 Glu Asn Gln Leu Glu Asp Ala Cys Glu His Le #u Gly Glu Tyr Leu Glu         435           #       440           #       445 Ala Tyr Trp Arg Ala Thr His Thr Ser Ser Se #r Thr Pro Met Thr Pro     450               #   455               #   460 Leu Leu Gly Arg Asn Val Gly Ser Thr Ala Le #u Ser Pro Tyr Pro Thr 465                 4 #70                 4 #75                 4 #80 Ala Ile Ser Gly Leu Gln Ser Gln Arg Met Ar #g His Ser Asn His Ser                 485   #               490   #               495 Thr Glu Asn Ser Pro Ile Glu Arg Arg Ser Le #u Met Thr Ser Asp Glu             500       #           505       #           510 Asn Tyr His Asn Glu Arg Ala Arg Lys Ser Ar #g Asn Arg Leu Ser Ser         515           #       520           #       525 Ser Ser Gln His Ser Arg Asp Asn Tyr Pro Le #u Val Glu Glu Asp Tyr     530               #   535               #   540 Pro Asp Ser Tyr Gln Asp Thr Tyr Lys Pro Hi #s Arg Asn Arg Gly Ser 545                 5 #50                 5 #55                 5 #60 Xaa Xaa Pro Gly Gly Cys Ser His Asp Ser Ar #g His Arg Leu                 565   #               570 (2) INFORMATION FOR SEQ ID NO:8:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 618 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Met Gln Cys Cys Gly Leu Val His Arg Arg Ar #g Val Arg Val Ser Tyr 1               5    #                10   #                15 Gly Ser Ala Asp Ser Tyr Thr Ser Arg Pro Se #r Xaa Asp Ser Asp Val             20       #            25       #            30 Ser Leu Glu Glu Asp Arg Glu Ala Val Arg Ar #g Glu Ala Glu Arg Gln         35           #        40           #        45 Ala Gln Ala Gln Leu Glu Lys Ala Lys Thr Ly #s Pro Val Ala Phe Ala     50               #    55               #    60 Val Arg Thr Asn Val Arg Tyr Ser Ala Ala Gl #n Glu Asp Asp Val Pro 65                   #70                   #75                   #80 Val Pro Gly Met Ala Ile Ser Phe Glu Ala Ly #s Asp Phe Leu His Val                 85   #                90   #                95 Lys Glu Lys Phe Asn Asn Asp Trp Trp Ile Gl #y Arg Leu Val Lys Glu             100       #           105       #           110 Gly Cys Glu Ile Gly Phe Ile Pro Ser Pro Va #l Lys Leu Glu Asn Met         115           #       120           #       125 Arg Leu Gln His Glu Gln Arg Ala Lys Gln Gl #y Lys Phe Tyr Ser Ser     130               #   135               #   140 Lys Ser Gly Gly Asn Ser Ser Ser Ser Leu Gl #y Asp Ile Val Pro Ser 145                 1 #50                 1 #55                 1 #60 Ser Arg Lys Ser Thr Pro Pro Ser Ser Ala Xa #a Xaa Xaa Xaa Xaa Xaa                 165   #               170   #               175 Xaa Ile Asp Ile Asp Ala Thr Gln Leu Asp Al #a Glu Glu Asn Asp Ile             180       #           185       #           190 Pro Ala Asn His Arg Ser Pro Lys Pro Ser Al #a Asn Ser Val Thr Ser         195           #       200           #       205 Pro His Ser Lys Glu Lys Arg Met Pro Phe Ph #e Lys Lys Thr Glu His     210               #   215               #   220 Thr Pro Pro Tyr Asp Val Val Pro Ser Met Ar #g Pro Val Val Leu Val 225                 2 #30                 2 #35                 2 #40 Gly Pro Ser Leu Lys Gly Tyr Glu Val Thr As #p Met Met Gln Lys Ala                 245   #               250   #               255 Leu Phe Asp Phe Leu Lys His Arg Phe Glu Gl #y Arg Ile Ser Ile Thr             260       #           265       #           270 Arg Val Thr Ala Asp Ile Ser Leu Ala Lys Ar #g Ser Val Leu Asn Asn         275           #       280           #       285 Pro Ser Lys His Ala Ile Ile Glu Arg Ser As #n Thr Arg Ser Xaa Ser     290               #   295               #   300 Leu Ala Glu Val Gln Ser Glu Ile Glu Arg Il #e Phe Glu Leu Ala Arg 305                 3 #10                 3 #15                 3 #20 Thr Leu Gln Leu Val Val Leu Asp Ala Asp Th #r Ile Asn His Pro Ala                 325   #               330   #               335 Gln Leu Ser Lys Thr Ser Leu Ala Pro Ile Il #e Val Tyr Val Lys Ile             340       #           345       #           350 Ser Ser Pro Lys Val Leu Gln Arg Leu Ile Ly #s Ser Arg Gly Lys Ser         355           #       360           #       365 Gln Ala Lys His Leu Asn Val Gln Met Val Al #a Ala Asp Lys Leu Ala     370               #   375               #   380 Gln Cys Pro Pro Gln Glu Ser Phe Asp Val Il #e Leu Asp Glu Asn Gln 385                 3 #90                 3 #95                 4 #00 Leu Glu Asp Ala Cys Glu His Ile Ala Asp Ty #r Leu Glu Ala Tyr Trp                 405   #               410   #               415 Lys Ala Thr His Pro Pro Ser Ser Asn Leu Pr #o Asn Pro Leu Leu Ser             420       #           425       #           430 Arg Thr Leu Ala Thr Ser Thr Leu Pro Leu Se #r Pro Thr Leu Ala Ser         435           #       440           #       445 Asn Ser Gln Gly Ser Gln Xaa Xaa Xaa Gly As #p Gln Arg Thr Asp Arg     450               #   455               #   460 Ser Ala Pro Xaa Arg Ser Ala Ser Gln Ala Gl #u Glu Glu Pro Cys Leu 465                 4 #70                 4 #75                 4 #80 Glu Pro Val Lys Lys Ser Gln His Arg Xaa Se #r Ser Ser Ala Thr His                 485   #               490   #               495 Gln Asn His Arg Ser Gly Thr Gly Arg Gly Le #u Ser Arg Gln Glu Thr             500       #           505       #           510 Phe Asp Ser Glu Thr Gln Glu Ser Arg Asp Se #r Ala Tyr Val Glu Pro         515           #       520           #       525 Lys Glu Asp Tyr Ser His Glu His Val Asp Ar #g Tyr Val Pro His Arg     530               #   535               #   540 Glu His Asn His Arg Glu Glu Ser His Ser Se #r Asn Gly His Arg His 545                 5 #50                 5 #55                 5 #60 Arg Glu Pro Arg His Arg Thr Arg Asp Met Gl #y Arg Asp Gln Asp His                 565   #               570   #               575 Asn Glu Cys Ser Lys Gln Arg Ser Arg His Ly #s Ser Lys Asp Arg Tyr             580       #           585       #           590 Cys Asp Lys Glu Gly Glu Val Ile Ser Lys Ar #g Arg Ser Glu Ala Gly         595           #       600           #       605 Glu Trp Asn Arg Asp Val Tyr Ile Arg Gln     610               #   615 (2) INFORMATION FOR SEQ ID NO:9:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 554 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Met Val Gln Lys Thr Ser Met Ser Arg Gly Pr #o Tyr Pro Pro Ser Gln 1               5    #                10   #                15 Glu Ile Pro Met Glu Val Phe Asp Pro Ser Pr #o Gln Gly Lys Tyr Ser             20       #            25       #            30 Lys Arg Lys Gly Arg Phe Lys Arg Ser Asp Gl #y Ser Thr Ser Ser Asp         35           #        40           #        45 Thr Thr Ser Asn Ser Phe Val Arg Gln Gly Se #r Ala Glu Ser Tyr Thr     50               #    55               #    60 Ser Arg Pro Ser Xaa Asp Ser Asp Val Ser Le #u Glu Glu Asp Arg Glu 65                   #70                   #75                   #80 Ala Leu Arg Lys Glu Ala Glu Arg Gln Ala Le #u Ala Gln Leu Glu Lys                 85   #                90   #                95 Ala Lys Thr Lys Pro Val Ala Phe Ala Val Ar #g Thr Asn Val Gly Tyr             100       #           105       #           110 Asn Pro Ser Pro Gly Asp Glu Val Pro Val Gl #u Gly Val Ala Ile Thr         115           #       120           #       125 Phe Glu Pro Lys Asp Phe Leu His Ile Lys Gl #u Lys Tyr Asn Asn Asp     130               #   135               #   140 Trp Trp Ile Gly Arg Leu Val Lys Glu Gly Cy #s Glu Val Gly Phe Ile 145                 1 #50                 1 #55                 1 #60 Pro Ser Pro Val Lys Leu Asp Ser Leu Arg Le #u Leu Gln Glu Gln Lys                 165   #               170   #               175 Leu Arg Gln Ser Arg Leu Ser Ser Ser Lys Se #r Gly Asp Asn Ser Ser             180       #           185       #           190 Ser Ser Leu Gly Asp Val Val Thr Gly Thr Ar #g Arg Pro Thr Pro Pro         195           #       200           #       205 Ala Ser Gly Asn Glu Met Thr Asn Leu Ala Ph #e Glu Leu Glu Pro Leu     210               #   215               #   220 Asp Leu Glu Glu Asp Glu Ala Glu Leu Gly Gl #u Gln Ser Gly Ser Ala 225                 2 #30                 2 #35                 2 #40 Lys Thr Ser Val Ser Ser Val Thr Thr Pro Pr #o Pro His Gly Thr Arg                 245   #               250   #               255 Ile Pro Phe Phe Lys Lys Thr Glu His Val Pr #o Pro Tyr Asp Val Val             260       #           265       #           270 Pro Ser Met Arg Pro Ile Ile Leu Val Gly Pr #o Ser Leu Lys Gly Tyr         275           #       280           #       285 Glu Val Thr Asp Met Met Gln Lys Ala Leu Ph #e Asp Phe Leu Lys His     290               #   295               #   300 Leu Phe Asp Gly Arg Ile Ser Ile Thr Arg Va #l Thr Ala Asp Ile Ser 305                 3 #10                 3 #15                 3 #20 Leu Ala Lys Arg Ser Val Leu Asn Asn Pro Se #r Lys His Ile Ile Ile                 325   #               330   #               335 Glu Arg Ser Asn Thr Arg Ser Xaa Ser Leu Al #a Glu Val Gln Ser Glu             340       #           345       #           350 Ile Glu Arg Ile Phe Glu Leu Ala Arg Thr Le #u Gln Leu Val Ala Leu         355           #       360           #       365 Asp Ala Asp Thr Ile Asn His Pro Ala Gln Le #u Ser Lys Thr Ser Leu     370               #   375               #   380 Ala Pro Ile Ile Val Tyr Ile Lys Ile Thr Se #r Pro Lys Val Leu Gln 385                 3 #90                 3 #95                 4 #00 Arg Leu Ile Lys Ser Arg Gly Lys Ser Gln Se #r Lys His Leu Asn Val                 405   #               410   #               415 Gln Ile Ala Ala Ser Glu Lys Leu Ala Gln Cy #s Pro Pro Xaa Glu Met             420       #           425       #           430 Phe Asp Ile Ile Leu Asp Glu Asn Gln Leu Gl #u Asp Ala Cys Glu His         435           #       440           #       445 Leu Ala Glu Tyr Leu Glu Ala Tyr Trp Lys Al #a Thr His Pro Pro Ser     450               #   455               #   460 Ser Thr Pro Pro Asn Pro Leu Leu Asn Arg Th #r Met Ala Thr Ala Ala 465                 4 #70                 4 #75                 4 #80 Leu Ala Ala Ser Pro Ala Pro Val Ser Asn Xa #a Xaa Xaa Leu Gln Xaa                 485   #               490   #               495 Xaa Xaa Val Gln Val Leu Thr Ser Leu Arg Ar #g Asn Leu Xaa Xaa Xaa             500       #           505       #           510 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa         515           #       520           #       525 Xaa Xaa Ser Phe Trp Gly Gly Leu Glu Thr Se #r Gln Arg Gly Gly Gly     530               #   535               #   540 Ala Val Pro Gln Gln Gln Glu His Ala Met 545                 5 #50 (2) INFORMATION FOR SEQ ID NO:10:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 658 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Met Val Gln Lys Ser Gly Met Ser Arg Gly Pr #o Tyr Pro Pro Ser Gln 1               5    #                10   #                15 Glu Ile Pro Met Glu Val Phe Asp Pro Ser Pr #o Gln Gly Lys Tyr Ser             20       #            25       #            30 Lys Arg Lys Gly Arg Phe Lys Arg Ser Asp Gl #y Ser Thr Ser Ser Asp         35           #        40           #        45 Thr Thr Ser Asn Ser Phe Val Arg Gln Gly Se #r Ala Glu Ser Tyr Thr     50               #    55               #    60 Ser Arg Pro Ser Xaa Asp Ser Asp Val Ser Le #u Glu Glu Asp Arg Glu 65                   #70                   #75                   #80 Ala Leu Arg Lys Glu Ala Glu Arg Gln Ala Le #u Ala Gln Leu Glu Lys                 85   #                90   #                95 Ala Lys Thr Lys Pro Val Ala Phe Ala Val Ar #g Thr Asn Val Gly Tyr             100       #           105       #           110 Asn Pro Ser Pro Gly Asp Glu Val Pro Val Gl #n Gly Val Ala Ile Thr         115           #       120           #       125 Phe Glu Pro Lys Asp Phe Leu His Ile Lys Gl #u Lys Tyr Asn Asn Asp     130               #   135               #   140 Trp Trp Ile Gly Arg Leu Val Lys Glu Gly Cy #s Glu Val Gly Phe Ile 145                 1 #50                 1 #55                 1 #60 Pro Ser Pro Val Lys Leu Asp Ser Leu Arg Le #u Leu Gln Glu Gln Thr                 165   #               170   #               175 Leu Arg Gln Asn Arg Leu Ser Ser Ser Lys Se #r Gly Asp Asn Ser Ser             180       #           185       #           190 Ser Ser Leu Gly Asp Val Val Thr Gly Thr Ar #g Arg Pro Thr Pro Pro         195           #       200           #       205 Ala Ser Ala Lys Gln Lys Gln Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa     210               #   215               #   220 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa 225                 2 #30                 2 #35                 2 #40 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa                 245   #               250   #               255 Xaa Xaa Xaa Xaa Lys Ser Thr Glu His Val Pr #o Pro Tyr Asp Val Val             260       #           265       #           270 Pro Ser Met Arg Pro Ile Ile Leu Val Gly Pr #o Ser Leu Lys Gly Tyr         275           #       280           #       285 Glu Val Thr Asp Met Met Gln Lys Ala Leu Ph #e Asp Phe Leu Lys His     290               #   295               #   300 Arg Phe Asp Gly Arg Ile Ser Ile Thr Arg Va #l Thr Ala Asp Ile Ser 305                 3 #10                 3 #15                 3 #20 Leu Ala Lys Arg Ser Val Leu Asn Asn Pro Se #r Lys His Ile Ile Ile                 325   #               330   #               335 Glu Arg Ser Asn Thr Arg Ser Xaa Ser Leu Al #a Glu Val Gln Ser Glu             340       #           345       #           350 Ile Glu Arg Ile Phe Glu Leu Ala Arg Thr Le #u Gln Leu Val Ala Leu         355           #       360           #       365 Asp Ala Asp Thr Ile Asn His Pro Ala Gln Le #u Ser Lys Thr Ser Leu     370               #   375               #   380 Ala Pro Ile Ile Val Tyr Ile Lys Ile Thr Se #r Pro Lys Val Leu Gln 385                 3 #90                 3 #95                 4 #00 Arg Leu Ile Lys Ser Arg Gly Lys Ser Gln Se #r Lys His Leu Asn Val                 405   #               410   #               415 Gln Ile Ala Ala Ser Glu Lys Leu Ala Gln Cy #s Pro Pro Xaa Glu Met             420       #           425       #           430 Phe Asp Ile Ile Leu Asp Glu Asn Gln Leu Gl #u Asp Ala Cys Glu His         435           #       440           #       445 Leu Ala Glu Tyr Leu Glu Ala Tyr Trp Lys Al #a Thr His Pro Pro Ser     450               #   455               #   460 Arg Thr Pro Pro Asn Pro Leu Leu Asn Arg Th #r Met Ala Thr Ala Ala 465                 4 #70                 4 #75                 4 #80 Leu Ala Val Ser Pro Ala Pro Val Ser Asn Xa #a Xaa Xaa Leu Gln Xaa                 485   #               490   #               495 Xaa Xaa Gly Pro Tyr Leu Val Ser Gly Asp Gl #n Pro Leu Asp Arg Ala             500       #           505       #           510 Thr Gly Glu His Ala Ser Val His Glu Tyr Pr #o Gly Glu Leu Gly Gln         515           #       520           #       525 Pro Pro Gly Leu Tyr Pro Ser Asn His Pro Pr #o Gly Arg Ala Gly Thr     530               #   535               #   540 Leu Trp Ala Leu Ser Arg Gln Asp Thr Phe As #p Ala Asp Thr Pro Gly 545                 5 #50                 5 #55                 5 #60 Ser Arg Asn Ser Val Tyr Thr Glu Pro Gly As #p Ser Cys Val Asp Met                 565   #               570   #               575 Glu Thr Asp Pro Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Ser Glu Gly Pro Gly             580       #           585       #           590 Pro Gly Asp Pro Ala Gly Gly Gly Thr Pro Pr #o Ala Arg Gln Gly Ser         595           #       600           #       605 Trp Glu Glu Glu Glu Asp Tyr Glu Glu Glu Me #t Thr Asp Asn Arg Asn     610               #   615               #   620 Arg Gly Arg Asn Lys Ala Arg Tyr Cys Ala Gl #u Gly Gly Gly Pro Val 625                 6 #30                 6 #35                 6 #40 Leu Gly Arg Asn Lys Asn Glu Leu Glu Gly Tr #p Gly Gln Gly Val Tyr                 645   #               650   #               655 Ile Arg (2) INFORMATION FOR SEQ ID NO:11:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 472 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Met Lys Lys Leu His Leu Gly Ala Lys His Ly #s Gly Lys Ser Tyr Lys 1               5    #                10   #                15 Pro Phe Arg Asn Lys Xaa Asn Arg Arg Gly Se #r Ala Asp Ser Asn Tyr             20       #            25       #            30 Ser Gln Pro Ser Xaa Xaa Ser Asp Leu Ser Le #u Asp Glu Glu Lys Glu         35           #        40           #        45 Ser Leu Arg Arg Glu Lys Glu Arg Gln Ala Le #u Ser Gln Leu Asp Lys     50               #    55               #    60 Ala Arg Ser Lys Pro Val Ala Phe Ala Val Ar #g Thr Asn Val Ala Tyr 65                   #70                   #75                   #80 Asp Gly Ala Ile Asp Asp Asp Ser Pro Val Gl #n Gly Gly Ala Val Ser                 85   #                90   #                95 Phe Glu Ile Arg Glu Phe Leu His Ile Lys Gl #u Lys Tyr Asp Asn Asn             100       #           105       #           110 Trp Trp Ile Gly Arg Leu Val Lys Glu Gly Cy #s Gly Val Gly Phe Ile         115           #       120           #       125 Pro Ser Pro Ala Lys Leu Asp Asn Ile Arg Me #t Gln Asn Gln Xaa Xaa     130               #   135               #   140 Thr Arg Pro Ser Arg Leu Tyr Gly Thr Lys Xa #a Xaa Xaa Xaa Xaa Gly 145                 1 #50                 1 #55                 1 #60 Ser Ser Ser Gly Asn Leu Gly Ala Gly Gly Gl #n Ala Gly Ala Glu Pro                 165   #               170   #               175 Ser Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Xaa Xaa Xaa Xaa Xaa             180       #           185       #           190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa #a Asp Ser Met Gly Pro         195           #       200           #       205 Gly Arg His Gly Lys Thr Pro Ala Ala Ala Al #a Asn Lys Glu Lys Arg     210               #   215               #   220 Lys Pro Phe Phe Lys Lys Gln Glu Thr Ala Se #r Pro Tyr Asp Val Val 225                 2 #30                 2 #35                 2 #40 Pro Ser Met Arg Pro Val Val Leu Val Gly Pr #o Ser Leu Lys Gly Tyr                 245   #               250   #               255 Glu Val Thr Asp Met Met Gln Lys Ala Leu Ph #e Asp Phe Leu Lys His             260       #           265       #           270 Arg Phe Glu Gly Arg Ile Ile Ile Thr Arg Va #l Met Ala Asp Ile Ser         275           #       280           #       285 Leu Ala Lys Arg Ser Ile Met Asn Asn Pro Se #r Lys Arg Ala Ile Met     290               #   295               #   300 Glu Arg Ser Ser Ser Arg Ser Asp Cys Leu Gl #y Lys Val Gln Glu Glu 305                 3 #10                 3 #15                 3 #20 Ile Glu Arg Ile Phe Glu Leu Ala Arg Ser Le #u Gln Leu Val Val Leu                 325   #               330   #               335 Asp Cys Asp Thr Ile Asn His Pro Ser Gln Le #u Ala Lys Thr Ser Leu             340       #           345       #           350 Ala Pro Thr Ile Val Tyr Leu Lys Ile Ser Se #r Ser Lys Val Leu Gln         355           #       360           #       365 Arg Leu Ile Lys Ser Arg Gly Lys Ser Gln Al #a Lys Asn Leu Ser Val     370               #   375               #   380 Gln Met Val Ala Ala Glu Lys Leu Ala Gln Cy #s Pro Pro Xaa Asp Met 385                 3 #90                 3 #95                 4 #00 Phe Asp Val Ile Leu Asp Glu Asn Gln Leu Gl #u Asp Ala Cys Glu His                 405   #               410   #               415 Ile Ala Glu Tyr Leu Glu Thr Tyr Trp Lys Al #a Thr His Pro Asp Ile             420       #           425       #           430 Arg Ala Val Pro Xaa Pro Ile Ala Arg Pro Le #u Pro Gln Glu Ala Ser         435           #       440           #       445 Pro Ser Ala Asp Pro Ala Arg Leu Gly Pro Th #r Pro Pro Val Thr Xaa     450               #   455               #   460 Xaa Xaa Pro Gly Val Val Arg Leu 465                 4 #70 (2) INFORMATION FOR SEQ ID NO:12:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 93 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..93     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: ATG AAG AAG CTT CAT CTG GGT GCC AAG CAC AA #G GGC AAG TCC TAC AAG       48 Met Lys Lys Leu His Leu Gly Ala Lys His Ly #s Gly Lys Ser Tyr Lys   1               5  #                 10  #                 15 CCC TTT AGG AAT AAG AAT CGT CGG GGT TCT GC #C GAC TCG AAC TAC            #93 Pro Phe Arg Asn Lys Asn Arg Arg Gly Ser Al #a Asp Ser Asn Tyr              20      #             25      #             30 (2) INFORMATION FOR SEQ ID NO:13:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 31 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Met Lys Lys Leu His Leu Gly Ala Lys His Ly #s Gly Lys Ser Tyr Lys   1               5  #                 10  #                 15 Pro Phe Arg Asn Lys Asn Arg Arg Gly Ser Al #a Asp Ser Asn Tyr              20      #             25      #             30 (2) INFORMATION FOR SEQ ID NO:14:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 141 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..141     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: ATG GTG CAG CGC GCC TCT TCC TCG GAT GCA CC #C TCC GTT CAG GGT GGC       48 Met Val Gln Arg Ala Ser Ser Ser Asp Ala Pr #o Ser Val Gln Gly Gly              35      #             40      #             45 CAA CAT CGA GAG TCT CGA TTT GGC CTT GGA TA #C CCC TCC TAC CAG AGT       96 Gln His Arg Glu Ser Arg Phe Gly Leu Gly Ty #r Pro Ser Tyr Gln Ser          50          #         55          #         60 GGA TAC AAC AAA CTA TTC ACA CAG GGT TCT GC #C GAC TCG AAC TAC          14 #1 Gly Tyr Asn Lys Leu Phe Thr Gln Gly Ser Al #a Asp Ser Asn Tyr      65              #     70              #     75 (2) INFORMATION FOR SEQ ID NO:15:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 47 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Met Val Gln Arg Ala Ser Ser Ser Asp Ala Pr #o Ser Val Gln Gly Gly   1               5  #                 10  #                 15 Gln His Arg Glu Ser Arg Phe Gly Leu Gly Ty #r Pro Ser Tyr Gln Ser              20      #             25      #             30 Gly Tyr Asn Lys Leu Phe Thr Gln Gly Ser Al #a Asp Ser Asn Tyr          35          #         40          #         45 (2) INFORMATION FOR SEQ ID NO:16:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 48 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 10..48     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: ACGCCGTGA GAA TTG CGG AAC CAA CAG GGT TCT GCC # GAC TCG AAC TAC         48           Glu Leu Arg Asn Gln  #Gln Gly Ser Ala Asp Ser Asn Tyr                    # 50                  # 55                  # 60 (2) INFORMATION FOR SEQ ID NO:17:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Glu Leu Arg Asn Gln Gln Gly Ser Ala Asp Se #r Asn Tyr   1               5  #                 10 (2) INFORMATION FOR SEQ ID NO:18:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 156 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: GGCGGACAAG CAGGTGCGGA GCCATCTCGA GGTAGCACAC CCCCCACACC TG #GTATGACA     60 CACATTTCAT TCTCCTGATA TCCCTACAGT ACAACACCGC GCAAGAAAAA CA #AAGGTGAC    120 GAATCAGATT CCATGGGACC AGGACGACAC GGCAAG       #                   #      156 (2) INFORMATION FOR SEQ ID NO:19:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 60 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..60     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: GGC GGA CAA GCA GGT GCG GAG CCA TCT CGA GA #T TCC ATG GGA CCA GGA       48 Gly Gly Gln Ala Gly Ala Glu Pro Ser Arg As #p Ser Met Gly Pro Gly      15              #     20              #     25 CGA CAC GGC AAG             #                   #                   #       60 Arg His Gly Lys  30 (2) INFORMATION FOR SEQ ID NO:20:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 20 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Gly Gly Gln Ala Gly Ala Glu Pro Ser Arg As #p Ser Met Gly Pro Gly   1               5  #                 10  #                 15 Arg His Gly Lys              20 (2) INFORMATION FOR SEQ ID NO:21:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 42 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..42     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: GGC GGA CAA GCA GAT TCC ATG GGA CCA GGA CG #A CAC GGC AAG              #  42 Gly Gly Gln Ala Asp Ser Met Gly Pro Gly Ar #g His Gly Lys                  25  #                 30 (2) INFORMATION FOR SEQ ID NO:22:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 14 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Gly Gly Gln Ala Asp Ser Met Gly Pro Gly Ar #g His Gly Lys   1               5  #                 10 (2) INFORMATION FOR SEQ ID NO:23:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 81 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..81     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: GGC GGA CAA GCA GGT GCG GAG CCA TCT CGA GG #T AGC ACA CCC CCC ACA       48 Gly Gly Gln Ala Gly Ala Glu Pro Ser Arg Gl #y Ser Thr Pro Pro Thr  15                  # 20                  # 25                  # 30 CCT GAT TCC ATG GGA CCA GGA CGA CAC GGC AA #G                   #         81 Pro Asp Ser Met Gly Pro Gly Arg His Gly Ly #s                  35  #                 40 (2) INFORMATION FOR SEQ ID NO:24:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 27 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Gly Gly Gln Ala Gly Ala Glu Pro Ser Arg Gl #y Ser Thr Pro Pro Thr   1               5  #                 10  #                 15 Pro Asp Ser Met Gly Pro Gly Arg His Gly Ly #s              20      #             25 (2) INFORMATION FOR SEQ ID NO:25:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 93 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..93     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GGC GGA CAA GCA GGT GCG GAG CCA TCT CGA GG #T AGC ACA CCC CCC ACA       48 Gly Gly Gln Ala Gly Ala Glu Pro Ser Arg Gl #y Ser Thr Pro Pro Thr          30          #         35          #         40 CCT GGT GAC GAA TCA GAT TCC ATG GGA CCA GG #A CGA CAC GGC AAG            #93 Pro Gly Asp Glu Ser Asp Ser Met Gly Pro Gl #y Arg His Gly Lys      45              #     50              #     55 (2) INFORMATION FOR SEQ ID NO:26:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 31 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Gly Gly Gln Ala Gly Ala Glu Pro Ser Arg Gl #y Ser Thr Pro Pro Thr   1               5  #                 10  #                 15 Pro Gly Asp Glu Ser Asp Ser Met Gly Pro Gl #y Arg His Gly Lys              20      #             25      #             30 (2) INFORMATION FOR SEQ ID NO:27:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 54 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..54     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: GGC GGA CAA GCA GGT GAC GAA TCA GAT TCC AT #G GGA CCA GGA CGA CAC       48 Gly Gly Gln Ala Gly Asp Glu Ser Asp Ser Me #t Gly Pro Gly Arg His   1               5  #                 10  #                 15 GGC AAG                 #                   #                   #           54 Gly Lys (2) INFORMATION FOR SEQ ID NO:28:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 18 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Gly Gly Gln Ala Gly Asp Glu Ser Asp Ser Me #t Gly Pro Gly Arg His   1               5  #                 10  #                 15 Gly Lys (2) INFORMATION FOR SEQ ID NO:29:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 63 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..63     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: GGC GGA CAA GCA GAT CCC TAC AGT ACA ACA CC #G CGC AAG AAA AAC AAA       48 Gly Gly Gln Ala Asp Pro Tyr Ser Thr Thr Pr #o Arg Lys Lys Asn Lys      20              #     25              #     30 GGA CGA CAC GGC AAG            #                   #                   #    63 Gly Arg His Gly Lys  35 (2) INFORMATION FOR SEQ ID NO:30:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 21 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Gly Gly Gln Ala Asp Pro Tyr Ser Thr Thr Pr #o Arg Lys Lys Asn Lys   1               5  #                 10  #                 15 Gly Arg His Gly Lys              20 (2) INFORMATION FOR SEQ ID NO:31:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 79 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..75     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: GGC GGA CAA GCA GGT GCG GAG CCA TCT CGA GG #T AGC ACA CCC CCC ACA       48 Gly Gly Gln Ala Gly Ala Glu Pro Ser Arg Gl #y Ser Thr Pro Pro Thr              25      #             30      #             35 CCT GGT ATG ACA CAC ATT TCA TTC TCC TGAT   #                   #          79 Pro Gly Met Thr His Ile Ser Phe Ser          40          #         45 (2) INFORMATION FOR SEQ ID NO:32:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 25 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: Gly Gly Gln Ala Gly Ala Glu Pro Ser Arg Gl #y Ser Thr Pro Pro Thr   1               5  #                 10  #                 15 Pro Gly Met Thr His Ile Ser Phe Ser              20      #             25 (2) INFORMATION FOR SEQ ID NO:33:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 52 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..36     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: CCG ACG CCT CCA GTT ACA CCG GGT GTT GTG CG #C CTG TAATAGAGGA            4 #6 Pro Thr Pro Pro Val Thr Pro Gly Val Val Ar #g Leu                  30  #                 35 ACCTCT                  #                   #                   #           52 (2) INFORMATION FOR SEQ ID NO:34:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 12 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Pro Thr Pro Pro Val Thr Pro Gly Val Val Ar #g Leu   1               5  #                 10 (2) INFORMATION FOR SEQ ID NO:35:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 74 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..57     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: CCG ACG CCT CCA GCA TTC ACA GCA CGT GAC AT #A CCC GGT CCC TTT ACA       48 Pro Thr Pro Pro Ala Phe Thr Ala Arg Asp Il #e Pro Gly Pro Phe Thr          15          #         20          #         25 ACA ATG CTA TAGAGGAGGA AACCTCT         #                   #              74 Thr Met Leu      30 (2) INFORMATION FOR SEQ ID NO:36:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 19 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: Pro Thr Pro Pro Ala Phe Thr Ala Arg Asp Il #e Pro Gly Pro Phe Thr   1               5  #                 10  #                 15 Thr Met Leu (2) INFORMATION FOR SEQ ID NO:37:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 76 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..63     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: CCG ACG CCT CCA GTA GAT GGC GAG GAG TTT GT #C GAT GAG CAG GAT CCC       48 Pro Thr Pro Pro Val Asp Gly Glu Glu Phe Va #l Asp Glu Gln Asp Pro  20                  # 25                  # 30                  # 35 AGG ATG GGC ATG TCC AGGAGGAACC TCT      #                   #             76 Arg Met Gly Met Ser                  40 (2) INFORMATION FOR SEQ ID NO:38:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 21 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: Pro Thr Pro Pro Val Asp Gly Glu Glu Phe Va #l Asp Glu Gln Asp Pro   1               5  #                 10  #                 15 Arg Met Gly Met Ser              20 (2) INFORMATION FOR SEQ ID NO:39:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 24 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..12     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: CCG ACG CCT CCA GGAGGAACCT CT        #                   #                24 Pro Thr Pro Pro              25 (2) INFORMATION FOR SEQ ID NO:40:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 4 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: Pro Thr Pro Pro   1 (2) INFORMATION FOR SEQ ID NO:41:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 45 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: CDS           (B) LOCATION: 1..45     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: CCG ACG CCT CCA GGT AAA GGA ACA CCT GCC CG #C TCG TTC GGG CTC            #45 Pro Thr Pro Pro Gly Lys Gly Thr Pro Ala Ar #g Ser Phe Gly Leu   5                 #  10                 #  15 (2) INFORMATION FOR SEQ ID NO:42:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 15 amino  #acids           (B) TYPE: amino acid           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: Pro Thr Pro Pro Gly Lys Gly Thr Pro Ala Ar #g Ser Phe Gly Leu   1               5  #                 10  #                 15 (2) INFORMATION FOR SEQ ID NO:43:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 1631 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: mat_ #peptide           (B) LOCATION: 33..1631     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: ACCGTTTGTG ATTCCATAAC AATTTGTGAG CCATGAAGAA GCTTCATCTG GG #TGCCAAGC     60 ACAAGGGCAA GTCCTACAAG CCCTTTAGGA ATAAGAATCG TCGGGGTTCT GC #CGACTCGA    120 ACTACTCACA ACCGTCATCC GATCTGTCGC TAGACGAGGA AAAGGAATCG CT #TCGGCGAG    180 AAAAGGAACG TCAGGCCTTA AGCCAGTTGG ATAAAGCGAG GAGCAAACCA GT #GGCGTTCG    240 CTGTGCGAAC CAACGTAGCA TACGATGGCG CCATCGACGA CGATTCGCCG GT #GCAGGGCG    300 GAGCAGTTTC GTTCGAGATC CGGGAATTCC TGCACATCAA AGAGAAGTAC GA #CAATAACT    360 GGTGGATCGG CCGGCTGGTC AAGGAGGGCT GTGATGTGGG CTTCATACCC AG #CCCCGCTA    420 AGCTAGACAA CATTCGCATG CAGAACCAAA CCAGACCCTC AAGACTGTAT GG #CACAAAGG    480 GCTCGTCGAG CGGGAATCTT GGTGCGGGCG GACAAGCAGG TGCGGAGCCA TC #TCGAGATT    540 CCATGGGACC AGGACGACAC GGCAAGACAC CGGCGGCGGC GGCCAACAAG GA #GAAGCGAA    600 AGCCATTCTT CAAGAAACAG GAGACGGCCA GTCCCTACGA CGTGGTGCCC TC #GATGCGTC    660 CCGTCGTCCT GGTGGGGCCC AGTTTGAAGG GCTACGAGGT GACCGACATG AT #GCAGAAAG    720 CCCTCTTCGA CTTCCTCAAG CACCGCTTCG AGGGCCGCAT CATCATCACC CG #GGTGATGG    780 CCGACATCTC GCTGGCCAAG CGCTCCATCA TGAACAATCC CTCGAAGCGG GC #CATCATGG    840 AGCGATCCTC CAGCCGGAGC GACTGCCTCG GCAAGGTGCA GGAGGAGATC GA #GCGCATCT    900 TCGAGCTGGC CCGCTCGCTC CAGCTGGTCG TGCTCGATTG TGATACAATC AA #TCATCCGT    960 CACAACTAGC GAAAACTTCA TTAGCGCCAA CAATAGTGTA CTTAAAGATT AG #TAGTAGTA   1020 AGGTTTTACA GCGTTTGATC AAATCACGTG GCAAGTCGCA GGCGAAAAAC CT #CTCCGTCC   1080 AAATGGTTGC CGCCGAGAAG CTAGCCCAAT GTCCACCGGA TATGTTCGAT GT #AATCCTAG   1140 ACGAGAATCA GCTGGAAGAC GCCTGCGAGC ACATTGCCGA GTACTTGGAG AC #GTATTGGA   1200 AGGCCACCCA CCCGGACATT CGAGCAGTGC CGCCCATCGC CCGCCCCCTG CC #GCAGGAGG   1260 CCTCGCCCTC CGCAGATCCC GCGCGTCTGG GACCGACGCC TCCAGTTACA CC #GGGTGTTG   1320 TGCGCCTGTA AACTGCCGCA ATCCGCGCCA AACCCCTTCT ACTCGATTTC TC #ACATTCTT   1380 CCGGGTGTTT TCCTAGATCA GCTCAACTCA ACCCAAATCA GCTCAGTTAT AA #TATATACT   1440 ATATATATAT ATGTACATGT ATTCCGTTAT TGTCGAACCT TATGTTTTCA CC #ATTTCAAG   1500 TTGCAAAAGC AAATCATCTA ATCGTTTAGA TCTGGTTTAG AGGAACCTCT TA #CCAGCACA   1560 GCCGCCGACA ACCGACCTCG GTACGCCACC AGGAGCGCGG CGGAGGAGTG GG #CGCAGGCG   1620 GCGGAGGTGG A                #                   #                   #     1631 (2) INFORMATION FOR SEQ ID NO:44:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 26 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: Pr #imer P6     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 6           (D) OTHER INFORMATION:  #/note= “inosine”     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 12           (D) OTHER INFORMATION:  #/note= “inosine”     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 21           (D) OTHER INFORMATION:  #/note= “inosine”     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: ATHGYNATGY TNTTYTTYAT NTAYGC           #                   #              26 (2) INFORMATION FOR SEQ ID NO:45:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 26 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: Pr #imer P7     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 6           (D) OTHER INFORMATION:  #/note= “inosine”     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 15           (D) OTHER INFORMATION:  #/note= “inosine”     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 18           (D) OTHER INFORMATION:  #/note= “inosine”     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 21           (D) OTHER INFORMATION:  #/note= “inosine”     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: TCRTCNARRT GRTGNGGNCC NARDAT           #                   #              26 (2) INFORMATION FOR SEQ ID NO:46:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 4 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: Peptide           (B) LOCATION: 2           (D) OTHER INFORMATION:  #/note= “any amino acid except proline”     (ix) FEATURE:           (A) NAME/KEY: Peptide           (B) LOCATION: 3           (D) OTHER INFORMATION:  #/note= “serine or threonine”     (ix) FEATURE:           (A) NAME/KEY: Peptide           (B) LOCATION: 4           (D) OTHER INFORMATION:  #/note= “any amino acid except proline”     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: Asn Xaa Xaa Xaa 1 (2) INFORMATION FOR SEQ ID NO:47:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 4 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: Peptide           (B) LOCATION: 1           (D) OTHER INFORMATION:  #/note= “arginine or lysine”     (ix) FEATURE:           (A) NAME/KEY: Peptide           (B) LOCATION: 2           (D) OTHER INFORMATION:  #/note= “any amino acid except proline”     (ix) FEATURE:           (A) NAME/KEY: Peptide           (B) LOCATION: 3           (D) OTHER INFORMATION:  #/note= “any amino acid except proline”     (ix) FEATURE:           (A) NAME/KEY: Peptide           (B) LOCATION: 4           (D) OTHER INFORMATION:  #/note= “serine or threonine”     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: Xaa Xaa Xaa Xaa 1 (2) INFORMATION FOR SEQ ID NO:48:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 4 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: Peptide           (B) LOCATION: 1           (D) OTHER INFORMATION:  #/note= “serine or threonine”     (ix) FEATURE:           (A) NAME/KEY: Modified-sit #e           (B) LOCATION: 2           (D) OTHER INFORMATION:  #/note= “any amino acid except proline”     (ix) FEATURE:           (A) NAME/KEY: Modified-sit #e           (B) LOCATION: 3           (D) OTHER INFORMATION:  #/note= “any amino acid except proline”     (ix) FEATURE:           (A) NAME/KEY: Modified-sit #e           (B) LOCATION: 4           (D) OTHER INFORMATION:  #/note= “Aspartic acid or glutamic acid”     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: Xaa Xaa Xaa Xaa 1 (2) INFORMATION FOR SEQ ID NO:49:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 25 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 11           (D) OTHER INFORMATION:  #/note= “Cysteine or Threonine”     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 14           (D) OTHER INFORMATION:  #/note= “Cysteine or Threonine”     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 17           (D) OTHER INFORMATION:  #/note= “Cysteine or Threonine”     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: GTGGATCCAA NAANGANTGG TGGAT           #                   #               25 (2) INFORMATION FOR SEQ ID NO:50:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 25 base  #pairs           (B) TYPE: nucleic acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 11           (D) OTHER INFORMATION:  #/note= “Cysteine or Threonine”     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 14           (D) OTHER INFORMATION:  #/note= “Cysteine or Threonine”     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 23           (D) OTHER INFORMATION:  #/note= “Glycine or Alanine”     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: ACGGATCCGC NTTNTGCATC ATNTC           #                   #               25 (2) INFORMATION FOR SEQ ID NO:51:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 9 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: Ser Thr Pro Pro Thr Pro Pro Thr Asp 1               5 (2) INFORMATION FOR SEQ ID NO:52:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: Met Phe Asp Glu Thr Trp His Lys Phe Asp Va #l His Gly Thr Gln Phe 1               5    #                10   #                15 Leu Asp Tyr Asn Asp Leu Pro Arg Phe Val As #n Ala Leu             20       #            25 (2) INFORMATION FOR SEQ ID NO:53:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pr #o Asp Ala Thr Gln Phe 1               5    #                10   #                15 Met Glu Phe Glu Lys Leu Ser Gln Phe Ala Al #a Ala Leu             20       #            25 (2) INFORMATION FOR SEQ ID NO:54:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pr #o Asp Ala Thr Gln Phe 1               5    #                10   #                15 Ile Glu Phe Cys Lys Leu Ser Asp Phe Ala Al #a Ala Leu             20       #            25 (2) INFORMATION FOR SEQ ID NO:55:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pr #o Asp Ala Thr Gln Phe 1               5    #                10   #                15 Ile Glu Phe Cys Lys Leu Ser Asp Phe Ala Al #a Ala Leu             20       #            25 (2) INFORMATION FOR SEQ ID NO:56:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: Met Phe Tyr Glu Ile Trp Glu Lys Phe Asp Pr #o Glu Ala Thr Gln Phe 1               5    #                10   #                15 Ile Glu Tyr Leu Ala Leu Ser Asp Phe Ala As #p Ala Leu             20       #            25 (2) INFORMATION FOR SEQ ID NO:57:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: Met Phe Tyr Glu Thr Trp Glu Lys Phe Asp Pr #o Asp Ala Thr Gln Phe 1               5    #                10   #                15 Ile Asp Tyr Ser Arg Leu Ser Asp Phe Val Th #r Asp Leu             20       #            25 (2) INFORMATION FOR SEQ ID NO:58:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: Lys Ile Ser Tyr Leu Asp Val Leu Leu Ala Va #l Thr Gln Glu Val Leu 1               5    #                10   #                15 Gly Asp Thr Thr Glu Met Glu Ala Met Arg Le #u Ser Ile             20       #            25 (2) INFORMATION FOR SEQ ID NO:59:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59: Lys Ile His Cys Leu Asp Ile Leu Phe Ala Le #u Thr Lys Glu Val Leu 1               5    #                10   #                15 Gly Asp Ser Gly Glu Met Asp Ala Leu Lys Gl #n Thr Met             20       #            25 (2) INFORMATION FOR SEQ ID NO:60:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60: Glu Phe Lys Arg Ile Trp Ala Glu Tyr Asp Pr #o Glu Ala Lys Gly Arg 1               5    #                10   #                15 Ile Lys His Leu Asp Val Val Thr Leu Leu Ar #g Arg Ile             20       #            25 (2) INFORMATION FOR SEQ ID NO:61:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61: Glu Phe Lys Lys Ile Trp Ala Glu Tyr Asp Pr #o Glu Ala Thr Gly Arg 1               5    #                10   #                15 Ile Lys His Leu Asp Val Val Thr Leu Leu Ar #g Arg Ile             20       #            25 (2) INFORMATION FOR SEQ ID NO:62:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62: Glu Phe Lys Arg Ile Trp Ser Glu Tyr Asp Pr #o Glu Ala Lys Gly Arg 1               5    #                10   #                15 Ile Lys His Leu Asp Val Val Thr Leu Leu Ar #g Arg Ile             20       #            25 (2) INFORMATION FOR SEQ ID NO:63:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: Glu Phe Lys Ala Ile Trp Ala Glu Tyr Asp Pr #o Glu Ala Lys Gly Arg 1               5    #                10   #                15 Ile Lys His Leu Asp Val Val Thr Leu Leu Ar #g Arg Ile             20       #            25 (2) INFORMATION FOR SEQ ID NO:64:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64: Glu Phe Lys Arg Ile Trp Ser Glu Tyr Asp Pr #o Glu Ala Lys Gly Arg 1               5    #                10   #                15 Ile Lys His Leu Asp Val Val Thr Leu Leu Ar #g Arg Ile             20       #            25 (2) INFORMATION FOR SEQ ID NO:65:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 29 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: single           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65: Glu Phe Ile Arg Leu Trp Ser Glu Tyr Asp Pr #o Asp Ala Lys Gly Arg 1               5    #                10   #                15 Ile Lys His Leu Asp Val Val Thr Leu Leu Ar #g Lys Ile             20       #            25 (2) INFORMATION FOR SEQ ID NO:66:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel consensus (Repeat I)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66: Gln Cys Ile Thr Met Glu Gly Trp Thr Asp Va #l Leu Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:67:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Drosophila (Repeat I)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67: Gln Cys Val Thr Leu Glu Gly Trp Thr Asp Va #l Leu Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:68:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Carp Skel (Repeat I)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68: Gln Cys Ile Thr Thr Glu Ser Trp Thr Asp Va #l Leu Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:69:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Rabbit Skel, Human Br, Rat Br-D,                Rat Br-C, # Rat Aorta, Rab. Heart, Rat Br-B, Rab. Br-1,  #Rat Br-A (Repeat I)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69: Gln Val Leu Thr Gly Glu Asp Trp Asn Ser Va #l Met Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:70:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel consensus (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70: Gln Ile Leu Thr Gly Glu Asp Trp Asn Ser Va #l Met Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:71:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: Ca #lcium channel Drosophila (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: Gln Ile Met Thr Gly Glu Asp Trp Asn Ala Va #l Met Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:72:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: Ca #lcium channel Carp Skel (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72: Gln Val Leu Thr Gly Glu Glu Trp Asp Ser Il #e Met Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:73:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Rabbit Skel (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: Gln Cys Ile Thr Met Glu Gly Trp Thr Asp Va #l Leu Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:74:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Human brain and Rat Br-D           (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74: Gln Ile Leu Thr Gly Glu Asp Trp Asn Ala Va #l Met Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:75:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Rat Br-C, Rat Aorta, Rab.                Heart, Ra #t Br-B, Rab. Br-1, Rat Br-A (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75: Gln Ile Leu Thr Gly Glu Asp Trp Asn Ser Va #l Met Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:76:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel consensus (Repeat I)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76: Arg Leu Met Thr Gln Asp Tyr Trp Glu Asn Le #u Tyr Gln 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:77:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel para, Rat BrII, Rat BrIII,                Rat Heart #, Rat Skel mu1, Eel (Repeat I)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77: Arg Leu Met Thr Gln Asp Phe Trp Glu Asp Le #u Tyr Gln 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:78:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel consensus (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Me #t Trp Asp 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:79:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel para (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: Arg Val Leu Cys Gly Glu Trp Ile Glu Ser Me #t Trp Asp 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:80:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel Rat BrII, Rat BrIII           (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80: Arg Val Leu Cys Gly Glu Trp Ile Glu Ser Me #t Trp Asp 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:81:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel Rat Heart, Rat Skel mu1           (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81: Arg Ile Leu Cys Gly Glu Trp Ile Glu Ser Me #t Trp Asp 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:82:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel Eel (Repeat II)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82: Arg Ala Leu Cys Gly Glu Trp Ile Glu Ser Me #t Trp Asp 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:83:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel consensus (Repeat III)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83: Thr Val Ser Thr Phe Glu Gly Trp Pro Glu Le #u Leu Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:84:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Drosophila (Repeat III)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84: Thr Val Ser Thr Phe Glu Gly Trp Pro Gly Le #u Leu Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:85:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Carp Skel (Repeat III)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85: Thr Ile Ser Thr Phe Glu Gly Trp Pro Glu Il #e Leu Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:86:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 14 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Rabbit Skel, Human Br,Rat Br-D,                Rat Br-C, # Rat Aorta, Rabbit Heart, Rat Br-B, Rabbit Br-1 #, Rat Br-A (Repeat III)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86: Thr Val Ile Ser Thr Phe Glu Gly Trp Pro Gl #u Ile Leu Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:87:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel consensus (Repeat IV)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87: Arg Cys Ala Thr Gly Glu Ala Trp Gln Glu Il #e Met Leu 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:88:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 12 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Drosophila (Repeat IV)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88: Arg Ser Ala Thr Gly Glu Ala Trp Glu Ile Me #t Met 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:89:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Carp Skel (Repeat IV)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89: Arg Val Ala Thr Gly Glu Gln Trp Pro Lys Va #l Ile Leu 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:90:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: ca #lcium channel Rabbit Skel, Human Br,Rat Br-D,                Rat Br-C, # Rat Aorta, Rabbit Heart, Rat Br-B, Rabbit Br-1 #,Rat Br-A (Repeat IV)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90: Arg Cys Ala Thr Gly Glu Gln Trp Pro Lys Va #l Ile Leu 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:91:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel consensus (Repeat III)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: Gln Val Ala Thr Phe Lys Gly Trp Met Asp Il #e Met Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:92:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel para, Rat BrII, Rat BrIII,                Rat Heart # (Repeat III)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92: Gln Val Ala Thr Phe Lys Gly Trp Ile Gln Il #e Met Asn 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:93:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel Rat Skel mu1 (Repeat III)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93: Gln Val Ala Thr Phe Lys Gly Trp Met Asp Il #e Met Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:94:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel Eel (Repeat III)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94: Gln Val Ser Thr Phe Lys Gly Trp Met Asp Il #e Met Tyr 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:95:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel consensus (Repeat IV)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95: Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly Il #e Leu Ala 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:96:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel para (Repeat IV)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96: Gln Met Ser Thr Ser Ala Gly Trp Asp Gly Va #l Leu Asp 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:97:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel Rat BrII, Rat BrIII, Rat                Heart (Re #peat IV)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97: Gln Ile Ser Thr Ser Ala Gly Trp Asp Gly Va #l Leu Asp 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:98:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel Rat Skel mu1 (Repeat IV)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98: Glu Ile Thr Thr Ser Ala Gly Trp Asp Gly Le #u Leu Asn 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:99:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 13 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)   (viii) POSITION IN GENOME:           (A) CHROMOSOME/SEGMENT: so #dium channel Eel (Repeat IV)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99: Glu Ile Thr Thr Ser Ala Gly Trp Asp Gly Le #u Leu Leu 1               5    #                10 (2) INFORMATION FOR SEQ ID NO:100:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 6 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: cDNA     (ix) FEATURE:           (A) NAME/KEY: misc_ #feature           (B) LOCATION: 6           (D) OTHER INFORMATION:  #/note= “inosine”     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100: Asn Asn Asp Trp Trp Asn 1               5 (2) INFORMATION FOR SEQ ID NO:101:      (i) SEQUENCE CHARACTERISTICS:           (A) LENGTH: 6 amino  #acids           (B) TYPE: amino acid           (C) STRANDEDNESS: Not R #elevant           (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: cDNA     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101: Asp Met Met Gln Lys Ala 1               5 

What is claimed is:
 1. An isolated gene comprising a DNA molecule encoding an invertebrate calcium channel subunit, wherein said DNA molecule encodes the amino acid sequence consisting of SEQ ID NO.
 3. 2. A recombinant DNA vector comprising an isolated gene according to claim
 1. 3. A vector according to claim 2, wherein said vector is selected from the group consisting of a plasmid, virus, and bacteriophage.
 4. A vector according to claim 2, wherein said DNA sequence is inserted into said vector in proper orientation and correct reading frame such that the DNA sequence may be expressed by a cell transformed with said vector.
 5. A vector according to claim 4, wherein said DNA sequence is operatively liked to a promoter sequence.
 6. A composition of matter comprising a vector according to claim 2, wherein the DNA is operably linked to a control sequence.
 7. A cell transformed with a vector according to claim
 2. 8. A method of expressing a functional invertebrate calcium channel, comprising: transforming a host cell with a gene according to claim 1; and culturing said host cell under conditions such that said gene is expressed, thereby forming a functional channel.
 9. An isolated gene comprising a DNA molecule encoding an invertebrate calcium channel subunit, wherein said DNA molecule encodes the amino acid sequence consisting of SEQ ID NO.
 4. 10. A recombinant DNA vector comprising an isolated gene according to claim
 9. 11. A vector according to claim 10, wherein said vector is selected from the group consisting of a plasmid, virus, and bacteriophage.
 12. A vector according to claim 10, wherein said DNA sequence is inserted into said vector in proper orientation and correct reading frame such that the DNA sequence may be expressed by a cell transformed with said vector.
 13. A vector according to claim 12, wherein said DNA sequence is operatively linked to a promoter sequence.
 14. A composition of matter comprising a vector according to claim 10, wherein the DNA is operably linked to a control sequence.
 15. A cell transformed with a vector according to claim
 10. 16. A method of expressing a functional invertebrate calcium channel, comprising: transforming a host cell with a gene according to claim 9; and culturing said host cell under conditions such that said gene is expressed, thereby forming a functional channel. 